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In hyperendemic malarious regions adults develop protective immunity to 
Plasmodium falciparum infection. In order for this immunity to develop the host 
immune system must be able to recognise the parasite. One stage at which this 
occurs is prior to red blood cell invasion when the extracellular form of the parasite, 
the merozoite, presents the host immune system with a number of potential 
immunogens termed merozoite surface antigens. Antibodies to merozoite surface 
antigens are able to inhibit the growth and development of the parasite in vitro. This 
thesis explores the mechanisms by which merozoite surface antigen -specific 
antibodies exert this inhibition. 
The affinity, fine specificity and Fc- mediated effects of antibodies may affect their 
functional activity. Immortalised B cell lines producing merozoite surface antigen - 
specific human monoclonal antibodies were generated in order to investigate the 
effect of these factors on their growth inhibitory activity in vitro. The preliminary 
characterisation of these mAbs is described in chapter 3. However, sufficient 
quantities of these mAbs could not be generated for their functional activity to be 
investigated in vitro. 
Current dogma holds that the primary function of antibodies is to provide a 
molecular link between antigen recognition and pathogen destruction. However, all 
Abs have the ability to catalyse a reaction between singlet oxygen and water to 
generate hydrogen peroxide. This thesis explored the hypothesis that this antibody - 
catalysed water -oxidation pathway is responsible for the intraerythrocytic growth 
inhibition exerted by MSP -1 -19- specific Abs. An in vitro ACWO assay was 
developed to test this hypothesis and data suggest that ACWO may occur in infected 
RBCs associated with an anti- MSP -1 -19 monoclonal antibody. 
Antibodies specific to an intrinsically unstructured region from the C- terminal half of 
merozoite surface protein 3.3, designated MSP3.3C, are highly effective at inhibiting 
iii 
the in vitro growth of P. falciparum. This thesis explored the mechanisms 
responsible for this inhibition. This inhibition is caused by inhibition of the 
intraerythrocytic development of the parasite and not by inhibition of merozoite 
invasion. MSP3.3C specific Abs can access the intraerythrocytic parasite post 
invasion and completely arrest parasite development by inducing parasite death. 
The findings presented in this thesis expand current knowledge of the mechanisms 
by which MSA- specific Abs inhibit the growth of P. falciparum in vitro. This may 
prove informative both in terms of our understanding of naturally acquired antibody 
mediated immunity to P. falciparum asexual stages and in furthering effective 
vaccine design against this deadly pathogen. 
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1 Introduction 
1.1 General background 
1.1.1 Malaria: the prevailing state of an ancient disease 
Historical references, some greater than four thousand years old, describing the poor 
health, paroxysmal fevers and enlarged spleens of individuals residing in marshland 
areas, attest to the antiquity of coexistence between malaria parasites and their Homo 
sapien host. Over these millennia malaria has had a profound impact on our 
genomic evolution; genetic polymorphisms conferring resistance to the disease, 
particularly those affecting red blood cells (RBCs), have been selected for in high 
frequency in endemic populations (Flint et al., 1998). These genetic polymorphisms, 
which include the haemoglobinopathy haemoglobin S (Hill et al., 1991), the alpha 
and beta thalassaemias (Flint et al., 1986) and glucose -6- phosphate dehydrogenase 
deficiency (Ruwende et al., 1995), have left a large burden of genetic disease in 
human populations (Weatherall and Clegg, 2001). 
Malaria continues to exert a significant burden on the human population; 216 million 
clinical cases and 1.2 million malaria deaths (mostly of children under 5 years of 
age) are estimated to have occurred in 2010 alone (Murray et al., 2012; World 
Malaria Report 2011, 2011). Although increased control activities in sub -Saharan 
Africa have resulted in a significant decrease in malaria deaths since 2004 (Murray et 
al., 2012), insecticide -resistant vectors and drug- resistant parasites remain a threat to 
the global eradication of malaria. 
1.1.2 Malaria parasites and their vectors 
In 1880, the French scientist Charles Louis Alphonse Laveran discovered that 
malaria was caused by a parasitic protozoan, which he named Oscillaria malaria, 
and not by the bacterium Bacillus malariae, the leading suspect of the time. We now 
1 
know that five species of protozoan apicomplexan parasites of the genus 
Plasmodium are able to infect humans; Plasmodium falciparum (P. falciparum), 
Plasmodium knowlesi (P. knowlesi), Plasmodium malariae (P. malariae), 
Plasmodium ovale (P. ovale) and Plasmodium vivax (P. vivax). P. knowlesi is 
thought to be primarily zoonotic in origin (Cox- Singh, 2012), whilst the other four 
species of parasite are spread from one human to another by the bite of the female 
Anopheles mosquito vector. Within this genus of 465 species, approximately 70 
species are thought to act as human malaria vectors in the wild (Warrell and Gilles, 
2003). 
1.1.3 Clinical manifestations of the disease 
The clinical presentations of malaria depend upon the species and strain of the 
infecting parasite, and the immunological status of the infected individual. Intense 
cyclical fevers are the hallmark of malarial infection and typically coincide with 
RBC lysis. Such fevers occur every 24 hours (h) in P. knowlesi infection, every 48 h 
in P. falciparum, P. ovale and P. vivax infection, and every 72 h in P. malariae 
infection. Accompanying symptoms include headache, nausea, and muscular aches, 
among others. Untreated cases of malaria are characterised by enlargement of the 
spleen. The most severe form of malaria is caused by complicated P. falciparum 
infection, during which life -threatening complications can arise, including renal 
failure, hepatic dysfunction, severe anaemia and cerebral malaria. In P. vivax and P. 
ovale malaria, relapse may occur years after initial infection due to reactivation of 
the dormant liver -stage form of the parasite (hypnozoites). 
1.1.4 P. falciparum life cycle 
Infection begins with inoculation of the infective stages, sporozoites, into the human 
host when the mosquito takes a blood meal. The majority of these sporozoites find a 
blood vessel, travel in the peripheral blood circulation, and reach the liver within 60 
minutes of inoculation. Once there, sporozoites rapidly invade liver hepatocytes, 
where they undergo asexual multiplication (exoerythrocytic schizogony), which 
results in the production of many (> 10,000) uninucleate merozoites, a process which 
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takes - 6 days. These liver stage schizonts rupture from infected hepatocytes, 
releasing merozoites which invade RBCs. In erythrocytes, the parasite undergoes a 
second phase of asexual multiplication (schizogony) to produce 8 -16 daughter 
merozoites per infected RBC. These infectious offspring are released when the RBC 
lyses and go on to invade other RBCs. This cycle of -10 -fold parasite multiplication 
continues and it is this stage of the infection that is responsible for malarial 
pathogenesis. 
Some of the merozoites entering RBCs do not undergo schizogony but instead 
differentiate into male and female gametocytes that circulate in the peripheral blood 
until they are ingested by a female Anopheline mosquito. Within the mosquito, the 
male gametocyte divides into 8 flagellated microgametes, which escape the 
enveloping RBC and swim to the female macrogamete. Fertilisation occurs, 
resulting in the formation of a motile zygote (the ookinete) within the lumen of the 
mosquito gut. The ookinete moves between or through the cells of the stomach wall 
to become a conspicuous oocyst. Within the oocyst a third round of asexual 
multiplication occurs (sporogony), producing sporozoites that migrate to the salivary 






















Figure 1 Schematic life cycle of Plasmodium falciparum 
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1.2 Merozoite invasion and developmental stages of 
the erythrocytic cycle 
1.2.1 The intraerythrocytic developmental cycle of P. 
falciparum 
Whilst the 48 hour long erythrocytic cycle of P. falciparum is a continuous, dynamic 
process, four distinct stages of parasite development can be distinguished based on 
morphological characteristics. The intraerythrocytic developmental cycle initiates 
with the invasion of a RBC by the extracellular merozoite and is followed by the 
formation of the parasitophorous vacuole during the ring stage. The parasite then 
embarks on a highly metabolic growth stage, the trophozoite stage. In the schizont 
stage, the parasite undergoes multiple rounds of replication in preparation for 
reinvasion of new RBCs. The different parasite stages were initially defined but 
based on light microscopic observation of morphological characteristics. More 
recently, large scale proteomics assays have confirmed that each of these 
developmental stages is distinguished by a unique protein content related to the 
specialised functionalities of that specific stage (Foth et al., 2011; Hall et al., 2005; 
Le Roch et al., 2004). 
1.2.1 The merozoite 
P. falciparum merozoites are ellipsoidal in shape and small in size, measuring 
approximately 1.3 µm long by 0.9 gm wide. They have a short flat -ended apical 
prominence, surrounded by 3 polar rings, within which a group of secretory 
organelles are housed; the dense granules, micronemes and rhoptries. An irregular 
and variably shaped nucleus is located in the posterior half of the merozoite. 
Projecting tufts of fine filaments form a structured coat overlying the entire 
merozoite surface, beneath which lies the trilaminar pellicle, consisting of the 
merozoite plasma membrane (PM) and beyond the apical pole region, the two 
membranes of the inner membrane complex (IMC) (Bannister et al., 2000b). 
Underneath the pellicle lie two or three microtubules (Bannister and Mitchell, 1995), 
a single elongated mitochondrion (Slomianny and Prensier, 1986) and an apicoplast 
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(Hopkins et al., 1999; Köhler et al., 1997). A single cytosomal ring is located on the 
side of the merozoite beneath the PM in a small gap in the IMC (Aikawa et al., 1966; 
Bannister et al., 2000b; Slomianny, 1990). 
At least 11 merozoite surface proteins (MSPs) have been identified. A number of 
these, including MSP -1 and MSP -2, are attached to the PM though a C- terminal 
glycosylphosphatidylinositol (GPI) -lipid anchor, while others, such as MSP -3, MSP - 
6, and MSP -7, lack either a GPI anchor or transmembrane domain and are thought to 
associate with the surface through non -covalent interactions with other MSPs. 
MSP -1, the most abundant protein on the merozoite surface, is initially synthesised 
during the trophozoite and schizont stages as a - 185 kilodalton (kDa) precursor 
protein (Holder and Freeman, 1982; Holder and Freeman, 1984), which exists in a 
complex with MSP -6 and MSP -7 (Pachebat et al., 2001; Trucco et al., 2001). MSP -1 
undergoes a primary cleavage event during schizogany to yield four fragments of 83, 
28, 38 and 42 kilodaltons (kDa) (Holder et al., 1985; Holder et al., 1987; Lyon et al., 
1986a; Lyon et al., 1987; McBride and Heidrich, 1987). These fragments remain in 
a non -covalently linked complex on the merozoite surface until, during merozoite 
invasion, a secondary processing event occurs, cleaving the 42 kDa fragment into 
two fragments of 33 kDa and 19 kDa. The latter fragment is retained on the 
merozoite surface throughout invasion whilst all other fragments are thought to be 
shed either before or during the invasion process (Blackman et al., 1990). These 
primary and secondary cleavage events are carried out by the subtilisin -like serine 
proteases, PfSUB1 (Koussis et al., 2009) and PfSUB2 (Blackman and Holder, 1992; 
Harris et al., 2005), respectively. 
P. falciparum MSP -3 is a somewhat diverse - 48 kDa protein that contains 12 copies 
of a heptad amino acid motif arranged in 3 contiguous blocks of four. These blocks 
are linked by short non -repetitive sequences and the hydrophobic amino acid alanine 
occupies the first and fourth positions within each heptad (McColl et al., 1994; 
Oeuvray et al., 1994). These regions may form coiled -coil a- helices and a synthetic 
peptide containing one of the blocks of four heptads was found to contain an a -helix 
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but did not form multimers of itself in solution (Mulhern et al., 1995). Three MSP -3 
orthologues have been identified in P. vivax (MSP -3a, MSP -3(3, and MSP -3y), which 
contain alanine -rich heptad repeat sequences similar to those found in P. falciparum 
MSP -3 (Galinski et al., 1999; Galinski et al., 2001). MSP -6 contains significant 
sequence similarity to MSP -3 in its C- terminal half, and along with 7 other proteins 
forms the MSP -3 family of proteins with designations of MSP -3.1 through MSP -3.8 
(Singh et al., 2009). 
1.2.2 Merozoite invasion 
Merozoite invasion is an efficient, highly orchestrated process in which the 
recognition, attachment and entry of an uninfected RBC by the extracellular 
merozoite occurs in - 90 seconds (Gilson and Crabb, 2009b). Prior to invasion 
merozoites must be released from the host cell that has housed them during their 
development. This involves disruption of both the parasite vacuolar and RBC 
membranes in a multistep process (Salmon et al., 2001; Wickham et al., 2003), 
which allows the non -motile merozoites to be ejected at high pressure into the 
circulating blood where they can encounter new RBCs. 
The initially reversible, low affinity RBC- merozoite interaction occurs between 
elements of the merozoite's proteinaceous fibrillar projections and the RBC (Dvorak 
et al., 1975). MSPs are abundantly present all over the merozoite surface and have 
consequently been implicated as the molecular mediators of this interaction. 
Specifically, there is some evidence that MSP -1 and MSP -7 may mediate this initial 
merozoite -RBC interaction as disruption of their function, through specific antibody 
binding or gene knockout, respectively, impedes invasion (Blackman et al., 1990; 
Kadekoppala et al., 2008). Recently, synthetic MSP -11 peptides have been shown to 
both bind RBCs and inhibit merozoite invasion in vitro, suggesting that MSP -11 may 
also help mediate the RBC- merozoite interaction (Obando- Martinez et al., 2010). 
However, direct evidence for any such interactions are currently lacking. 
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Initial contact of the merozoite with a RBC elicits the emanation of rhythmic 
oscillations across the erythrocyte surface, disrupting the merozoite such that it 
becomes reoriented with the apical prominence facing the erythrocyte membrane. 
This results in the formation of a tight 4 nanometre (nm) membrane -to- membrane 
interaction (tight junction) between the parasite and the RBC, an essential and 
irreversible step which commits the parasite to host cell entry. This step is thought to 
be mediated by pairs of merozoite ligand- erythrocyte receptor interactions, each pair 
defining a redundant invasion pathway. Merozoite ligands identified include 
members of the erythrocyte -binding like (EBL) and reticulocyte binding like (PJRh) 
protein families and some of their binding partners on the RBC surface have been 
identified (Lobo et al., 2003; Sim et al., 1994; Tham et al., 2010). 
The tight junction, whilst retaining its suberythrocytic electron density, moves 
posteriorly over the merozoite as the parasite moves into the RBC, powered by an 
internal actin -myosin motor (Baum et al., 2006; Keeley and Soldati, 2004) and 
shedding its surface coat as it does so. Succeeding moving junction formation, 
rhoptry organelles secrete proteins and lipids into the host cell that are incorporated 
into the parasitophorous vacuole membrane (PVM). Merozoite internalisation is 
estimated to be complete within 17 seconds (Gilson and Crabb, 2009b), at which 
time the merozoite inside the RBC is completely enclosed by the PVM. 
Apical membrane antigen 1 (AMA -1) is synthesised in precursor form as an 83 kDa 
type I integral transmembrane protein (Narum and Thomas, 1994) and is targeted to 
micronemes (Bannister et al., 2003). Near the time of merozoite egress from the host 
RBC, AMA -1 is proteolytically processed to yield a 66 kDa protein that is 
translocated to and distributed over the entire merozoite surface (Healer et al., 2002). 
The mature form of AMA -1 contains a large extracellular domain, folding into three 
interacting domains with several protruding highly polymorphic loops. A 
hydrophobic trough in this ectodomain is the binding site for a complex of rhoptry 
neck proteins; RON2, RON4 and RON5 (Cao et al., 2009; Collins et al., 2009). The 
RON complex is thought to be translocated from the rhoptry neck into the 
erythrocyte membrane such that the parasite may be supplying both receptor and 
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ligand during host cell invasion (Gilson and Crabb, 2009a; Lamarque et al., 2011; 
Richard et al., 2010). Eventually, the vast majority of the AMA -1 ectodomain is 
shed from the merozoite surface via juxtamembrane cleavage by PfSUB2 and 
intramembrane cleavage mediated by an unknown factor (Harris et al., 2005; Howell 
et al., 2005; Howell et al., 2003), a process which may be essential for parasite 
survival (Olivieri et al., 2011). 
1.2.3 The ring stage parasite 
The ring stage begins shortly after invasion, with the parasite flattening into a 
biconcave discoidal shape with a diameter of 2 to 3.7 gm. The thick perimeter of the 
disk contains the majority of organelles, including a variably shaped nucleus and 
most of the ribosomes. The thinner centre contains the smooth membrane 
organelles. The exact shape of the disc varies, in some cases flat, but more often 
taking on a curved cuplike form (Bannister et al., 2004). 
The developing parasite takes up and degrades large quantities of haemoglobin from 
the RBC cytosol, a costly process for the parasite, both in terms of the energy 
required and the toxic risk of free haem molecules. Haemoglobin degradation 
provides amino acids that are essential for parasite growth (Francis et al., 1997; 
Krugliak et al., 2002; McKerrow et al., 1993) and is thought to maintain the osmotic 
stability of the growing parasite (Lew et al., 2004; Lew et al., 2003). 
The ring stage parasite endocytoses the haemoglobin -rich erythrocyte cytosol 
through a single active cytosome into small vesicles. Initially these food vacuoles 
are enclosed by two membranes, the inner and outer, derived from the PVM, and the 
parasite PM, respectively. As haemoglobin degradation proceeds, the inner 
membrane degrades, and small crystals of haemozoin, the product of haemoglobin 
degradation by the parasite, appear within single membrane vacuoles. 
A distinctive class of double -membraned vesicles, which do not form part of the 
cytosomal system, appear at the parasite surface of rings, their outer membrane fused 
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with the parasite PM such that the inner vesicle gives the appearance of being 
exported into the PV space. It has been suggested that these vesicles may be 
involved in the export of membrane from the parasite surface into the PVM, which 
needs to expand in order to accommodate the growing parasite (Bannister et al., 
2004). 
The ring stage endures for a considerable proportion of the asexual cycle, with some 
pathogenesis occurring during this time due to the adherence of iRBCs to vessel 
walls (Cooke et al., 2001; Pouvelle et al., 2000). This stage ends as the parasite takes 
on a more spheroidal shape and becomes a trophozoite around 25 h into the cycle. 
1.2.4 The trophozoite stage 
The trophozoite stage is characterised by rapid parasite growth, adoption of a 
rounded shape and the appearance of haemozoin in a single food vacuole. As the 
parasite continues to grow it exports membranes - Maurer's clefts, the 
tubulovesicular network (TVN), small vesicles, and knobs - and other structures 
into the RBC it inhabits (Cooke et al., 2004; Haldar et al., 2001; Przyborski et al., 
2003). 
The TVN consists of spirals and loops of double membrane, often extending from 
the PVM to wrap around regions of host cytoplasm. The TVN shares antigenic 
similarity with the PVM, including the integral membrane proteins exported protein 
1 (EXP -1) (Kara et al., 1988) and exported protein 2 (EXP -2) (Fischer et al., 1998), 
and some members of the early transcribed membrane protein family (ETRAMPS) 
(Spielmann et al., 2003). 
Maurer's clefts are stacks of flattened lamellae of long slender membranes with an 
electronluscent lumen and an electron dense coat, mostly lysing near and parallel to 
the erythrocyte PM, to which they are attached by filamentous .links (Kriek et al., 
2003). Maurer's clefts can first be detected in early ring stages, where they are 
highly motile. Upon progression into the trophozoite stage their position becomes 
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fixed (Grüring et al., 2011). Several integral membrane proteins are resident in 
Maurer's clefts, including membrane -associated histidine -rich protein 1 ( MAHRP 1) 
(Spycher et al., 2003), skeletal binding protein 1 (SBP1) (Blisnick et al., 2000), ring 
exported protein 2 (REX2) (Spielmann et al., 2006) and Pf332 (Hinterberg et al., 
1994). 
Knobs are produced by the deposition of the Knob- associated histidine -rich protein 
(KAHRP) at the RBC cytoskeleton, which produces an angular prominence. 
Attached to knobs are members of the membrane embedded P. falciparum 
erythrocyte membrane protein 1 (PfEMP1) family of clonally variant proteins, 
surface exposed proteins that mediate, at least in part, the attachment of more mature 
stages of P. falciparum to the vascular endothelium of different organs, including the 
brain. This sequestration is one of the the main causes of P. falciparum malaria 
induced morbidity and mortality and the reason that only ring stages are seen in the 
blood of infected patients. Within the iRBC cytoplasm, there are many small (15 to 
25 nm) vesicles, frequently associated with Maurer's clefts and the RBC PM. 
During its development inside the mature human erythrocyte, which is a terminally 
differentiated cell lacking either intracellular organelles or endocytotic machinery 
(Chasis et al., 1989), the parasite establishes a de novo trafficking system. The 
parasite employs this system to export several hundred soluble and membrane - 
embedded proteins into the RBC compartment in order to foster its virulence, 
stabilise the host cell cytoskeleton and obtain nutrients from host plasma. 
In order to access the RBC cytosol, parasite proteins must traverse both the parasite 
PM and the PVM. A hydrophobic signal sequence located either close to or up to 80 
amino acids from the N- terminus facilitates insertion into the endoplasmic reticulum 
(ER) and is required to traffic proteins to the PV (Adisa et al., 2003; Cheresh et al., 
2002; Waller et al., 2000; Wickham et al., 2001). Typically, in order for the protein 
to cross the PVM a second pentameric signal sequence known .as the Plasmodium 
export element (PEXEL) is required (Hiller et al., 2004; Marti et al., 2004). This 
motif has the consensus R/KxLxE /Q /D, where x is any amino acid, and is located a 
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short distance downstream of the ER signal sequence. In the ER, the PEXEL motif 
is cleaved at the C- terminal side of the conserved Leucine residue by the aspartic 
protease plasmepsin V, to generate a new N- terminus which becomes acetylated 
(Boddey et al., 2010; Chang et al., 2008). 
The Plasmodium translocon of exported proteins (PTEX) is the putative protein 
trafficking machinery responsible for the export of proteins across the PVM and into 
the RBC cytosol. Five proteins comprising PTEX have been identified; heat shock 
protein 101 (HSP101), thioredoxin 2 (TRX2), PTEX150, PTEX88 and EXP -2. 
HSP101, a AAA+ ATPase chaperone, hydrolyses ATP to putatively unfold cargo 
proteins prior to driving them across the PVM and EXP -2 is thought to homo- 
oligomerise in order to form the membrane spanning channel (Bullen et al., 2012; de 
Koning -Ward et al., 2009). However, definitive proof that PTEX acts as the protein 
translocon is so far lacking. 
PEXEL -containing membrane proteins and parasite proteins that do not contain a 
PEXEL motif are exported across the PVM into the RBC. Given that only soluble 
proteins have been shown to associate with PTEX it remains to be determined 
whether separate trafficking pathways exist for these exported proteins. It has been 
suggested that parasite membrane proteins are loaded into nascent Maurer's clefts as 
they bud off from the PVM thus providing a route for export of these parasite 
proteins. However, the recent finding that Maurer's clefts are generated prior to the 
synthesis of most exported proteins argues against this (Grüring et al., 2011). 
1.2.5 The Schizont stage 
During the schizont stage the parasite beings to move away from trophic activities, 
including cytosomal feeding, and undergoes a series of mutliplications of its nucleus, 
mitochondrion, apicoplast and Golgi complex, while creating and assembling 
merozoite components in preparation for merozoite egress and invasion. 
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Schizont development can be divided into seven different stages based on 
ultrastructural changes (Margos et al., 2004) and these are outlined below. The 
parasite undergoes four rounds of endomitotic division, corresponding to stages 1 to 
4, to generate sixteen daughter nuclei, although this number varies from 8 to 32 
within a given schizont, thus suggesting that schizogony is an asynchronous process 
with relaxed regulation of final numbers (Margos et al., 2004). During the second 
stage, centres of merozoite assembly become visible near to the spindle pole bodies, 
comprising a Golgi -like cisterna and budding of a cluster of coated vesicles from the 
outer nuclear membrane (Bannister et al., 2000a). Merozoite apexes start to form; 
rhoptry precursors in the form of small spheroidal vesicles are present and the early 
stages of the pellicle and polar ring formation become visible. 
Towards the end of stage 4 the final assembly of merozoites begins, as surface clefts, 
lined by the pellicle, begin to deepen around the foci of apical organelle formation. 
Nuclei now finish their division and migrate into each merozoite bud, accompanied 
by the mitochondrion and apicoplast which multiplied during earlier stages. 
Micronemes are formed in stage 5 (Bannister et al., 2003) and dense granules at 
stage 6. All the apical organelles are formed from the Golgi cisterna; rhoptries 
through the fusion of small Golgi- derived vesicles, where as micronemes and dense 
granules bud off directly from its cisterna. The mitochondria, apicoplast and 
micronemes are transported to their apical destination along the merozoite's 
subpellicular microtubules, now fully assembled along one side of the bud. By the 
sixth stage, the merozoites are nearly completely formed but remain attached to the 
residual parasite body by narrow stalks. The residual body consists of a mass of 
haemozoin crystals encased within the pigment vacuole membrane, surrounded by a 
parasite PM. By the final stage of schizont development the merozoites are fully 
mature and are fully detached from the residual body (Margos et al., 2004). 
For merozoites to enter the bloodstream they must exit both the PVM encasing the 
developing merozoites and the RBC membrane. The molecular details of this 
process are still being worked out. It is thought that parasite- encoded proteases carry 
out a series of proteolytic events that result in merozoite exit from the RBC 
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following the rupture of the PVM and RBC membrane. The order in which these 
two membranes rupture is still a matter of debate (Salmon et al., 2001; Wickham et 
al., 2003). 
1.3 Antibody mediated immunity to malaria 
1.3.1 Immunity to malaria: an overview 
P. falciparum infection in malaria naive individuals results in the onset of clinical 
symptoms associated with this disease. Yet in hyperendemic malarious regions 
malaria parasites are detected in the blood of asymptomatic individuals, indicating 
the presence of acquired protective immunity to P. falciparum infection in these 
populations. This immunity is thought to develop in three sequential stages - firstly, 
clinical immunity that reduces the risk of death from malaria; then anti -disease 
immunity that reduces the intensity of clinical symptoms; and after this, anti -parasite 
immunity which directly reduces the number of parasites within an infected 
individual (Schofield and Mueller, 2006). 
The immune status of an individual is a product of the number and frequency of 
malaria inoculations experienced. Clinical immunity to severe attacks of malaria 
may be achieved after only one or two infections (Gupta et al., 1999). Consequently, 
young children less than 5 years of age are at high risk of severe malaria and death, 
as exemplified by this age -group accounting for the majority of deaths caused by 
malaria in Sub -Saharan Africa (Bryce et al., 2005). Clinical immunity to non -life 
threatening symptoms of malaria requires more and frequent inoculations of malaria, 
such that as children enter their primary school years, they will typically have low 
disease rates but retain significant parasitaemias. High parasite densities and 
prevalence often remain throughout childhood as clinical manifestations of the 
disease progressively decrease. Effective antiparasite immunity is only obtained 
after very many frequent inoculations and consequently is only obtained well into 
adulthood. 
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Due to the correlation between the age of an individual and the stage of malarial 
immunity attained, antimalarial immunity in endemic populations is often said to be 
"age- dependent." A more accurate description would be "duration of exposure" 
dependent, although there are age- dependent aspects to the attainment of malarial 
immunity. For example, extremely young children find it very difficult to acquire 
effective protective immunity to malaria, while older children and adults find it 
easier to do so (Baird, 1995; Baird et al., 1991). 
Antimalarial immunity is non -sterilising, meaning that ongoing exposure to the 
pathogen is required in order to maintain immunity, and that parasites are present in 
blood of clinically immune individuals. Even relatively short periods of non - 
exposure, in the order of six months to a year, are enough for immunity to be lost. 
This is exemplified by immigrants from Sub -Saharan Africa living in Europe, who 
upon returning from a trip to their native endemic area during which they haven't 
taken prophylactic treatment, often present at hospital with malaria (Monge- Maillo 
and López -Vélez, 2012). 
An individual living in a malaria endemic area is subject to a series of inoculations of 
malaria parasites that are both genetically and antigenically different from one 
another. Antimalarial immunity is strain -specific in the sense that protective 
immunity naturally acquired to one parasite strain, defined as parasites derived from 
a single natural inoculation, are better at protecting against re- infection with the 
homologous strain than with heterologous strains (Cavanagh et al., 2004; Conway et 
al., 2000; Eisen et al., 2002; Eisen et al., 1998; Jeffery, 1966). 
The P. falciparum genome encodes several large hypervariable polymorphic gene 
families called the variant surface antigens (VSAs) (Baruch et al., 1995; Cheng et al., 
1998; Kyes et al., 1999). An individual parasite expresses only one member of a 
VSA family at any given time (Chen et al., 1998; Scherf et al., 1998) but within a 
clonal parasite population there is switching between the expression of the individual 
genes of a VSA family (Kyes et al., 2001). This phenomenon is termed clonal 
antigenic variation and in order to regulate the infection the host must produce an 
14 
immune response to each antigenic variant as it arises. This variant specific 
immunity may explain how a single malaria infection can persist over many months 
or years. Antigenic polymorphism and variation are both thought to be immune 
evasion strategies utilised by the parasite and to contribute to the large number and 
frequency of inoculations required to achieve immunity in endemic populations 
(Mendis et al., 1991; Reeder and Brown, 1996). 
1.3.2 Evidence for antibody mediated immunity to malaria 
Several lines of evidence support a role for B cells and antibody in naturally acquired 
immunity to malaria. Firstly, the passive transfer of immunoglobulin G (IgG) 
purified from the serum of malaria immune individuals to children suffering from 
heavy P. falciparum infection results in a significant reduction in parasitaemia and 
the alleviation of clinical symptoms of the disease (COHEN et al., 1961; 
McGREGOR et al., 1963; Sabchareon et al., 1991). Secondly, during the first three 
months of life infants living in areas of high transmission intensity develop mild 
symptoms and low parasitaemias relative to the number of infective bites they 
receive (Snow et al., 1998). This has been attributed to the passive transfer of 
immune IgG from mother to infant as (i) levels of maternal and infant IgG match at 
birth (Logie et al., 1973), (ii) the length of time that this protection persists in infants 
approximately corresponds to the length of time that maternal IgG is predicted to be 
present for (Duah et al., 2010) and (iii) adult immune IgG blocks the cytoadherence 
of core blood iRBCs to microvascular endothelial cells more effectively than that of 
adult haemoglobin A- containing iRBCs (Amaratunga et al., 2011). However, direct 
evidence of an association between the level of maternal IgG and disease 
susceptibility in young infants is so far lacking. Thirdly, the presence and level of 
antibodies to defined malarial antigens has been associated with resistance to both 
symptomatic (Cavanagh et al., 2004; Egan et al., 1996; Mawili -Mboumba et al., 
2003; Meraldi et al., 2004; Metzger et al., 2003; Polley et al., 2006) and 
asymptomatic malaria (Hogh et al., 1992; Riley et al., 1993) in endemic populations. 
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Data garnered from experimental models of malaria likewise suggest that antibodies 
are a crucial component of the protective immune response to malaria. The transfer 
of immune IgG or malarial antigen -specific mAbs to naive mice or monkeys can 
reduce or prevent infection in the recipient (Gysin et al., 1996; Narum et al., 2000; 
Spencer Valero et al., 1998) . Mice lacking B cells cannot clear parasites from P. 
chabaudi chabaudi AS infection and develop a chronic infection (Langhorne et al., 
1998; Weid et al., 1996). 
1.3.3 Characteristics of the antibody response 
Seroepidemiological studies have shown that antibody responses that protect against 
clinical malaria are only acquired after repeat exposure, and once acquired, malaria - 
specific antibody levels, particularly in children, rapidly decline in the absence of 
ongoing exposure to the parasite (Akpogheneta et al., 2008; Cavanagh et al., 1998; 
Kinyanjui et al., 2007). This may go some way to explain why acquired immunity to 
malaria takes so long to develop, and why immunity is sometimes lost in the absence 
of continuous exposure. However, long -lived antibody responses do develop, 
particularly in older individuals (Drakeley et al., 2005; Taylor et al., 1996), and the 
cellular mechanisms underlying short-lived malaria specific antibody responses 
remain to be fully elucidated. 
The distribution of immunoglobulin isotypes found in malaria immune individuals is 
skewed towards those of the cytophilic IgG 1 and IgG3 subclasses. In contrast a 
prevalence of non -cytophilic immunoglobulin isotypes is found among unprotected 
individuals. This isotype imbalance has been proposed to explain the delayed 
acquisition of protective immunity seen in malaria endemic regions (Bouharoun- 
Tayoun and Druilhe, 1992). 
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1.3.4 Merozoite surface antigens as targets of antibody 
mediated immunity 
From the 5268 proteins predicted to be encoded by the P. falciparum genome 
(Gardner et al., 2002), it has been possible to identify some of the antigenic targets of 
naturally acquired antibody mediated immunity (AMI) to P. falciparum infection. 
As MSAs are directly exposed to Abs in the bloodstream prior to invasion, it follows 
that they may be targets of naturally acquired AMI. Indeed there are a number of 
lines of evidence to suggest that this is the case. 
If the prevalence or level of antibodies to a defined antigenic target correlates with 
resistance to or decreased frequency of clinical malaria, this can be taken as 
supportive evidence that this antigen in a target of protective immunity. Antibody 
responses to a number of MSAs have been correlated with resistance to clinical 
malaria, including the Block 2 region of MSP -1 (Cavanagh et al., 2004; Conway et 
al., 2000; Osier et al., 2008), MSP -1 -19 (Egan et al., 1996), MSP -2 (Metzger et al., 
2003; Osier et al., 2008; Polley et al., 2006) and MSP -3 (Osier et al., 2008; 
Roussilhon et al., 2007). Such studies have enabled the identification of antigenic 
targets of clinical immunity but in order to identify antigenic targets of anti- parasite 
immunity it is necessary to look for a correlation between the presence of antibodies 
and reduced risk of asymptomatic malaria infection. Such a correlation has been 
demonstrated for antibodies against MSP -1 (Chizzolini et al., 1988; Egan et al., 
1996). 
Population genetic analysis can be used to identify parasite antigens that are under 
strong selection by the host immune response. There is frequency- dependent 
selection on antigens, such that a pathogen with an allelic type at a low frequency in 
the population is more likely to escape an acquired immune response than a pathogen 
with a high frequency allelic type. As the advantage of the rare allelic form is soon 
lost if becomes more common, no single allele at that locus will reach fixation. In 
the case of polymorphic antigens encoded by single gene loci, this would result in 
selection maintaining different alleles within populations. Consequently, by 
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identifying which polymorphic loci are under strong balancing selection, one can 
identify which loci are targets of an allele -specific protective immune response. 
Such population genetic analyses have identified that a number of MSAs, including 
MSP -1 block 2, MSP -3.4, and MSP -7, as targets of acquired immunity (Conway et 
al., 2000; Tetteh et al., 2009). 
Where successful protection from immunisation with malarial antigens in 
experimental models of malaria has been shown to correlate with, or be dependent 
upon, specific antibody responses, this has been taken as support for that antigen 
being a target of protective immunity. Numerous studies have provided such support 
for various regions of MSP -1 as targets of the protective immune response (Chang et 
al., 1996; Daly and Long, 1995; Ling et al., 1995; Siddiqui et al., 1987). 
There are undoubtedly numerous antigenic targets of antibody mediated protective 
immunity yet to be identified, not least because novel blood stage specific P. 
falciparum antigens are still being described (Trieu et al., 2011). Although there are 
numerous lines of evidence that support the notion that MSAs are targets of antibody 
mediated protective immunity, a correlation between MSA- specific antibodies and 
protection does not explicitly prove causation. For this reason, researchers have tried 
to identify the causative mechanisms by which MSA -specific Abs bring about 
protective immunity. 
1.3.5 Mechanisms of antibody mediated immunity to 
merozoite surface antigens 
In vitro growth inhibition assays (GIAs) involve the addition of antimalarial 
antibodies to late trophozoite infected erythrocytes and the measurement of 
parasitaemia following the next invasion cycle. A lower parasitaemia relative to 
control cultures indicates that these antibodies inhibit the asexual growth of the 
parasite, either through disruption of merozoite invasion or interference with the 
subsequent intraerythrocytic development of the parasite. Antibodies to numerous 
MSAs have been shown to inhibit the in vitro growth of P. falciparum in GIAs, 
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including MSP -1 (Blackman et al., 1990), MSP -2 (Clark et al., 1989), MSP -6 and 
MSP- 7(Kauth et al., 2006). This inhibition is mediated by binding of Ab alone, as 
no other effector cells of the immune system are present in these assays. 
The binding of antibodies to the merozoite surface can prevent erythrocyte invasion 
through a number of different mechanisms. Antibodies to MSP -1 are able to 
agglutinate merozoites (Bergmann -Leitner et al., 2009; Lyon et al., 1997; Lyon et al., 
1986b), thereby preventing their dispersal and ability to invade new erythrocytes. 
Antibodies are able to block the physical interaction between the merozoite antigens 
they bind to and their protein interaction partners. MSP -1 has been implicated in the 
attachment of the merozoite to the erythrocyte surface, and the binding of specific 
antibody has been shown to reverse this process (Perkins and Rocco, 1988). 
Antibodies specific to MSP -142, MSP -6, and MSP -7 are able to prevent secondary 
processing of MSP -1 by the subtilisin -like protease PfSUB1 (Bergmann -Leitner et 
al., 2006; Blackman et al., 1994; Guevara Patiño et al., 1997; Woehlbier et al., 2010), 
an essential prerequisite for merozoite invasion to occur (Child et al., 2010). 
Encouragingly, the same Ab function has been detected in the sera of individuals 
naturally exposed to malaria, although this was not correlated with growth inhibitory 
activity of that sera in vitro (Nwuba et al., 2002). Other MSP -1 specific Abs block 
the binding of these processing inhibitory anti -MSP -1 Abs and have accordingly 
been termed "blocking Abs" (Blackman et al., 1994; Guevara Patiño et al., 1997). 
Interestingly, some blocking Abs recognise epitopes that are spatially distinct in 
primary sequence to those recognised by the process inhibitory antibodies (Guevara 
Patiño et al., 1997). 
Some MSP -119- specific antibodies do not interfere with the process of merozoite 
invasion, but adversely affect the development of the parasite inside the RBC post 
invasion (Arnot et al., 2008; Bergmann -Leitner et al., 2009; Moss et al., 2012; 
Woehlbier et al., 2006). The mechanism of this intraerythrocytic inhibition is 
unknown, although anti -MSP -119 Abs have been shown to locate to the food vacuole 
post invasion (Dluzewski et al., 2008), which has lead some to speculate that these 
antibodies may interfere with food vacuole formation (Moss et al., 2012). 
19 
Some MSA- specific antibodies do not display growth inhibitory activity in vitro on 
their own but instead act in combination with effector cells of the immune system to 
inhibit the asexual growth of P. falciparum. This occurs during a process known as 
antibody- dependent cellular inhibition (ADCI), in which an interaction between 
monocytes and antibodies via their FcyRIIa and FcyRIIIa receptors results in the 
release of undefined soluble monocyte- derived factors, which mediate inhibition of 
parasitaemia (Bouharoun -Tayoun et al., 1990; Bouharoun -Tayoun et al., 1995; 
Jafarshad et al., 2007). ADCI activity requires antibody to bind its cognate antigen; 
targets of ADCI so far identified include MSP -1 block 2 (Galamo et al., 2009), MSP - 
3 (Oeuvray et al., 1994), and glutamate -rich protein (GLURP) (Theisen et al., 2000). 
Opsonised merozoites have been shown to be phagocytosed by neutrophils in vitro 
(Kumaratilake et al., 1991; Kumaratilake et al., 1990), and neutrophil respiratory 
bursts are triggered by opsonised merozoites and enhanced by cytokines 
(Kumaratilake et al., 1997). Recently, a novel high throughput in vitro assay that 
measures the reactive oxygen species (ROS) generated by polymorphonuclear 
neutrophils (PMNs) in the presence of merozoites and immune IgG, termed antibody 
dependent respiratory burst (APRB), was found to correlate with naturally acquired 
clinical protection in endemic areas (Joos et al., 2010). Merozoites opsonised by 
MSP -2- specific Abs have been shown to be phagocytosed by monocytes in vitro, and 
this mechanism may explain some or all of the reduction in parasitaemia seen during 
ADCI (Stubbs et al., 2011). 
As discussed earlier, there is an antibody subclass bias in response to P. falciparum 
infection, with cytophilic antibody subclass responses associated with protection to a 
higher degree than those of non -cytophilic subclasses. It is therefore interesting to 
note that the mechanisms of ADCI and APRB both rely on cytophilic antibody 
classes - this has lead some to suggest that these are important mechanisms in the in 
vivo response to P. falciparum infection. 
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1.4 Why this thesis? 
The blood stage of P. falciparum infection is responsible for the symptomatic 
manifestations that result from this infection. It therefore follows that a reasonable 
strategy for therapeutic intervention would be to disrupt the growth of the parasite at 
this stage. Antibody mediated immunity is thought to compose a significant part of 
the protection developed against P. falciparum infection in endemic populations. 
Antigens expressed on the surface of the extracellular merozoite, being directly 
exposed to the human immune system, are deemed an obvious target for this 
antibody- mediated immunity. Indeed, there are multiple lines of evidence to support 
the notion that merozoite surface antigen specific antibodies play an important role in 
protective immunity to blood stage P. falciparum infection. This has lead to the 
development of numerous merozoite surface candidate vaccine antigens, which to 
date have proved at best partially effective in clinical trials (for recent reviews please 
see (Anders et al., 2010; Chauhan et al., 2010)). Some of the mechanisms by which 
antibodies to MSAs are able to inhibit P. falciparum growth have been identified. 
This thesis aims to delve deeper into these mechanisms, looking at antibodies 
specific to both well- characterised and novel merozoite surface vaccine candidate 
antigens. This is done with the view that gaining further insight into the mechanisms 
by which growth inhibitory antibodies act may increase our understanding of both 
parasite developmental processes and naturally acquired antibody mediated 
immunity, which may ultimately aid effective vaccine development. 
1.5 Aims of this thesis 
The general aim of this thesis was to investigate the mechanisms by which antibodies 
to merozoite surface antigens inhibit the growth of P. falciparum in vitro. My three 
results chapters address the following specific aims: 
1. To generate human monoclonal antibodies to MSAs as useful reagents with which 
to investigate mechanisms of in vitro growth inhibition. 
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2. To investigate the hypothesis that the mechanism underpinning growth inhibition 
by anti -MSP -119 antibodies is via an antibody- dependent water oxidationprocess, 
generating reactive oxygen species. 
3. To elucidate how antibodies to a novel merozoite surface antigen target (MSP3.3) 
inhibit P. falciparum growth in vitro. 
The order in which these results chapters are presented reflects the development of 
my ideas and hypotheses over the time of my PhD project. 
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2 Materials and Methods 
This chapter describes materials and methods common to two or more results 
chapters of this thesis. Materials and methods specific to a single chapter can be 
found in the materials and methods section of that chapter. 
2.1 Long term culture and manipulation of P. 
falciparum 
2.1.1 Freezing of P. falciparum 
Cultures with a high percentage of ring forms were selected for deep freezing. The 
culture was placed in a 15 mL falcon tube and centrifuged at 900 x G for 5 minutes. 
The supernatant was removed and deep freezing solution (28% glycerol, 3% D- 
sorbitol, 0.65% NaCl) was added drop by drop with mixing at a ratio of 1 volume of 
deep freezing solution to 1 volume of packed cells. RBCs were aliquoted into 
cryovials and stored at -70 °C overnight in a cryo 1 °C freezing container, then in 
liquid nitrogen for longer storage. 
2.1.2 Thawing of P. falciparum 
Parasites were maintained in liquid nitrogen for long -term storage, and removed 
when needed for culture. Cells were placed in a 37 °C incubator until fully thawed 
and then transferred to a 15 mL falcon tube. For a 1 mL packed cell volume (pcv), 
200 µL of a 12% solution of NaCI in dH2O was added drop by drop with constant 
mixing. RBCs were allowed to equilibrate for 3 mins at room temperature (RT) 
before the addition of 10 mL of a 1.8 % solution of NaC1 in dH2O drop by drop with 
constant mixing. This was followed by the addition of 10 mL of a 0.9% NaC1, 0.2% 
dextrose solution in dH2O dropwise. RBCs were centrifuged (900 x G, 5 mins), the 
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supernatant removed and the cells resuspended in complete medium to a 5% 
haematocrit. Thereafter the culture was maintained under standard conditions. 
2.1.3 Routine culturing of P. falciparum 
Manipulations of live P. falciparum parasites were carried out in a class II 
microbiological safety cabinet located within a containment level 3 culture room. 
Parasites were cultured in RPMI 1640 medium (Irivitrogen) supplemented with 2 
mM glutamine, 25 mM glucose, 25 jig mL "I gentamicin, 2 mM NaOH and 10 % 
pooled normal human serum (Scottish National Blood Transfusion Service), referred 
to as "complete medium" from this point. Parasite cultures were incubated at 37 °C, 
5 %CO2. 
0+ human RBCs (Scottish National Blood Transfusion Service) were isolated from 
whole blood by passage through a leukocyte depletion filter. RBCs were washed 3 
times with RPMI 1640 (900 x G, 5 mins), resuspended at 50% haematocrit in 
complete medium and stored at 4 °C. 
Complete culture medium was changed daily by aspirating off the medium present in 
the culture flask and resuspending parasites in fresh complete medium at 5% 
haematocrit. Parasite cultures were diluted with uninfected RBCs as required to 
maintain a parasitaemia between 0.5% and 5 %. During routine culturing 
parasitaemia growth was monitored using Giemsa -stained thin blood smears. 
2.1.4 Giemsa staining 
Approximately 10 µL of the parasite culture at 5% haematocrit was pipetted onto a 
microscope slide and spread thinly with a clean microscope slide. Thin blood smears 
were air -dried, fixed with 100% methanol for 30 secs and air -dried again. Slides 
were stained with Giemsa solution in phosphate buffered saline (PBS), pH 7.2. For 
routine monitoring of cultures staining was for 15 minutes with a 20% Giemsa 
solution. For morphological analysis of parasites staining was for 45 minutes with a 
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10% Giemsa solution. In both cases slides were then rinsed with water, air -dried 
again and a drop of immersion oil added in order to view the slide under a light 
microscope (100 x objective). 
2.1.5 Laboratory isolates of P. falciparum 
Laboratory strains used were single genotype clonal parasite populations, which had 
been adapted to long -term culture in vitro. The Wellcome strain, originating from 
Western Africa (del Portillo et al., 1987), was used. 
2.1.6 Sorbitol synchronisation 
Sorbitol synchronisation kills mature parasite stages via osmotic lysis; parasites less 
than 20 hours old are impermeable to sorbitol and therefore remain intact post 
sorbitol treatment, along with uninfected RBCs (Lambros and Vanderberg, 1979). 
P. falciparum infected RBC cultures were pelleted by centrifugation (900 x G, 5 
mins), the supernatant discarded and the cell pellet resuspended to its original 
volume in aqueous 5% D- sorbitol (Sigma) for 5 minutes at RT. An excess of RPMI 
1640 was added and the cells were pelleted again (900 x G, 5 minutes), washed twice 
with RPMI 1640 and returned to standard culture conditions. 
2.1.7 Mycoplasma contamination detection 
As Mycoplasma are not visible on Giemsa- stained smears a polymerase chain 
reaction (PCR) detection kit (MycoSensor PCR assay kit, Stratagene) was employed 
to regularly check for mycoplasmal contamination. 100 µL aliquots of cell culture 
medium were heated at 95 °C for 5 minutes in a 1.5ml Eppendorf tube and then 
briefly centrifuged. 10 µL of StrataClean resin was added to each cell culture 
supernatant and the two components mixed together. The tube was spun briefly 
(1200 x G, 1 min) to pellet the resin and an aliquot of the supernatant taken for use as 
a template in the PCR reaction. The following were mixed in a clean PCR tube: 5 
µL 10 x Taq reaction buffer, 0.4 µL 20 mM dNTP mix, 2 µL Mycoplasma primer 
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mix, 4 µL internal control template, 0.5 µL Tag DNA polymerase, 5 µL test 
supernatant and 33.1 µL sterile dH2O. PCR program: 10 min at 94 °C, 35 x (30 s at 
94 °C, 60 s at 55 °C, 60s at 72 °C), followed by a 4 °C holding step. A positive 
control DNA sample and a negative control (dH2O) were included. PCR products 
were resolved on an agarose gel. The presence of a 500 base pair (bp) band 
indicated that the PCR reaction was successful whereas a band of 315 bp indicated 
that mycoplasmal contamination was present. 
2.2 Antibody purification and labelling 
2.2.1 Total IgG purification 
Immunoglobulin G (IgG) was purified on a Akta Prime chromatography system 
using 1 mL or 5 mL HiTrap Protein G columns (GE Healthcare). Protein G is a cell 
surface protein of group G Streptococci that binds to the Fc region of IgG with high 
affinity. Samples from which IgG was to be purified (human B cell 
supernatants /mouse hybridoma supernatants /immunised rabbit sera) were diluted 
with or dialysed into PBS, passed through a 0.22 µM filter, followed by application 
to the column. The column was washed with 20 mM sodium phosphate, pH 7, to 
remove unbound proteins before elution of the IgG with 0.1 M glycine -HCI, pH 2.7, 
into tubes containing 1 /5`h elution volume 1 M Tris -HCI, pH 9.0 neutralisation 
buffer. Eluted IgG fractions were dialysed extensively into PBS. The protein 
concentration of purified IgG was determined by measuring the absorbance at 280 
nm on a Nanodrop spectrophotometer (Labtech). Where required, purified IgG was 
concentrated using Amicon Ultra centrifugal filter units (50 -kDa cutoff; Millipore). 
2.2.2 Antibody labelling 
Purified antibodies were dialysed extensively into PBS and the concentration 
adjusted to 2 mg mL "'. Sodium bicarbonate buffer was added to the antibody 
solution at a final concentration of 0.1M. The labelling dye (Alexa Fluor 488 or 
Alexa Fluor 633) was reconstituted in DMSO at a concentration of 10 mg mL"'. 100 
µL of this reactive dye solution was added per 10 mg of antibody solution. The 
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reaction was then incubated in the dark for 1 h at RT with continuous stirring. Dye - 
conjugated antibody was separated from unreacted labelling reagent by gel filtration 
on a HiPrep 26/10 desalting column (GE healthcare) pre -equilibriated with 5 column 
volumes of PBS. The reaction mixture was loaded onto the column by injection and 
dye- conjugated antibody collected in 5 mL fractions. The protein concentration of 
dye- conjugated IgG was determined by measuring the absorbance at 280 nm on a 
Nanodrop spectrophotometer (Labtech). Where required, dye- conjugated IgG was 
concentrated using Amicon Ultra centrifugal filter units (50 -kDa cutoff; Millipore). 
2.3 Flow cytometry 
Samples were acquired using on a Becton Dickinson (BD) LSR II flow cytometer 
using BD FACS Diva software or on a BD FACScan flow cytometer using BD 
Cellquest software. Flow cytometry data were analysed with FlowJo version 9.4.11 
software (Tree Star, Inc.). A list of the fluorophores used to stain parasites and the 
flow cytometer settings used to detect them are displayed in Table 2.1. 
Fluorophore Excitation 
(nm) 





Hoescht 33342 343 483 355 450/40 BD LSR II 
DAPI 345 455 355 450/40 BD LSR II 
Coriphosphine 0 460 575 488 530/30 (green 
fluorescence) 
630 LP (red 
fluorescence) 
BD FACscan 
DCF 495 529 488 525/50 BD LSR II 
Alexa Fluor 488 499 519 488 525/50 BD LSR II 
DHR 505 534 488 525/50 BD LSR II 
JC -1 monomer 
form 
514 529 488 525/50 BD LSR Il 
JC -1 
J- aggregate form 
585 590 488 610/20 BD LSR II 
Alexa Fluor 633 632 648 633 660/20 BD LSR II 
Table 2.1 Flow cytometry dyes and flow cytometer settings 
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2.4 Immunofluorescence assay 
Immunofluorescence assay (IFA) is a technique used to visualise parasite antigens 
using an antigen -specific primary antibody followed by a secondary antibody 
conjugated to a fluorochrome. Serial dilutions of test samples were made in PBS 
containing 1% bovine serum albumin (BSA) and 0.01% sodium azide. A 25 µL 
volume of each dilution was added, in duplicate, to wells of a multispot slide 
containing acetone -fixed parasites and incubated at room temperature for 30 minutes. 
Antibody solutions were aspirated using a Pasteur pipette attached to a vacuum pump 
and slides washed three times with PBS. The slides were dried for 10 minutes at 50 
°C, then each spot was incubated with 15 µL fluorescein isothiocyanate (FITC)- 
conjugated anti -mouse IgG or FITC -conjugated anti -human IgG for 30 minutes at 
room temperature. Slides were washed a further 3 times in PBS, stained with 0.5 µg 
mL"1 4',6- diamidino -2- phenylindole (DAPI) /PBS and mounted in Citifluor (Citifluor 
Limited). Antibody- reactive parasites were viewed by FITC fluorescence and 
parasite nuclei by DAPI fluorescence with incident light of 390 -440 nm and 450 -490 
nm respectively, using a fluorescence microscope with a 100 x objective. 
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3 The isolation and characterisation of 
merozoite surface antigen- specific human 
monoclonal antibodies 
3.1 Introduction 
MSP -1 is a -- 195 kDa protein that ubiquitously covers the merozoite surface. 
Comparison of variant MSP -1 nucleotide sequences among different P. falciparum 
isolates has led to the demarcation of 17 distinct MSP -1 blocks characterised by their 
content of conserved, dimorphic or polymorphic sequences (Tanabe et al., 1987). 
Sequences of the highly polymorphic block 2 region of MSP -1 fall into one of three 
allelic types: K1, MAD20 and RO33, the first two of which vary greatly between 
isolates due to the extensive polymorphism of the tripeptide repeats present in each 
serotype (Cavanagh et al., 2004; Jiang et al., 2000; Miller et al., 1993). In contrast, 
the C- terminal MSP -119 region is highly conserved among isolates. Cysteine -rich 
MSP -119 is composed almost entirely of 2 tandemly repeated epidermal growth 
factor (EGF) -like domains (Blackman et al., 1991; Cooper, 1993). The structure of 
recombinant P. falciparum MSP -1 -19 has demonstrated that these EGF domains are 
arranged side -by -side (Morgan et al., 1999; Pizarro et al., 2003), however no 
function has been ascribed to these domains to date. 
MSP -2 is a highly polymorphic protein unique to P. falciparum that is GPI -anchored 
to the merozoite surface. In consists of a central variable region bounded by 
conserved N- terminal and C- terminal regions (Fenton et al., 1991; Smythe et al., 
1990). The central variable region is composed of sequence repeats interspersed 
with non -repetitive dimorphic sequences, which enable classification of all MSP -2 
sequences into one of the two allelic families, named after the P.falciparum isolates 
3D7 and FC27. 
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MSP -1 Block 2, MSP -119 and MSP -2 are thought to be targets of the protective 
immune response to blood stage P. falciparum infection. Several lines of evidence 
support this conclusion. Firstly, reduced risks of clinical malaria episodes are 
associated with serum IgG antibodies to MSP -1 Block 2 (Cavanagh et al., 2004; 
Conway et al., 2000; Polley et al., 2003), MSP -119 (al -Yaman et al., 1996; Egan et 
al., 1996; Riley et al., 1992) and MSP -2 (al -Yaman et al., 1995; Metzger et al., 2003; 
Polley et al., 2006). Secondly, data from animal models are supportive of these 
MSAs playing a role in protective immunity. Vaccination with recombinant MSP - 
119 (Ahlborg et al., 2002; Hirunpetcharat et al., 1997; Wipasa et al., 2002) or MSP -2 
(Lougovskoi et al., 1999; Saul et al., 1992) antigens and passive transfer of MSP -119 
antibodies confer protection in mouse models of malaria (Daly and Long, 1995). 
Aotus lemurinus griseimembra are protected against virulent P. falciparum challenge 
following the generation of MSP 1 Block 2- specific or MSP -119 -specific antibodies 
in response to MSP -1 Block 2 (Cavanagh et al., manuscript in preparation) or MSP - 
142 immunisation (Chang et al., 1996), respectively. A synthetic MSP -1 Block 2 
construct containing all possible tripeptide repeat combinations seen within naturally 
occurring Block 2 sequences in addition to the semi -conserved Block 1 has been 
constructed. This novel polymorphic parasite antigen is immunogenic in 
experimental animals (Cowan et al., 2011). Thirdly, polymorphism in the genes 
encoding MSP -1 Block 2 and MSP -2 is actively maintained by balancing selection, 
indicating that an effective host immune response is generated against each allelic 
form of these two antigens (Conway, 1997; Conway et al., 2000). 
MSP -1 and MSP -2 have received considerable attention as candidate vaccine 
antigens. However, to date no vaccine candidates based on these antigens have 
demonstrated high efficacy in human clinical trials, despite the strong 
aforementioned evidence that these antigens are targets of the protective immune 
response. Would identifying the critical epitopes targeted by these protective 
antibody responses, in addition to dissecting the functional mechanisms 
underpinning them, inform more effective vaccine design? 
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In vitro assays can be used to elucidate the mechanisms by which antibodies inhibit 
the growth of P. falciparum. Allele -specific growth inhibition by human anti -MSP -1 
Block 2 antibodies has been demonstrated in an ADCI assay (Galamo et al., 2009), 
however antibodies alone are not inhibitory, with the exception of a report of 
inhibitory activity with one mouse monoclonal antibody (Locher et al., 1996). 
Antibodies to MSP -119 are able to inhibit the growth of P. falciparum in vitro 
through a number of mechanisms, including agglutinating merozoites released from 
schizonts (Gilson et al., 2008), preventing PfSUB2 mediated secondary processing of 
MSP -1 (Blackman et al., 1994; Woehlbier et al., 2010) and interference with parasite 
growth post invasion (Bergmann -Leitner et al., 2009; Woehlbier et al., 2006). 
Human antibodies to MSP -2 are effective mediators of ADCI (Flueck et al., 2009; 
McCarthy et al., 2011). 
Antibodies used to investigate anti- parasite effector mechanisms have primarily been 
mouse mAbs produced using hybridoma technology or whole IgG /antigen -specific 
IgG purified from the sera of immunised experimental animals or malaria- exposed 
humans. The advantage of using mouse mAbs is that the functional activity of an 
antibody can be mapped to the precise epitope it recognises. The following example 
illustrates the importance of identifying the fine specificity of antibody responses in 
order to understand the mechanisms by which anti -parasite effector mechanisms 
operate. Naturally acquired antibodies to MSP -1 include antibodies that inhibit the 
secondary processing of MSP -1, termed processing -inhibitory antibodies, in addition 
to non -inhibitory antibodies which disrupt this processing -inhibitory activity, 
referred to as blocking antibodies (Guevara Patino et al., 1997; Nwuba et al., 2002). 
Therefore, eliciting Abs able to inhibit merozoite invasion through vaccination with 
MSP -119 would be a wasted effort if blocking antibodies were simultaneously 
acquired. Furthermore, the fine specificity of MSP -119 antibodies has been shown to 
be predictive of protection from P. falciparum infection and high density 
parasitaemia (Okech et al., 2004). 
Identifying the fine specificity of an antibody response additionally allows 
examination of the binding affinity of the antibody, which may in turn affect its 
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functional phenotype. For example, in one study affinity- enhancing mutations in 
anti -AMA1 shark Ig new antigen receptors resulted in an increase in their functional 
GIA activity (Henderson et al., 2007). Well- characterised mAbs with GIA activity 
are against conformational epitopes, whereas many of the antigenic targets of ADCI 
are predicted to be intrinsically unstructured proteins (IUPs). Intriguingly, given that 
one might expect antibody interactions with IUPs to be of a fairly low affinity, it has 
been hypothesised that affinity may explain the difference in functional activity of 
these antibodies (Anders et al., 2010). More recently, a study in a malaria endemic 
region of Tanzania found that the affinity of antibodies to AMA 1 and MSP -2 was 
associated with a lower risk of developing malaria during the follow -up period of the 
study, when subjects were parasite -positive at the beginning of the study (Reddy et 
al., 2012). The affinity of antibodies may also play a role in immune effector 
mechanisms to pregnancy- associated malaria. A recent study found that a higher 
proportion of high avidity anti- VAR2CSA antibodies were associated with a 
significantly lower risk of pregnant women developing placental malaria at the time 
of delivery (Tutterrow et al., 2012). 
Some of the protective effects of MSA- specific antibodies are mediated trough the 
interaction of their Fc region with the Fc receptors (FcR) of immune effector cells 
and/or complement. There are important differences between the FcR systems of 
mice and humans, for example there are no known murine counterparts of human 
FcyRIIa, FcyRIIc and FcyRIIlb (Ravetch and Lanier, 2000). Naturally acquired 
antibodies from malaria immune individuals belong to the cytophilic IgGI and IgG3 
subclasses (Ferreira et al., 1998) and these antibody isotypes can elicit phagocytic 
signals through binding of FcyRIIa. The inability of mouse antibodies to activate 
signalling through binding human FcyRIIa precludes full analysis of potential Fc- 
mediated antiparasite effects using mouse mAbs. This is illustrated by the fact that 
ADCI requires synergistic activation of FcyRIIa and FcyRIIIa (Jafarshad et al., 
2007). 
The problems of investigating Fc- mediated effects using mouse mAbs or IgG 
purified from the serum of immunised experimental animals can be overcome by 
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using human antibodies purified from the sera of malaria- exposed individuals. 
However, it can be ethically and logistically difficult to obtain antibodies in 
sufficient quantities for use in IgG -hungry in vitro inhibition assays via this method. 
In addition, these antibodies are finite in their supply and polyclonal, thus not 
allowing for the investigation of the effects of antibody -epitope fine specificity. 
Therefore full dissection of antibody functional activities is not possible using mouse 
mAbs and affinity -purified IgG from immunised animals or malaria- exposed humans 
due to the lack of information they provide about the fine specificity and Fc- 
mediated effects of the immune response. Human antibodies represent an ideal 
alternative with which to investigate anti -parasite effector mechanisms. Initial 
endeavours demonstrated that human mAbs could be generated by immortalising B 
cells with Epstein Barr -virus (EBV) ( Kozbor and Roder, 1981; Steinitz et al., 1977; 
Steinitz et al., 1979) or by fusing B cells with a suitable partner to produce 
hybridomas (Karpas et al., 2001; Kozbor et al., 1982). However, until recently these 
methods had a very low efficiency. 
An efficient method of human memory B cell immortalisation with Epstein -Barr 
virus (EBV) in the presence of irradiated mononuclear cells and a polyclonal 
memory B cell activator has been described (Traggiai et al., 2004). B cells 
producing antibodies of interest can be cloned from polyclonal B cell pools 
immortalised via this method and the desired mAbs isolated from the resultant 
supernatant. This method has been successfully employed to isolate VAR2CSA- 
specific human mAbs, which have proved useful in identifying functionally 
important epitopes within this CSA- binding molecule (Barfod et al., 2007; Barfod et 
al., 2010). This chapter describes efforts to isolate and characterise human mAbs 
specific to MSAs generated via this method. 
3.2 Aims of this chapter 
The research presented in this chapter aimed: 
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1. To isolate human MSA- specific mAbs from the EBV- transformed memory B 
cells of malaria exposed individuals. 
2. To determine the IgG subclass of MSA -specific human mAbs. 
3. To determine the light chain isotype of MSA -specific human mAbs. 
4. To identify the epitopes recognised by these MSA -specific human mAbs. 
5. To establish the affinity of these MSA -specific human mAbs. 
6. To investigate the functional activities of these human mAbs in in vitro growth 
inhibition assays such as GIA and ADCI and how these might relate to 
characteristics of the mAbs established under aims 2 -5. 
3.3 Materials and methods 
3.3.1 Media 
The following media were used for culture and manipulation of peripheral blood 
mononuclear cells (PBMCs): 
B cell medium: RPMI medium 1640 - L- Glutamine supplemented with 10% ultra 
low IgG fetal bovine serum ( Invitrogen), 4 mM L- Glutamine (Invitrogen) and 1% 
penicillin -streptomycin (Invitrogen). 
CPGT medium: RPMI medium 1640 - L- Glutamine supplemented with 10% ultra 
low IgG fetal bovine serum (Invitrogen), 4 mM L- Glutamine ( Invitrogen), 1% 
penicillin streptomycin (Invitrogen), 323.83 nM CpG oligonucleotide (made to order, 
Oligo Factory) and 374 nM holotransferrin from human plasma (616424, Millipore). 
3.3.2 CpG Oligonucleotide 
A CpG phosphorothioate oligodeoxynucleotide (ODN) was synthesised by Oligo 
Factory. The sequence of the ODN is 5'TCG TCG TTT TGT CGT TTT GTC 
GTT3' (Hartmann and Krieg, 2000). The lyophilised ODN was reconstituted to 5 
mg m1 ;1 in sterile dH2O, heated at 65 °C for 5 minutes and placed at 20 °C for long- 
term storage. 
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3.3.3 PBMC isolation from whole blood 
40 mL of venous blood was collected in vacuettes (Greiner bio -one). Whole blood 
was diluted with 1 x PBS at a ratio 1:2 and aliquots of 20 mL of this mixture added 
to leucosep tubes (Greiner Bio -One) pre -filled with separation medium (Ficoll- 
Paque). Leucosep tubes were centrifuged at 800 x G for 15 minutes, which results in 
the separation of whole blood into different fractions. As much as possible of the top 
layer (consisting of plasma) was removed without . disrupting the layer beneath it. 
The cell fraction below this, containing PBMCs, was harvested and transferred to a 
50 mL falcon tube. The PBMC layer was resuspended in 20 mL of B cell medium 
and centrifuged at 300 x G for 10 minutes. The supernatant was taken off and the 
cells washed once more with 20 mL B cell medium (769 g for 10 minutes). 
3.3.4 Irradiation of isolated PBMCs 
Isolated PBMCs were resuspended in B cell medium at a concentration of 1 x 106 
cells /mL and irradiated with 50 gray of gamma -radiation. Irradiated cells were spun 
down at 769 g for 5 minutes and washed twice with B cell medium. Following this, 
irradiated PBMCs were resuspended in CPGT medium at the required concentration. 
3.3.5 EBV stock preparation 
B95 -8 is a marmoset EBV -transformed leukocyte cell line that produces infectious 
(transforming) EBV (Miller et al., 1972). Exponentially growing B95 -8 cells were 
diluted to 0.5 x 106 cells mL "' in B cell medium and incubated with 100 nM phorbol 
myristate acetate (PMA) for 2 hours at 37 °C. Cells were washed 3 times in Hanks' 
balanced salt solution (Invitrogen) then resuspended in B cell medium at a 
concentration of 1 x 106 cells mL-I. The cells were incubated at 37 °C, 5% CO2 for 
48 hours. Following this, the B95 -8 cells were centrifuged (500 x G, 8 minutes) and 
the EBV- containing supernatant harvested. Harvested supernatants were passed 
through a 0.22 µM membrane and then maintained at -80 °C for long term storage. 
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3.3.6 B cell immortalisation 
PBMCs were maintained in liquid nitrogen for long -term storage before use. 
PBMCs were placed in a 37 °C incubator until fully thawed and then transferred to a 
15 mL falcon tube. 5 mL of B cell medium was added drop -wise with mixing to the 
thawed PBMCs. The PBMCs were centrifuged at 500 x G for 8 minutes and then 
washed a further two times with B cell medium. 
B cell purifications were carried out using Miltenyi Biotec CD22 microbeads and 
MS columns according to the manufacturer's instructions. A separation filter was 
used when applying PBMCs to the MS column in order to prevent cell clumping. 
Eluted cells were centrifuged at 769 x G for 8 minutes and resuspended at a 
concentration of 1 x 105 cells mL-' in CPGT medium. An equal volume of EBV 
supernatant was added to this cell suspension and transfection allowed to occur over 
a 5 hour incubation at 37 °C, 5% CO2. Following this, B cells were diluted in CPGT 
medium to a concentration of 0.5 x 104 cells mL-I. Then, 50 [IL of this cell 
suspension was dispensed into the wells of a round- bottomed microtitre plate 
(Sigma -aldrich). An equal volume (50 µL) of irradiated PBMCs at a concentration 
of 1 x 106 cells mL-' in CPGT medium were dispensed into each well. Plates were 
incubated at 37 °C, 5% COZ. 
3.3.7 Cloning of polyclonal immortalised B cell pools 
Polyclonal B cell pools of interest were cloned by limiting dilution and/or single cell 
sorting. 
3.3.7.1 Cloning by limiting dilution 
PBMCs were isolated from venous blood and irradiated as described above. The 
number of live cells present was determined by trypan blue exclusion. Each 
polyclonal B cell line was diluted with CPGT medium to two different densities; 20 
live cells mL-' and 80 live cells mL-1. 25 pL of the irradiated PBMC suspension was 
dispensed into the wells of a flat -bottomed 384 -well microtitre plate, after which 25 
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µL of the 20 cells mL "' suspension of B cells was added to each plate well. 25 µL of 
the irradiated PBMC suspension was dispensed in the wells of another flat -bottomed 
384 -well microtitre plate, to which 25 µL of the 80 cells mL "' suspension of B cells 
was added to each plate well. 
3.3.7.2 Cloning by single cell sorting sorting 
PBMCs were isolated from venous blood and irradiated as described above. 
Irradiated PBMCs were resuspended in CPGT medium at a concentration of 0.5 x 
106 cells mU'. 50 µL of the irradiated PBMC suspension was dispensed into the 
wells of a flat -bottomed 384 -well microtitre plate. Polyclonal B cell lines were 
washed with RPMI 1640 and resuspended in - 3 mL RPMI at a density of 1 x 105 
cells mL -I. The B cells were then sorted on a FACSAria cell sorter such that one B 
cell was deposited into each well of the 384 -well microtitre plate containing 
irradiated PBMCs. 
3.3.7.3 Cloning by fluorescence- activated cell sorting 
1 x 106 EBV- transformed B cells were centrifuged (500 x G, 8 minutes) and 
resuspended in 100 µL FACs buffer (1% BSA, 1 x PBS) containing 1.85 µg mL"' of 
Alexa fluor 663 -labeled recombinant MSP -1 Block 2 RO33 antigen. Cells were 
stained in the dark for 30 minutes and then washed extensively with FACs buffer 
prior to being resuspended in 300 µL FACs buffer. Stained B cells were run through 
a FACSAria cell sorter. Live B cells were gated on FSC and SSC. A second gate 
was applied to gated live B cells. This second gate was of Alexa fluor- MSP -1 Block 
2 RO33 positive B cells and was defined based on Alexa Fluor 633 -staining of MSP - 
1 Block 2 RO33- specific EBV -transformed B cells compared to Alexa Fluor 633 - 
staining of a stained negative control, namely EBV -transformed B cells from a 
malaria naive individual which did not produce MSP -1 Block 2 RO33 -specific 
antibodies (confirmed by ELISA). B cells within this gate were then sorted such that 
one B cell was deposited into each well of the 384 -well microtitre plate containing 
irradiated PBMCs (as described above). 
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3.3.7.4 Media supplementation 
The plates were incubated at 37 °C, 5% CO2. 7 and 14 days after cloning 15 µL of 
CPGT medium were added to plate wells. 21 days after cloning plates were 
examined by light microscopy for the presence of growing clones. 
3.3.7.5 Other supporting media 
For some cloning procedures immortalised B cells were cloned onto supportive 
media other than PBMCs. These were: 
i) irradiated Jurkat cells, an IL -2 producing T lymphocyte cell line 
ii) THP -1 cells that had been pre -incubated with 50 ng p.L "' PMA for 24 hours, prior 
to being washed and resuspended in CPGT medium 
iii) THP -1 cells the had been pre -incubated with 5 µg /mL PHA for 24 hours, prior to 
being washed and resuspended in CPGT medium 
iv) Jurkat cell supernatant 
v) Mixed lymphocyte reaction supernatant 
In all cases 50 iaL of supporting medium (if containing cells these were at a 
concentration of 0.5 x 106 cells mL"') were placed into wells of a 384 -well plate prior 
to the addition of B cells as described above. To all wells 2- Mercaptoethanol was 
added at a final concentration of 50 nM. 
3.3.8 Routine culturing of immortalised B cells 
Manipulations of immortalised B cells were carried out in a class II microbiological 
safety cabinet located within a containment level 2 culture room. Immortalised B 
cells were cultured in CPGT medium and incubated at 37 °C, 5% CO2. CPGT 
medium was changed twice weekly (or more frequently if required) by pelleting cells 
by centrifugation, aspirating off the supernatant and resuspending the cells in fresh 
CPGT medium. Cells were maintained at a density between 1 x 105 and 1x106 cells 
ml."' in T -25 or T -75 cell culture flasks or at a density of -3 x 107 cells /mL when 
maintained in CELLine 1000 two- compartment bioreactors (Integra Biosciences). 
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3.3.9 Enzyme -linked immunosorbant assay (ELISA) protocols 
The following buffers were used in the ELISA protocols detailed below: 
Coating buffer: 15 mM Na2CO3, 35 mM NaHCO3, pH 9.3 
Washing buffer: PBS supplemented with 0.05% Tween -20 
Blocking buffer: PBS supplemented with 0.05% w/v Tween-20 and 1% w/v 
skimmed milk powder 
Development buffer: 0.04 mg mL-I 0-phenylenediamine, 0.012% H202, 24.5mM 
citric acid monohydrate and 52 mM Na2HPO4, pH 5.0 
3.3.9.1 B cell supernatant ELISA screening 
All test B cell supernatants were added to duplicate wells on the same plate and on 
each plate a known positive and a known negative control were added in duplicate. 
96 -well microtitre plates (Greiner Bio One) were coated with 0.5 µg /mL recombinant 
antigen in coating buffer and incubated at 4 °C overnight. Plates were washed 3 
times with washing buffer and then blocked for 5 hours at RT with 100 µL /well 
blocking buffer. Plates were washed 3 times with washing buffer prior to the 
addition of 100 µL B cell supernatant, which had previously been diluted 1/2 with 
blocking buffer. Plates were incubated overnight at 4 °C. Plates were washed 3 
times with washing buffer before incubation with 100 µL /well horseradish 
peroxidase (HRP)- conjugated rabbit anti -human IgG (Dako Limited, UK) diluted 
1/6000 in blocking buffer for 3 hours at RT. Plates were washed 3 times with 
washing buffer. The reaction was developed by the addition of 10011L /well substrate 
buffer. Plates were incubated in the dark for 10 -15 minutes at RT. The reaction was 
stopped by the addition of 25 µL 2M H2SO4 per well. The optical density was read 
at 492 nm on a Labsystems Multiskan Ascent microtitre plate reader. 
3.3.9.2 Serum ELISA screening 
The ELISA method was the same as that described for B cell supernatant screening 
above, with the exception that the primary antibody source for the ELISA consisted 
of serum samples, diluted 1/500 in blocking buffer, not B cell supernatants. 
39 
3.3.9.3 Light chain isotype ELISA 
The ELISA method used was the same as that employed for the screening of B cell 
supernatants, with the following modifications. Plates were coated with 0.5 µg mL "' 
MSP -1 Block 2 GST fusion protein of the RO33 serotype. Secondary antibodies 
used were HRP- conjugated sheep anti -human kappa light chain (AP015, The 
Binding Site, UK) and HRP- conjugated sheep anti -human lambda light chain 
(AP017, The Binding Site, UK). 
3.3.9.4 IgG subclass ELISA 
The method used was the same as that employed for the screening of B cell 
supernatants, with the following modifications. Plates were coated with 0.5 µg mL-' 
MSP -1 Block 2 GST fusion protein of the RO33 serotype. Secondary antibodies 
used were HRP- conjugated polyclonal sheep anti -human IgG1 (ÁP006, The Binding 
Site, UK) and HRP- conjugated polyclonal sheep anti -human IgG3 (AP008, The 
Binding Site, UK). 
3.3.9.5 ELISA with biotinylated peptides 
A set of 131 biotinylated 12 -mer peptides spanning all possible linear epitopes 
located within the MSP -1 hybrid were synthesised by Mimotopes Proprietary 
Limited. Wells of ELISA plates (Immulon 4 HBX, Thermo Dynex) were coated 
with 100 µL 5 gg mL"' streptavidin and incubated at 37 °C until dry. Plates were 
washed 3 times in washing buffer and then blocked for 3 hours at RT with 200 µL 
per well of 1% (w /v) ByCoA (Croda Healthcare) dissolved in PBS. Following this, 
plates were washed 3 times in washing buffer and 300 ng of each peptide dispensed 
in duplicate into plate wells. Plates were incubated at 4 °C overnight. Plates were 
washed 3 times with washing buffer and 100 µL B cell supernatants, diluted 1/2 in 
PBS supplemented with 1% (w /v) ByCoA, were dispensed in duplicate into plate 
wells. Plates were incubated overnight at 4 °C. Plates were washed 3 times with 
washing buffer and then incubated with 100 µL /well HRP- conjugated rabbit anti- 
human IgG (Dako Limited) diluted 1/6000 in PBS supplemented with 1% (w /v) 
ByCoA for 3 hours at RT. Plates were then washed 3 times with wash buffer and 
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100 µL development buffer added to each well. Plates were incubated for 10 -15 
minutes in the dark at RT, after which the reaction was stopped by the addition of 25 
µL 2M H2SO4. The optical density was read at 492 nm on a Labsystems Multiskan 
Ascent microtitre plate reader. 
3.3.10 Expression and purification of recombinant merozoite 
suface antigens 
Plasmid pGEX constructs encoding GST, GST MSP -1 block 2 fusion proteins of the 
3D7, Palo Alto, MAD20, Wellcome, and RO33 isolates, GST MSP -2 fusion proteins 
of the Dd2 and CH150 /9 isolates and a GST MSP -1 -19 fusion protein were provided 
by Dr. David Cavanagh (Cavanagh and McBride, 1997; Polley et al., 2006). 2 
µL of each expression plasmid was transformed into chemically competent XL -1 E. 
coli (Stratagene) and plated onto LB agar plates containing 100 µg mL-' ampicillin. 
Starter cultures of 10 mL LB broth containing 100 jig mL -' ampicillin were 
inoculated with a single colony from a freshly streaked agar plate and incubated with 
shaking at 37 °C overnight. Conical flasks containing 1 L LB broth and 100 jig mL-' 
ampicillin were inoculated with 10 mL starter culture and incubated at 37oC with 
shaking until the optical density had reached 0.6 AU cm-I. At this point protein 
expression was induced by the addition of 1 mM isopropyl ß-D-1 - 
thiogalactopyranoside (IPTG). Cultures were incubated overnight at 30 °C with 
shaking, after which cells were centrifuged at 5000 x G and 4 °C for 10 minutes. The 
supernatant was poured off and cell pellets resuspended in 30 mL 50 mM Tris, 150 
mM NaC1 buffer, pH 8. The resuspended cells were then lysed by sonication and 1 U 
mL -' DNAse I was added. The samples were centrifuged at 500 x G for 20 minutes 
and the lysates collected in a 50 mL falcon tube. Clarified lysates were passed 
through a 0.22 µM filter. GST or GST fusion proteins were purified on an Akta 
Prime chromatography system, using 1mL GSTrap HP columns (GE Healthcare). 
The GSTrap HP column was pre -equilibriated with 5 column volumes of PBS and 
the lysate applied to the column. The column was washed with 5 column volumes of 
PBS and column -bound GST or GST fusion proteins eluted with 'elution buffer (50 
mM Tris pH8.0, 10mM reduced glutathione). Collected fractions were analysed by 
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BCA assay and SDS -PAGE for protein concentration and purity, respectively. 
Eluted proteins were dialysed extensively against PBS and then stored at -20 °C until 
further use. 
3.4 Results 
3.4.1 Screening and cloning of B cell immortalisations carried 
out at CMP 
An efficient method of human memory B cell immortalisation via EBV 
transformation in the presence of irradiated mononuclear cells and a polyclonal 
memory B cell activator has been developed (Traggiai et al., 2004). Here, this 
method was employed to immortalise CD22+ memory B cells isolated from the 
peripheral blood of malaria- exposed individuals. Pools of human B cells 
immortalised via this method were screened for reactivity in ELISA with the 
following recombinant GST fusion proteins: MSP -1 Block 2 antigens of 5 different 
serotypes (3D7, Palo Alto, MAD20, Wellcome and RO33), MSP -2 antigens of 2 
different serotypes (Dd2 and CH150 /9) and MSP -119. Additionally, all immortalised 
B cell pools were screened against recombinant GST alone in order to control for any 
anti -GST responses. Positive pools reactive with recombinant MSPs but not GST 
alone were cloned by limiting dilution and/or FACS sorting. Any resultant B cell 
clones were tested for reactivity against the relevant recombinant MSP by ELISA. 
Initially, two B cell immortalisation pools (DLB23 and DLB01) carried out by 
members of the human mAbs team at the Centre for Medical Parasitology (CMP), 
University of Copenhagen, were screened for reactivity with the aforementioned 
MSPs. Thirteen positive polyclonal pools from donor DLB23 were cloned by 
limiting dilution. Of these thirteen polyclonal lines, two lines generated clones with 
positive reactivity to MSPs. One of these clones, DLB23 -5A7 remained positive and 
was expanded. Attempts to re -clone the other polyclonal pools originally identified 
as positive were not successful, as these pools were no longer positive by the time 
the results of the first attempts at cloning were known. 
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Initial screening of the second immortalisation (donor DLB01) identified 26 
polyclonal wells with positive reactivity to the recombinant MSPs. Upon re- 
screening one week later, 7 polyclonal lines were still positive, of which 4 were 
successfully expanded, frozen down in liquid nitrogen and shipped to Edinburgh to 
be cloned. However, upon thawing and expansion in Edinburgh all 4 lines no longer 
gave positive reactions by ELISA. Table 3.1 summarises the main results of all B 
cell immortalisations carried out. 
3.4.2 B cell immortalisations carried out in Edinburgh 
The reagents and technology required to carry B cell immortalisations in Edinburgh 
were acquired. PBMC samples collected during a study in the Merehwa district of 
Zimbabwe were kindly provided by Dr. Francisca Mutapi. In the first instance, an 
immortalisation was carried out on CD22+ B cells isolated from the PBMCs of 
donor Zm7054 whose serum had tested positive in ELISA against MSP -1 -19, MSP - 
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M Yes 26 0 - - - 
Zm_7054 Magaya, 
Zimbabwe 
F Yes 11 0 - - - 
Dm Cameroon M Yes 4 4 LD 0 - 
Zm_684 Mutoko, 
Zimbabwe 
M Yes 56 4 Cell 
sorting 




M Yes 0 - - - - 
Zm_1074 Mutoko, 
Zimbabwe 
F No - - - - - 




Table 3.1 Summary of B cell immortalisations carried out. 
Details of PBMC donors used in, and outcomes during the process of, B cell 
immortalisations. LD stands for limiting dilution. 
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polyclonal pools as positive against recombinant MSPs, none of these pools 
remained positive after lines were expanded and cloned. 
Next, the serum of a visiting Ghanaian scientist who had recent exposure to malaria 
was tested by ELISA for reactivity with MSPs. This serum showed positive 
reactivity against MSP -2 (Dd2), MSP -2 (CH150 /9) and MSP -119 (Figure 3.1). Post 
immortalisation, 4 polyclonal B cell lines were identified as positive against 
recombinant MSPs in ELISA and cloned by FACs sorting. None of these lines 
generated positive clones. 
3.4.3 Screening of PBMC samples from malaria exposed 
individuals 
The serum of PBMC donors from the Murehwa district had previously been tested 
for reactivity against MSP -2 (Dd2), MSP -2 (CH150/9) and MSP -119 by members of 
the Mutapi group (IIIR). Positive reactivities against these antigens were low, which 
made it difficult to select PBMC donors likely to yield MSP -specific mAb producing 
B cells when immortalised. In order to increase the chance of isolating B cell clones 
producing MSA- specific antibodies, a set of serum samples from malaria exposed 
PBMC donors living in the Mutoko district of Zimbabwe, an area of higher malaria 
endemicity than the Murehwa district, were obtained. In total 41 serum samples 
were screened for reactivity of IgG antibodies with GST and the following GST 
fusion proteins in ELISA: 3D7 Block 2, Palo Alto Block 2, MAD20 Block 2, 
Wellcome Block 2, RO33 Block 2, MSP -2 (Dd2), MSP -2 (CH150 /9) and MSP -119. 
One or more serum samples showed positive reactivity against MSP -2 (Dd2), MSP -2 
(CH150 /9), MSP -1 -19, Palo Alto Block 2, MAD20 Block 2 and RO33 Block 2 
(Figure 3.2). Generally, higher reactivity was observed against MSP -119 and MSP -2 
than MSP -1 Block 2. Three donors whose serum displayed high reactivity to three 
or more antigens were prioritised for immortalisation; donors Zm 627, Zm_684 and 



















3D7 Block 2 Palo Alto Black 2 MAD20 Block 2 Wellcome Block 2 
R033Block2 MSP1Hydid GST MSP2(CH150) 
MSP2 (Dd2) MSP1-19 AMA1 (FVO) AMA1 (307) 
Figure 3.1 Screening of serum sample from donor Dm for IgG reactivity 
against recombinant MSP -1, MSP -2 and AMA -1 antigens. 
The specific antigens used are denoted in the figure legend. Circles indicate the 
mean reactivity of two duplicate wells of a sample against a given antigen in OD 
units measured at 492 nm. As a positive and negative control, respectively, each 
recombinant antigen was reacted with human immune serum known to react 
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Figure 3.2 Reactivity of serum IgG antibodies from malaria exposed 
individuals with recombinant MSP -1 and MSP -2 antigens. 
Circles indicate the reactivity of serum IgG antibodies from 41 malaria exposed 
individuals from the Mutoko region of Zimbabwe with the following recombinant GST 
fusion proteins; 3D7 Block 2 (pink), Palo Alto Block 2 (yellow), MAD20 Block 2 
(orange), Wellcome Block 2 (purple), RO33 Block 2 (black), MSP -2 (CH150/9) (dark 
blue), MSP -2 (Dd2) (red), MSP -1 -19 (green), in addition to GST alone (light blue). 
Each data point indicates the reactivity of serum IgG from a single individual 
against a single recombinant protein, shown as the mean of two duplicate wells in 










Figure 3.3 Reactivity of serum IgG antibodies from donor Ka with a 
recombinant antigen cocktail. 
Serum from donor Ka was tested at the dilutions indicated on the x -axis for reactivity 
of IgG antibodies with a recombinant antigen cocktail. The antigen cocktail 
contained the following recombinant antigens in equal concentrations; 3D7 Block 2, 
Palo Alto Block 2, MAD20 Block 2, Wellcome Block 2, R033 Block 2, MSP -2 
(CH150/9), MSP -2 (Dd2), MSP -1 -19 and MSP3.3. Positive and negative controls 
were a pool of hyperimmune sera and pooled European sera, respectively. For 
each sample, data points indicate duplicate ODs at 492 nm from individual wells. 
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3.4.5 Further B cell immortalisations 
B cell immortalisations were carried out on isolated CD22+ memory B cells from 
Mutoko donors Zm 627, Zm 684 and Zm 1074. Proliferation of B cells was not 
observed after EBV transformation of B cells from donor Zm 1074, implying that 
the transformation process had not been successful. Memory B cells from donor 
Zm 627 were successfully transformed but no positive polyclonal wells were 
detected when screened by ELISA. Immortalisation Zm_684 yielded a polyclonal 
line from which generated positive clones. 
Serum from another malaria- exposed visiting scientist was screened by ELISA for 
IgG antibodies with reactivity to a pool of recombinant MSPs (Figure 3.3). This 
serum was highly reactive in this ELISA, however, of 3 positive polyclonal lines 
cloned, none produced reactive clones. 
3.4.5 Clones 
At the end of this process, two of the polyclonal lines that had been cloned, one from 
donor DLB23 (DLB23 -5A7) and one from donor Zm_684 (684 -8B6), had resulted in 
a series of clones that were reactive with Block 2 RO33 in ELISA (Figure 3.4). 
Several clones from each original polyclonal line were expanded in culture. 
Whereas clones from 684 -8B6 expanded rapidly, clones from DLB23 -5A7 could not 
be expanded beyond 2 wells of a 96 -well plate. 
In total the polyclonal line DLB23 -5A7 was cloned four times. The problem was not 
isolating clones of interest but getting them to grow once they had been single -cell 
sorted. Therefore, cloning onto a variety of different supportive media was trialled 
with the aim of encouraging growth of clones producing the antibody of interest. 
These support media were: irradiated PBMCs from a EBV negative donor, irradiated 
Jurkat cells, irradiated PMA- activated THP 1 cells, irradiated PHA- activated THP 1 
cells, Jurkat cell supernatants and supernatants from human mixed lymphocyte 
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Figure 3.4 ELISA reactivity of IgG antibodies from B cell clone supernatants 
with MSP -1 Block 2 (RO33 serotype). 
B cell supernatants from clones isolated from the polyclonal lines DLB23 -5A7 and 
684 -8B6 were reacted with recombinant RO33 Block 2 in ELISA. Positive and 
negative control sera are indicated by the + and - signs, respectively. Data points 
represent duplicate optical densities from individual wells. 
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cells, as it has been reported that this helps single hybridoma cells grow to a self - 
sustaining population density (Lane et al., 1988). 
In order to increase the probability of isolating and propagating clones producing the 
mAb of interest, B cells from the polyclonal pool DLB23 -5A7 were stained with 
Alexa Fluor 633 -labelled MSP -1 Block 2 RO33 and only Alexa Fluor 633- positive B 
cells were cloned (Figure 3.5). Despite this effort no B cell clonal populations grew 
to a density that allowed culture volumes beyond the volume of single wells of a 96- 
well plate. 
In an attempt to circumvent this problem, the polyclonal line DLB23 -5A7 was grown 
in a two- compartment bioreactor with the aim that if a large quantity of antibody -rich 
B cell supernatant be collected, the mAb of interest could be purified on an antigen - 
specific column by affinity chromatography. A clonal line generated from 684 -8B6, 
684 -8B6 -3, was also expanded and grown in another two- compartment bioreactor. 
Total IgG was purified from 684 -8B6 -3 supernatant. This IgG did not react with 
parasites in IFA and was only weakly reactive in ELISA. Only small amounts of 
total IgG were purified from polyclonal DLB23 -5A7 supernatant. 
3.4.6 IgG subclass 
The antibody subclasses associated with protection to MSAs are IgGI and IgG3 
(Bouharoun -Tayoun and Druilhe, 1992; Cavanagh et al., 2004). Therefore, I. tested 
whether MSP- reactive Abs from the DLB23 -5A7 and 684 -8B6 lines were of the 
IgGI or IgG3 subclass by ELISA. B cell supernatants from each of three DLB23 - 
5A7 and 684 -8B6 lines were bound to immobilised recombinant Block 2 RO33 
antigen on ELISA plates in duplicate. Anti -human total IgG, anti -human IgGI and 
anti -human IgG3 secondary conjugated antibodies were reacted with antibodies from 
these B cell supernatants. For all three DLB23 -5A7 clones, the anti -human IgG3 
antibody gave significantly higher reactivity than anti -human IgG I. For all three 
684 -8B6 lines, the anti -human IgG 1 antibody gave significantly higher reactivity 
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Figure 3.5 Fluorescence- activated cell sorting of polyclonal pool DLB23 -5A7. 
EBV- transformed B cells from polyclonal pool DLB23 -5A7 (panel A) and from a non - 
malaria exposed European donor were stained with Alexa Fluor 633- labelled 
recombinant MSP -1 Block 2 R033 (panel B). First, healthy cells were gated on 
FSC -A and SSC -A (gate "intact "). Following this, a second gate, P1, was applied 
based on Alexa Fluor 633 (APC -A channel) Fluorescence. P1 -gated cells from 
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Figure 3.6 Antibody subclass determination of mAbs DLB23 -5A7 and 684 -8B6. 
ELISA plates were coated with GST Block 2 R033 antigen and B cell supernatants 
from each of 3 clonal DLB23 -5A7 and 684 -8B6 lines added. The reactivity of anti- 
human total IgG (black circles), anti -human IgG1 (red circles) and anti -human IgG3 
(blue circles) antibodies with these B cell supernatants is shown. Data points 
indicate duplicate ODs at 492 nm from individual wells. 
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3.4.7 Light chain isotype 
The light chain isotype of mAbs from DLB23 -5A7 and 684 -8B6 were determined by 
ELISA. B cell supernatants from an MSP -1 RO33 block 2 reactive line of DLB23 - 
5A7 and a similarly reactive line from 684 -8B6 were bound to immobilised 
recombinant Block 2 RO33 antigen on an ELISA plate in duplicate. Anti -human 
kappa light chain and anti -human lambda light chain antibodies were reacted with 
these B cell supernatants. For both DLB23 -5A7 and 684 -8B6 clones, the anti -human 
lambda light chain antibody gave significantly higher reactivity than anti -human 
kappa light chain antibody (Figure 3.7). 
3.4.8 Epitope mapping 
A peptide array consisting of 131 N- terminal biotinylated dodecapeptides with a 1 -2 
residue overlaps, covering all major linear epitopes in the Block 2 region of MSP -1, 
were used to fine -scale map the epitopes recognised by mAbs DLB23 -5A7 and 684 - 
8B6. The array contained all known repetitive sequences from the K1 and MAD20 
serotypes, all non -repetitive regions from the K1, MAD20 and RO33 serotypes, and 
peptides spanning the junctions between the individual Block 2 serotypes. Given 
that MSP -1 Block 2 is an intrinsically unstructured protein and thus unfolded 
(nonglobular) in solution, one would predict its epitopes to be linear. 
Consistent with the specificities of these mAbs determined by ELISA using 
recombinant Block 2 antigens, both mAbs reacted strongly with a set of peptides 
within the Block 2 RO33 serotype but did not react with peptides covering the K1 or 
MAD20 serotypes. These peptide reactivities were used to define a linear sequence 
containing all or the major components of the epitopes recognised by these mAbs. 
MAb 684 -8B6 recognised the sequence KDGANTQV, located at the extreme N- 
terminus of Block 2 RO33, where as mAb DLB23 -5A7 recognised the adjacent but 






















Figure 3.7 Antibody light chain isotype determination of mAbs DLB23 -5A7 and 
684 -8B6. 
ELISA plates were coated with GST Block 2 R033 antigen and B cell supernatants 
from DLB23 -5A7 or 684 -8B6 added to duplicate wells. The reactivity of anti -human 
total IgG, anti -human kappa light chain and anti -human lambda light chain 
antibodies with these B cell supernatants is displayed. Each bar indicates the mean 



















GpSQQpOpS+0Gp?4, pl-QpOpJ 05p++QQGp4JQ perC#Gp. Opp-evQ50055+V,k5G'sp1Cq 
Residue 
Figure 3.8 Recognition of peptide epitopes within MSP -1 Block 2 of the R033 
serotype by mAbs DLB23 -5A7 and 684 -8B6. 
Each bar indicates the reactivity of the mAb indicated against that amino acid 
residue, calculated as the sum of the mean ODs of duplicate wells tested against 
peptides containing that reside /number of peptides containing that residue. 
Residues in green are from the K1/R033 junction. All other resides are from the 
MSP -1 Block 2 R033 sequence with minimal epitopes displayed in red. 
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Primer Sequence 
Heavy chain sense 1 5' CCATGGGACTGGACCTGGAGSDTC 
Heavy chain sense 2 5' CCATGGAARCAYCTGTGGTTCTTY 
Heavy chain sense 3 5' CCATGGGACAYACTTTGYTMCACR 
Heavy chain sense 4 5' CCATGGGGGTCAACCGCCATCCTC 
Heavy chain sense 5 5' CCATGGTCTGTCTCCTTCCTCATC 
Heavy chain sense 6 5' CCATGGSARYYKKKVCTBHGCTGG 
Heavy chain anti -sense 5' CTCGAGTCATTTACCCGGAGACAGGGA 
Lambda sense 5' CATCATGTTTAAACAACATGRCCTGSDYYNYKCTNYKBCT 
Lambda anti -sense 5' ATCGATTCASGARCATTCYGYAGGGGCMACTGTCTT 
Table 3.2 Primers designed to generate human mAb heavy and light chain 
cDNA. 
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3.4.9 Cloning Ig chains 
Obtaining the two MSP -1 reactive mAbs via affinity purification from Integra vessel 
supernatants had not been successful. An alternative method of generating these 
mAbs would be to clone the heavy- and light- chain -encoding genes into an 
expression vector, which could then be transfected into a mammalian cell culture and 
the mAbs purified from transfected cell supernatants. In order to achieve this, sets of 
primers designed to amplify any human IgG heavy chain -encoding gene and any IgG 
lambda light chain -encoding gene were designed. These primers are listed in Table 
3.2. All primers were designed by aligning known human heavy and light chain IgG 
sequences (Robinson et al., 2012) with the exception of the sequence of the heavy 
chain IgG antisense primer which was obtained from a paper published by Mclean 
and colleagues (McLean et al., 2000). The primers were designed so that the IgG 
heavy- and light- chain -encoding genes could be cloned into the pTandem -1 vector. 
3.5 Discussion 
In 2004 research by Traggiai and colleagues demonstrated that the efficacy of B cell 
EBV transformation could be substantially improved by providing innate immune 
stimulation in the form of a toll -like receptor (TLR) 9 agonist (Traggiai et al., 2004). 
This technology has been utilised to define the structural and/or functional 
characteristics of human antibodies generated in response to a multitude of 
pathogens, a non -exhaustive list of which includes: P. falciparum (Barfod et al., 
2007; Barfod et al., 2010), Norovirus G11.4 (Lindesmith et al., 2012), Human 
Immunodeficiency Virus 1 (HIV -1) (Corti et al., 2010), Cytomegalovirus (Macagno 
et al., 2010) and Severe Acute Respiratory Syndrome Coronavirus (SARS -CoV) 
(Traggiai et al., 2004). The aim of this chapter was to generate immortalised clonal 
B cell lines producing MSP -specific mAbs to investigate the functional activities of 
these antibodies in defence against P. falciparum. 
I was able to partially characterise two MSP -1 specific mAbs from immortalised B 
cell lines. Consistent with previous findings that antibody responses generated to 
MSPs are of the cytophilic subclasses, one mAb was of the IgG1 subclass and the 
other of the IgG3 subclass. It has previously been reported that IgG subclass 
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responses to MSP -1 Block 2 are predominantly of the IgG3 subclass, where as the 
main IgG subclass seen in response to MSP -119 is IgG1 (Cavanagh et al., 2001; Jouin 
et al., 2001). ADCI is mediated by antibodies of the IgG1 and IgG3 subclasses, with 
IgG3 being the more inhibitory of the two (Jafarshad et al., 2007; Tebo et al., 2001). 
The ADRB activity of polymorphonuclear neutrophils is also mediated by these 
cytophilic immunoglobulins, but in contrast to ADCI the IgG1 subclass may play the 
prevalent role in this process (Joos et al., 2010). This suggests that the mechanism 
of antibody -mediated anti- parasite activity may vary depending upon the isotype of 
the antibody in question. With the problems encountered in this project with the 
expansion of immortalised B cell clones, insufficient quantities of the mAbs DLB23 - 
5A7 and 684 -8B6 were obtained. These monoclonal human antibodies would have 
been useful tools with which to investigate ADCI and ADRB assays in vitro whilst 
controlling for antigenic specificity. 
Both mAbs from the DLB23 -5A7 and 684 -8B6 B cell lines were of the lambda light 
chain isotype. A study of light chain isotype usage in anti -MSP -1 Block 2 antibodies 
found the kappa/lambda ratio to be highly skewed (Jouin et al., 2005). This study 
found that light chain usage of polyclonal serum antibodies specific to peptides from 
the central region of Block 2 RO33 were predominantly kappa, where as light chain 
usage of antibodies specific to a second C- terminal Block 2 RO33 peptide were 
mainly of the lambda isotype. The epitopes recognised by DLB23 -5A7 and 684 -8B6 
were N- terminal to these peptides, with only a one residue overlap between the 
epitope recognised by DLB23 -5A7 and the central Block 2 RO33 peptide used by 
Jouin and colleagues (Jouin et al., 2005). This may suggest that light chain isotype 
usage in Abs specific to epitopes within the N- terminal region of Block 2 RO33 are 
mainly of the lambda isotype. 
By using N- biotinylated peptides with a 1 residue overlap inepitope mapping ELISA 
experiments, I was able to identify the minimal epitopes recognised by mAbs 
DLB23 -5A7 and 684 -8B6. However, due to the low amounts of antibody produced 
by small scale cultures of these B cell lines, it was not possible to use these mAbs in 
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any in vitro functional assays, to correlate the fine specificity of these antibodies with 
their functional activity (or lack thereof). 
Unfortunately, sufficient quantities of MSP- specific human mAbs were not obtained 
during this project to allow investigation of their functional activity in vitro. This 
was due to a number of factors. 
Firstly, four attempts were made to clone the immortalised polyclonal line DLB23- 
5A7. In all cases the process of cloning was successful, in that clones producing 
MSP -1 Block 2 RO33- specific mAb were obtained. However, none of these clones 
could be successfully expanded beyond two wells of a 96 -well plate despite 
extensive efforts to provide the clones with a variety of conditions that were 
conducive to growth. It is possible that these clones did not grow because they were 
not stably transformed lines. B cells transformed with EBV are in the most part 
mortal and have low levels of telomerase activity (Counter et al., 1994; Sugimoto et 
al., 2004). This can result in progressive shortening of telomeres during each cell 
division, which leads to replicative senescence and results in permanent growth 
arrest (Shay and Wright, 2005; Stewart and Weinberg, 2006). Recently, in a study 
which aimed to obtain human mAbs specific to MSP -2 and a peptide from the gene 
PFF0165c of 16 EBV -immortalised B cell cultures from one donor only 3 were 
stably transformed and could be expanded to obtain mAbs of interest (Stubbs et al., 
2011). 
Recently, another improved method of establishing EBV -transformed B cells has 
been described (Hui -Yuen et al., 2011). In this method isolated PBMCs are 
transformed with EBV in the presence of the T cell immunosuppressant tacrolimus. 
This method allows prediction of successful EBV transformation through the 
identification of CD23h'CD58+ cells 3 -4 days post transformation. I cloned 
polyclonal DBL23 -5A7 onto irradiated PBMCs from an EBV seronegative 
individual in order to prevent T cell- mediated killing of EBV transformed B cells. 
However, growth of polyclonal pools with irradiated PBMCs from an EBV 
seronegative individual or a T cell immunosuppressive agent may have promoted 
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better growth of clones. In addition, the ability to identify successfully transformed 
cells via flow cytometry 3 -4 days after EBV- transformation as opposed to 3 weeks 
after EBV -transformation via light microscopy would have enabled earlier down - 
selection of immortalised polyclonal wells, allowing efforts to be focused on those 
wells that might yield clones of interest. 
Secondly, I experienced problems obtaining PBMC donor samples from areas of 
high malarial endemicity, as evidenced by the move to select donors from the 
Mutoko district instead of the Murehwa district, the former having a higher level of 
malarial endemicity than the latter. That said, the Mutoko district is a mesoendemic 
area for malaria (Mharakurwa et al., 2004) and access to PBMC samples from 
clinically immune individuals from a hyperendemic region may have proved more 
fruitful. 
Thirdly, a B cell line single -cell sorted from the polyclonal line 684 -8B6 was 
expanded into a two -compartment bioreactor and the supernatant harvested at regular 
intervals. When total IgG purified from this supernatant was tested for reactivity 
with parasites by IFA I was surprised to find that there was no reactivity. Whilst in 
culture, supernatants from this bioreactor had regularly been checked for reactivity 
with recombinant MSP -1 Block 2 RO33 by ELISA. However, upon re- examination 
of these ELISA results in light of the IFA results, the ODs, although positive were 
much lower than one would expect if all of the IgG present was specific for MSP -1 
Block 2 RO33. This was puzzling given that the polyclonal line 684 -8B6 was cloned 
by single cell sorting instead of limiting dilution precisely because it was assumed 
that this method gave a greater likelihood of single cell deposition. During single 
cell sorting a stringent gate can be applied, as was in this case, such that the chances 
of the deposition of a doublet into a given well is low. In cloning by limiting 
dilution, the frequency at which a given number of cells, n, is deposited into plate 
wells is modelled by a poisson distribution. Hence, although one might be using a 
dilution which increases the possibility of obtaining n =1 cells in a plate well, it is 
inevitable that on some occasions less than or greater than n =1 cells will be deposited 
in a ww e11. In addition, cell aggregates can form during the process of cloning by 
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limiting dilution. It is unlikely, although possible that a cell doublet was deposited 
into the plate well during cloning of this line. 
In any case, the most parsimonious explanation for the small amount of MSP -1 
Block 2- specific mAb produced during growth of the what was the putatively clonal 
684 -8B6 line, is that it was not actually clonal. It is quite possible that the single cell 
sorted line was initially clonal and that a B cell of different specificity was 
introduced into that well via a microdroplet during culture manipulations. 
Manipulations of cloned B cells were carried out in 384 -well plates, which are 
tecnically challenging to work with and the smaller distance between wells compared 
to a 96 -well plate increases the likelihood of cross -contamination between wells. 
Indeed, incidents of accidential contamination of clonal cell lines are well known. 
For example, the P. falciparum isolate FCR -3 is thought to have contaminated 9 
different isolates from disparate geographical regions, resulting in all 9 lines being 
identical to FCR -3 (Trager, 1993). If a B cell of another specificity was introduced 
by cross -contamination it may well have outcompeted the MSP -1 Block 2 R033- 
specific B cells during culture in the bioreactor, particularly if the contaminating cell 
had switched off Ig- production. A recurrent phenomenon during the B cell work 
presented here was that many polyclonal or clonal pools that were initially positive 
in ELISA lost reactivity by the time they reached high enough densities to be frozen 
down or cloned. This might be explained by the B cells of interest being 
outcompeted by B cells of other specificities. 
On reflection, there are two steps I could have taken to avoided this result. Firstly, I 
could have carried out several rounds of sub -cloning of this B cell line. Secondly, I 
could have tested B cell supernatant for parasite reactivity via IFA whilst the line 
was grown in the bioreactor. The IFA, being a less sensitive technique than ELISA 
would have alerted me to the fact that the line might not be clonal earlier. 
MSP -specific human mAbs would be highly useful reagents with which to 
investigate mechanisms of antibody- mediated inhibition of P. falciparum growth. 
The efficacy of human hybridoma production has greatly improved in recent years 
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(Yu et al., 2008a; Yu et al., 2008b) and the generation of MSP- specific mAbs via 
these methods might be productive in future. 
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4: Is antibody -catalysed water oxidation 
responsible for intraerythrocytic growth 
inhibition by MSP-119-specific antibodies? 
4.1 Introduction 
The prevailing dogma holds that the primary function of antibodies is to provide a 
molecular link between pathogen recognition and pathogen destruction by the 
complement cascade or receptor- mediated phagocytosis. However, in the 1980's 
two research groups independently demonstrated that the antibody molecule is itself 
capable of complex chemical catalysis (Pollack et al., 1986; Tramontano et al., 
1986): the antibody catalysis field was born. It has since become apparent that 
antibodies can be programmed to catalyse a multitude of chemical reactions (Janda et 
al., 1993; Jones et al., 2001; Li et al., 1994). 
A catalytic ability intrinsic to all antibodies, irrespective of their antigenic 
specificity, is the capacity to catalyse a reaction between singlet oxygen (102) and 
water (H2O) to generate hydrogen peroxide (H2O2): x'02 +H2O -+H2O2 +(x -1)302 
(Wentworth et al., 2000; Wentworth et al., 2001). During this antibody- catalysed 
water -oxidation pathway (ACWOP) antibodies use H2O as an electron source to 
facilitate its addition to 102 to form H203 as the first reaction product in a cascade of 
reactions that ultimately leads to the production of H2O2 (Wentworth et al., 2001). 
The reduction of 102 is thought to be due to oxidation of a conserved tryptophan 
residue in a buried region of the antibody (Wentworth et al., 2000; Wentworth et al., 
2001) and reaction intermediates are stabilised at the interface of antibody light and 
heavy chains (Datta et al., 2002). The 'O2 substrate in this reaction can be generated 
in vitro by UV irradiation, irradiation by white light in the presence of a 
photosensitiser such as haematoporphyrin IX or by thermal decomposition of 
endoperoxides (Wentworth et al., 2000). 
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How does the potential of the antibody molecule to carry out antibody- catalysed 
water oxidation (ACWO) relate to antibody immune effector function in vivo? 
Activation of the ACWO pathway in the presence of 102 produces holes in the cell 
wall of gram- negative bacteria, resulting in bacterial lysis and death (Wentworth et 
al., 2002). Production of H2O2 via the ACWO pathway was not sufficient for 
bacterial killing but a downstream species with the chemical signature of ozone (03) 
was (Wentworth et al., 2002). Does ACWO play any role in antibody- mediated 
immunity to blood stage P. falciparum infection? 
P. falciparum is subject to considerable levels of oxidative stress during the 
intraerythrocytic developmental cycle (IDC) and the parasite has developed an 
extensive redox system in order to maintain adequate antioxidant defence throughout 
this period. This redox network comprises over twenty proteins, including 
antioxidant enzymes such as the glutathione- and thioredoxin- dependent proteins 
(Becker et al., 2003; Rahlfs et al., 2003) and superoxide dismutase, in addition to low 
molecular weight antioxidants, the most prominent of which is glutathione. 
However, P. falciparum is devoid of genes encoding either catalase or a classical 
glutathione peroxidase (Sztajer et al., 2001) and it has been suggested that the 
mechanisms P. falciparum employs for its antioxidant defence may only just be 
adequate (Becker et al., 2004). Hence, in theory, the generation of H2O2 and 
downstream reactive oxygen species (ROS) via the ACWOP if parasite -specific 
antibodies were to be presented with a biological source of 102 could result in 
parasite death. 
For the ACWOP to be active, Ig and singlet oxygen need to juxtapose. A potential 
source of 102 during blood stage parasitaemia is that produced by the nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase pathway during the respiratory 
burst of activated phagocytes. It has been shown that antibodies utilise 102 produced 
by the platelet NADPH oxidase pathway to produce H2O2 via the ACWO pathway 
during platelet destruction (Nardi et al., 2001). 
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03 is short-lived and catalase is ubiquitous in biological systems, therefore in order 
for activation of ACWOP to harm the parasite, catalytic Ig would need to be located 
in or close to the parasite. MSP -119 specific antibodies bind to the extracellular 
merozoite and are carried into the RBC during merozoite invasion, where they 
persist until at least 35 hours after invasion (Moss et al., 2012). Parasites treated 
with anti- MSP -119 antibodies in vitro display aberrant intraerythrocytic development 
(Arnot et al., 2008; Bergmann -Leitner et al., 2009). Could this antibody- mediated 
parasite damage be due to activation of the ACWOP by internalised MSP -119 - 
specific antibodies? 
This chapter aims to test the hypothesis that anti- MSP -119 antibodies carried inside 
the RBC during merozoite invasion produce ROS via the ACWOP that are 
detrimental to the intraerythrocytic development of the parasite. 
4.2 Materials and methods 
4.2.1 Fluorescent dyes 
The fluorescent dyes listed below were employed in the in vitro ACWO assay to 
detect parasite DNA, intracellular ROS or antibody. As a significant proportion of 
this chapter deals with the method development of this assay, the general methods 
attaining to these dyes are listed below, however, specific dye concentrations are 
indicated in the relevant results section. 
4.2.1.1 Alexa Fluor 488 and Alexa Fluor 633 
The antibodies used in the in vitro ACWO assay, 12.8 and anti -Yml, were labelled 
with Alexa Fluor 488 or Alexa Fluor 633 so that the Abs could be detected by flow 
cytometry. Please see Chapter 2 for details of the labelling procedure. ÁF488 and 
AF633 are used in this Chapter as suffixes to denote an Ab that is labelled with 
Alexa Fluor 488 or Alexa Fluor 633, respectively. 
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4.2.1.2 DCFH-DA 
A chemically reduced, acetylated form of fluorescein, 2',7'- 
dichlorodihydrofluorescein diacetate (DCFH -DA) was employed to detect 
intracellular ROS. This nonfluorescent lipid -soluble probe is relatively resistant to 
oxidation and diffuses across cell membranes where it is hydrolysed by intracellular 
esterases to 2',7'- dichlorodihydrofluorescein (DCFH). Upon oxidation by 
intracellular ROS, DCFH yields the highly fluorescent dichlorofluorescein (DCF). 
Lyophilised DCFH -DA (C2938, Invitrogen) was reconstituted in DMSO to give a 10 
mM stock solution which was maintained at -20 °C in the dark for long -term 
storage. 
DCFH -DA was applied either pre- or post -IgG treatment during in vitro ACWO 
assays. Where DCFH -DA loading was pre -IgG treatment, DCFH -DA was diluted to 
the required working concentration in 300 µL uninfected RBCs at 5% haematocrit in 
PBS. Post staining, DCFH -DA loaded uninfected RBCs were washed with PBS (500 
x G, 5 minutes) and then used to dilute the parasite culture being used in the assay. 
Where DCFH -DA loading was post -IgG treatment DCFH -DA was diluted in 300 µL 
PBS to the required working concentration. Samples from experimental cultures 
were added to this solution and stained at 37 °C in the dark for 30 minutes. Post 
staining, cells were washed with PBS (500 x G, 5 minutes) and resuspended in 300 
µL PBS prior to cell acquisition by flow cytometry. 
4.2.1.3 Dihydrorhodamine 123 
Dihydrorhodamine 123 (DHR 123) is an uncharged ROS indicator that diffuses 
across cell membranes. Upon oxidation by intracellular ROS DHR 123 is converted 
to cationic rhodamine 123 (R 123), which localises to mitochondria and displays 
green fluorescence. 
A 5 mM stock solution of DHR 123 (D23806, Invitrogen) was diluted to the required 
concentration in 500 µL of uninfected RBCs at 5% haematocrit in RPMI 1640. 
Uninfected RBCs were stained for 20 minutes at 37 °C in the dark. Following this, 
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cells were washed with PBS (500g, 5 minutes) and resuspended in 300 µL PBS prior 
to in vitro ACWO assay setup. 
4.2.1.4 DAPI 
Samples from experimental or control cultures were added to 300 µL RPMI 
containing 1 µg mL -1 4',6'- diamidino -2- phenylindole (DAPI). Cells were stained 
for 30 minutes at RT in the dark prior to acquisition on a flow cytometer. 
4.2.1.5 Hoechst 33342 
Please see the general materials and methods section. 
4.2.2 Long -term culture and manipulation of murine 
hybridomas 
4.2.2.1 Hybridomas 
The following murine hybridomas were used: (i) 12.8, which produces an 
IgG2b/kappa antibody specific for an S -S dependent conformational epitope within 
the EGF -like domain 1 of MSP -119 (Conway et al., 1992; McBride and Heidrich, 
1987; Wilson et al., 1987) and (ii) hybridoma line 4D10, which produces a mAb 
specific for murine Yml, a chitinase -like protein. This hybridoma line was produced 
by Abnova Corporation, Taiwan and raised against the Yml peptide 
IPRLLLTSTGAGIID (Tara Sutherland, personal communication). The anti - 
Yml hybridoma line was gifted by Dr. Stephen Jenkins. 
4.2.2.1 Media 
The following media were used for culture and manipulation of murine hybridomas: 
Hybridoma growth medium: RPMI medium 1640 - L- glutamine (Invitrogen) 
supplemented with 10% ultra low IgG FBS (Invitrogen), 4 inM L- Glutamine 
(Invitrogen) and 1% penicillin streptomycin (Invitrogen). 
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Hybridoma freezing medium: 40% v/v hybridoma growth medium, 10% v/v sterile 
DMSO and 50% v/v FBS. 
Hybridoma thawing medium: RPMI medium 1640 - L- glutamine (Invitrogen) 
supplemented with 10% v/v ultra low IgG FBS (Invitrogen), 4 mM L- Glutamine 
(Invitrogen), 1% penicillin streptomycin (Invitrogen), 10% v/v BM Condimed 
(Roche) and 55 mM 2- mercaptoethanol. 
Celline 1000 medium compartment medium: RPMI medium 1640 - L- glutamine 
(Invitrogen). 
Celline 100 cell compartment medium: RPMI medium 1640 - L- glutamine 
(Invitrogen) supplemented with 10% v/v ultra low IgG FBS (Invitrogen). 
4.2.2.2 Thawing of hybridoma cells 
Hybridomas were maintained in liquid nitrogen for long -term storage. Hybridomas 
were thawed in a 37 °C water bath and then transferred to a 15 mL polypropylene 
centrifuge tube. 10 mL hybridoma growth medium was added dropwise with 
rotation. The tube was spun down for 5 minutes at 300 x G in a centrifuge. The 
supernatant was taken off and the cell pellet resuspended in 10 mL of thawing 
medium and the cells transferred to a T25 flask. 
4.2.2.3 Routine culture and manipulation 
Murine hybridomas were expanded in T75 flasks until 8 x 106 cells were obtained. 
These cells were spun down at 300 x G for 5 minutes, resuspended in 15 mL 
compartment medium and seeded into a Celline 1000 flask that had been pre - 
incubated at 37 °C, 5% CO2 with 500 mL media compartment medium in the 
medium compartment. 
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Twice a week hybridoma cells were transferred to a 50 mL falcon tube, centrifuged 
at 300 x G for 5 minutes and the supernatant (containing the mAb of interest) 
harvested. Cells were resuspended in 15 mL fresh cell compaament medium, at a 
diluted density if required, and returned to the cell compartment. 500 mL of medium 
compartment medium was poured off from the medium compartment and 
replenished with an equal volume of fresh medium compartment medium. 
4.2.2.4 Freezing 
Hybridoma cells were frozen down when growth was in the exponential phase. Cells 
were resuspended, transferred to a 50 mL polypropylene tube and centrifuged at 300 
x G for 5 minutes. The supernatant was removed and hybridoma cells resuspended 
in freezing medium at a concentration of 5 x 106 cells mL "1. Hybridomas were 
aliquoted into cryovials and stored at -70 °C overnight in a cryo 1°C freezing 
container, then in liquid nitrogen for longer storage. 
4.2.3 Antibody /protein irradiation and quantification of H2O2 
production 
H2O2 production by antibodies /proteins was measured using the Amplex Red 
hydrogen peroxide assay kit (A22188, Invitrogen). The Amplex Red reagent is a 
colourless substrate that reacts with H2O2 to produce the highly fluorescent product 
resorufin. 
Aliquots of antibody /protein solution (100 µL, 6.7 .tM protein in PBS, pH 7.4) were 
placed in glass vials, sealed and placed in the dark (treatment i) or irradiated with UV 
(treatment ii) or irradiated with UV in the presence of 40 µM haematoporphyrin IX 
(treatment iii). As controls 100 p.. aliquots of aprotinin (6.7 µM protein in PBS, pH 
7.4), PBS and 100 µM H202, and PBS alone were exposed to treatment (i). At 90 
minutes after the application of treatments, 40 pM catalase (C9322, Sigma -Aldrich) 
was added to all samples. 
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At 0, 30, 60, 90 and 95 minutes after the application of treatments to samples, 10 µL 
was taken from each sample and added into a well of a 96 -well microtiter plate 
containing 40 [IL reaction buffer. 50 µL Amplex Red reagent solution (400 µM 
Amplex Red Reagent, 2 U mL ' HRP in reaction buffer) was then added, and the 
plate was incubated in the dark for 30 mins. The optical density was read at 570 nm 
on a Labsystems Multiskan Ascent microtitre plate reader. The experiment was run 
in duplicate. 
4.2.4 Titration of mAbs 12.8 and anti -Ym1 in the in vitro 
ACWO assay 
P. falciparum parasites were synchronised by sorbitol treatment in order to yield a 
0 -18 h post invasion culture. A second sorbitol treatment was performed 34 h later 
in order to obtain a 0 -4 h post invasion culture. Synchrony of the 4 h cohort was 
maintained by sorbitol treatment every 48 hours until assay set up. 
4 mg mL-' solutions of anti- Yml -AF488 and 12.8 -AF633 in PBS were mixed in a 
1:1 ratio to give a solution in which both of these mAbs were present at a 
concentration of 2 mg mE'. This antibody solution was serially diluted two -fold 
finishing at a 1:16384 dilution. Then, 50 .tL of each dilution in PBS was dispensed 
in triplicate into the wells of a flat- bottomed microtitre plate (Costar, 3598). 
Following this, 50 µL of P.falciparum culture, consistently predominantly of late 
trophozoites and early schizonts, at 1% parasitaemia and 5% haematocrit, in twofold - 
concentration complete medium, was dispensed into each well. Therefore, at the 
outset of each assay parasites were present at 0.5% parasitaemia in complete culture 
medium at 2.5 % haematocrit. Plates were incubated at 37 °C, 5% CO2 for the 
duration of the assay. 
Sampling time points were 21, 40 and 46 h after assay set up. At each time point 10 
µL of resuspended parasites from each assay well were dispensed into 290 µL RPMI 
containing 1 µg mL' DAPI and stained for 30 mins at RT in the dark. Data from 
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these samples were then acquired on a BD LSR II flow cytometer. Data from 2000 
iRBCs were acquired for each sample. 
4.2.5 Comparison of the ability of Coriphosphine O, DAPI and 
Hoechst 33342 to stain early ring stage parasites 
A highly synchronous early ring -stage culture at 5% haematocrit was set up. 20 µL 
of resuspendedparasites from this culture were added to 280 µL aliquots of RPMI 
containing DAPI (1, 0.5, 0.25, 0.125, 0.0625 or 0.03125 µg mL"'), DAPI and 0.017% 
Triton X -100 (1, 0.5, 0.25, 0.125 µg mL"') Coriphosphine O (2, 1, 0.5, 0.25, 0.125 or 
0.0625 µg mL"') or Hoechst 33342 (10, 5, 2.5, 1.25, 00625 or 0.03125 µg mL "'). In 
addition, 20 µL of well -mixed 5% haematocrit uninfected RBCs were added to 280 
µL RPMI containing 1 µg mL"' DAPI, 1 µg mL "' DAPI and 0.017% Triton X -100, 2 
µg mL "' Coriphosphine O or 10 µg mL"' Hoechst 33342. Staining conditions were as 
follows: 60 minutes at 37 °C in the dark, 30 minutes at RT in the dark and 15 minutes 
at RT in the dark, for Hoechst 33342 -, DAPI- and Coriphosphine 0-staining, 
respectively. Following this, cells were acquired on a BD LSR II flow cytometer. 
4.2.6 In vitro ACWO assay 
A number of variations of the in vitro ACWO assay are presented in this chapter, 
which reflects the evolution of the assay over time. As such, the assay outline is 
described below. For precise concentrations of materials used and assay sampling 
time points, please see the relevant results section. 
Parasites were synchronised by sorbitol treatment in order to yield a -0 -18 h post 
invasion culture. Parasites were synchronised again 34 h later in order to obtain a 0- 
4 h post invasion culture. Synchrony of the 4 h culture was maintained by sorbitol 
treatment every 48 hours until assay setup. Where DCFH -DA loading was prior to 
assay treatments, uninfected RBCs pre -loaded with DCFH -DA were used to dilute 
this culture to 1 % parasitaemia, prior to addition to assay wells. 
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The experimental mAb treatment was 12.8 -ÁF633 and the negative control mAb 
treatment was anti- Yml- AF633. 50 µL of each mAb in PBS at the required 
concentration was dispensed in duplicate into the wells of a flat -bottomed microtitre 
plate (Costar, 3598). An equal volume (50 µL) of parasite culture at 0.5% 
parasitaemia and 5% haematocrit, consisting predominantly of schizonts in twofold - 
concentration complete medium, was dispensed into each well. Plates were 
incubated at 37 °C, 5% CO2. 
At sampling time points post invasion, 10 gL of resuspended cells from each well 
were sampled. For wells where DCFH -DA measurement was post -treatment, 
parasites were stained with DCFH -DA. Parasites were stained with DAPI or 
Hoechst 33342 in order to detect parasite DNA. Data were acquired on a BD 
FACScan fluorescence -activated cell analyser or a BD LSRII flow cytometer. 
4.3 Results 
4.3.1 Development of the in vitro ACWO assay 
4.3.1.1 Detection of intracellular ROS 
We hypothesised that ACWOP is operational during P. falciparum intraerythrocytic 
growth inhibition by internalised MSP -119 specific antibodies. Testing this 
hypothesis necessitated the development of a novel in vitro assay that could detect 
internalised anti- MSP -119 antibodies and measure parasite oxidative stress in order 
to determine whether there was any correlation between the two. 
The lipid soluble probe DCFH -DA was employed to detect intracellular ROS in the 
in vitro ACWO assay. Preliminary experiments were carried out to determine a 
working concentration of DCFH -DA that (i) did not cause blebbing /shrinking/lysis 
of cells and (ii) displayed a quantitative fluorescent shift upon encountering ROS 
intracellularly. 
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RBCs were loaded with DCFH -DA (0, 100, 200, 400 or 800 pM) and the DCF signal 
in the presence or absence of 200 µM 11202 measured by flow cytometry. Figure 4.1 
displays representative FACs plots of FSC versus SSC and FL -3 versus FL -1 
fluorescence from this experiment. Loss of forward or side scatter can indicate 
shrinking or lysis of cells and at concentrations less than or equal to 200 µM DCFH- 
DA there was no indication that this had occurred. Within the DCFH -DA 
concentration range at which no cell lysis had occurred the greatest shift in DCF 
fluorescence (FL -1 channel) upon H2O2 treatment was observed at 100 µM DCFH- 
DA. Hence, the optimal DCFH -DA concentration for the in vitro ACWO assay was 
determined to be 100 µM, which is of the same order of magnitude as that used by 
other researchers using DCFH -DA to measure ROS in human erythrocytes (Amer et 
al., 2003; Mandal et al., 2005). 
4.3.1.2 Stability of DCFH and DCF 
If RBCs are loaded with DCFH -DA prior to antibody treatment the DCF 
fluorescence measured at later time points is the sum of DCF that has accumulated in 
that RBC since DCFH -DA loading minus any leakage of DCF from the RBC. On 
the other hand if RBCs are loaded with DCFH -DA at time points after IgG treatment 
then DCF fluorescence is a measure of the ROS level of the iRBC at that particular 
time point. If DCF fluorescence was only measured at time points after antibody 
treatment then one might miss some, if not all ROS, if they are transient. On the 
other hand, only measuring DCF fluoresence that had accumulated over time would 
not allow one to pinpoint when ROS were being produced intracellularly. We 
therefore decided to measure DCF fluorescence both pre- and post -antibody 
treatment during the in vitro ACWO assay. 
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Figure 4.1 Titration of the intracellular ROS probe DCFH -DA. 
(A) FSC versus SSC contour plots (left hand panels) and FL3 versus FL1 dot plots 
(right hand panels) of RBCs pre -loaded with 100 pM DCFH -DA in the absence 
(upper panels) or presence of 200 pM H202 (lower panels). Gate R1 defines 
healthy RBCs. Gates R2 and R3 define RBCs of low DCF fluorescence and high 
DC fluorescence, respectively. (B) Percentage of RBCs with high DCF fluorescence 
(gate R3) when pre -loaded with 0, 100, 200, 400 or 800 pM DCFH -DA in the 
presence (red bars) or absence (black bars) or 200 pM H202. 
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It was therefore important to identify (i) that RBCs preloaded with DCFH -DA 
remained responsive to DCF production and (ii) that once DCF had been formed 
inside the RBC it remained detectable over time. Figure 4.2 displays a typical time 
course experiment of DCFH responsivenes and DCF stability. To measure DCFH 
responsivenes, RBCs were pre -loaded with DHCF -DA at the start of the assay and at 
hourly intervals samples were taken and tested for the ability to exhibit DCF 
fluorescence when exposed to 200 µM H2O2. To measure DCF stability, RBCs were 
pre -loaded with DHCF -DA and exposed to 200 µM H2O2 at the start of the 
experiment. DCF fluorescence was then monitored at hourly intervals. No reduction 
in either DCFH responsiveness or DCF stability was detected (Figure 4.2). 
4.3.1.3 Experimental and negative control antibodies 
The in vitro ACWO assay required a source of MSP -119 specific antibodies, which 
would serve as the experimental antibody and a non -P. falciparum- specific antibody, 
which would serve as a negative control. Given that this assay was being developed 
to test a hypothetical mechanism of antibody- mediated intraerythrocytic growth 
inhibition there was no positive control antibody available. 
The mouse mAb 12.8, which recognises a conformational epitope within the EGF- 
like domain 1 of MSP -119 was chosen as the experimental antibody. 12.8 is secreted 
from a mouse hybridoma cell line, thus providing a cheap, unvarying and unlimited 
supply of mAb of defined specificity. A hybridoma generated mAb specific to 
mutine Ym1 was used the negative control antibody. These mAbs were labelled 
with Alexa Fluor 633 so that they could be detected directly without needing to 
employ the use of secondary antibodies. 
Alexa Fluor 633 -labelled 12.8 (12.8- AF633), Alexa Fluor 633 -labelled anti -Yml 
(anti- Yml- AF633), unlabelled 12.8 and unlabelled anti -Yml were tested for 
reactivity with intact parasites by IFA to confirm (i) that anti -Yml did not react with 
P. falciparum and (ii) that Alexa Fluor labelling of antibodies had not affected 
antibody specificity. 12.8 reacted strongly with parasites, displaying an endpoint 
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Figure 4.2. Measurement of DCFH responsiveness and DCF stability in RBCs 
over time. 
To measure DCFH responsiveness (blue line), RBCs were pre -loaded with 100 pM 
DCFH -DA and incubated at 37oC, 5% 002. At hourly intervals for the next 6 
hours, samples were taken, exposed to 400 pM H202 and RBCs acquired by flow 
cytometry. To measure DCF stability (red line), RBCs were pre -loaded with DCFH- 
DA, exposed to 400 pM H202 and incubated at 37oC, 5% 002. At hourly intervals 
for the next 6 hours, samples were taken and RBCs acquired by flow cytometry. 
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even at high concentrations. Antibody labelling did not affect the reactivity of either 
antibody in IFA (Figure 4.3). 
4.3.1.4 12.8 and anti -Ym1 can carry out ACWO when presented with a 
source of 102 
Before determining whether 12.8 carried out catalytic ACWO during the 
intraerythrocytic developmental cycle it was important to determine that 12.8 and 
anti -Ym 1 were capable of carrying out catalytic ACWO when provided with a 
source of '02. Employing a method adapted from that used by Wentworth and 
colleagues (Wentworth et al., 2000), 12.8, 12.8- AF633, anti -Ym1 and anti -Ym1- 
AF633 were either not irradiated, or irradiated with UV light in the presence or 
absence of the photosensitiser haematoporphyrin IX, and hydrogen peroxide 
production measured using the Amplex Red reagent. Naive rabbit IgG and aprotinin 
served as positive and negative controls of ACWO activity, respectively (Wentworth 
et al., 2000). The time course of H202 production by these proteins is displayed in 
Figure 4.4. All mAbs produced H202 when irradiated with UV, with higher levels 
of H202 production in the presence of haematoporphyrin IX. Alexa Fluor 633 - 
labelling of Abs reduced H202 production by a factor of approximately half. 
Antibodies incubated in the absence of UV treatment did not produce H202. The 
specificity of the Amplex Red reagent for H202 was confirmed by the addition of 
catalase resulting in H202 levels dropping down to pre -irradiation (baseline) levels. 
UV irradiation of buffer alone did not result in any H202 production. 
4.3.2 Preliminary ACWO experiments 
We wanted to test the hypothesis that anti -MSP -119 antibodies internalised during 
merozoite invasion generated ROS via the ACWOP, which were detrimental to the 
intraerythrocytic development of the parasite. Given that abnormal forms of each 
intraerythrocytic parasite stage had been detected during intraerythrocytic growth 
inhibition by anti -MSP -119 antibodies (Arnot et al., 2008), we reasoned that 
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Figure 4.3 IFA reactivity of 12.8 and anti -Ym1. 
IFA endpoint titres of unlabelled and Alexa Fluor 633- labelled mAbs 12.8 and Ym1 
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Figure 4.4 12.8 and anti -Ym1 mAbs produce H2O2 when irradiated with UV. 
Time course of H202 production in PBS (pH 7.4) with UV (blue line), UV and HP 
(brown line) or no UV (black line) in the presence of 12.8, 12.8 (AF633), anti -Ym1, 
anti -Ym1 (AF633) or polyclonal naive rabbit IgG. The time course of H202 
production in PBS (pH 7.4) alone or supplemented with aprotinin or H202, when 
irradiated with UV is also shown. Red arrows indicate the addition of catalase to 
protein samples. Each data point indicates hydrogen peroxide production, shown 
as the mean of two duplicate samples in OD units measured at 570 nm. Error bars 
indicate the standard error of the mean (SEM). 
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period the parasite was developing inside the RBC, or alternatively could occur early 
in the parasite's intraerythrocytic development, with parasitostatic or parasitocidal 
effects being evident throughout the parasite's intraerythrocytic development. 
The rationale behind the design of the in vitro ACWO assay was that following 
invasion of RBCs in the presence of 12.8 -AF633, a unique population of iRBCs 
with high Alexa633 fluorescence would be detected that would be absent from 
cultures that had undergone invasion in the presence of anti -Yml- AF633. If this 
unique population of AF633 high iRBCs were identified, we wished to determine 
whether they were subject to a higher level of oxidative stress than iRBCs displaying 
low AF633 fluorescence. 
Synchronous schizont iRBCs were allowed to undergo invasion into uninfected 
RBCs or uninfected RBCs pre -loaded with DCFH -DA in the presence of i) no 
antibody, ii) 1 mg ml."' 12.8- AF633, or iii) 1 mg mL"' anti -Yml- AF633. 
Concomitantly, control uninfected RBCs or uninfected RBCs pre- loaded with 
DCFH -DA were incubated with 12.8 -AF633 or anti -Yml -AF633 in the absence of 
schizont iRBCs. Samples were taken at 17, 24, 39 and 44 hours post invasion. For 
treatment wells where uRBCs were not pre -loaded with DCFH -DA, samples were 
stained with DCFH -DA and then with DAPI prior to acquisition on a flow cytometer. 
For treatment wells where uRBCs were pre -loaded with DCFH -DA, samples were 
only stained with DAPI prior to being acquired on a flow cytometer. 
Figure 4.5 displays representative dot plots of Alexa633 versus DAPI fluorescence 
for each of the 5 experimental treatments. A population of DAPIh'gh, Alexa633h'gh 
parasites were identified in cultures that had undergone invasion in the presence of 
12.8 -AF633. However, the same frequency of iRBCs were identified within this 
gate in cultures that had undergone invasion in the presence of anti -Yml- AF633. 
Comparison of uRBCs that had been incubated in the presence or absence of 
antibody (i.e. comparing panel A with panels D and E) revealed Alexa633 staining of 
uRBCs in samples where uRBCs had been incubated in the presence of 12.8 -AF633 
or anti -Ym 1- AF633. This implied that these mAbs were binding non -specifically to 
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RBCs and this might explain the equal frequencies of parasites observed in the 
DAPIh'gh Alexa633h'gh gate in cultures that had undergone invasion in the presence of 
12.8 -AF633 and anti -Yml- AF633. 
Whilst carrying out preliminary ACWO experiments using DAPI as a parasite 
detection dye, several assays were carried out where parasites could not be detected 
post invasion by flow cytometry, although their presence could be detected on 
Giemsa- stained smears. We reasoned that this might be due to DAPI not being able 
to stain ring -stage parasites. To examine this hypothesis, the ability of DAPI, 
Coriphosphine -O and Hoechst 33342 to stain parasite DNA in a culture consisting 
predominantly of early ring stage parasites was assessed. In case the lack of DAPI 
staining was due to an inability of the dye to access parasite DNA, in parallel 
samples were also stained with DAPI containing the non -ionic detergent Triton X- 
100. Figure 4.7 displays the parasitaemia detected by flow cytometry using each of 
these dyes to detect parasite DNA. The three lowest concentrations of Hoechst 
33342 gave parasitaemia in reasonable agreement with that measured by manual 
counting of Giemsa- stained smears (10.43 %) (Figure 4.6 panel B). Coriphosphine O 
staining gave a similar, although slightly lower estimate of parasitaemia at the 
highest concentration of this dye tested (Figure 4.6 panel A). Across the range of 
concentrations tested, DAPI- stained samples gave parasitaemia estimates between 
1.83 and 2.33% (Fig 4.6 panel C). The addition of Triton X -100 to DAPI stained 
cultures did not increase the parasitaemia detected by DAPI staining (Fig 4.6 panel 
D). Given, that DAPI staining resulting in vast underestimates of ring stage 
parasitaemia, Hoescht 33342 was used to detect parasite DNA in all subsequent 
experiments. 
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A: Infected RBCs 
B: Infected RBCs + 12.8 (AF633) 
C: Infected RBCs + anti -Ym1 (AF633) 
D: Uninfected RBCs + 12.8 (AF633) 
E: Uninfected RBCs + anti -Ym1 (AF633) 
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Figure 4.5 Representative plots of Alexa633 versus DAPI fluorescence from a 
preliminary in vitro ACWO experiment. 
Representative Alexa633 versus DAPI dot plots of DCHF -DA loaded RBCs that had 
been incubated with schizont- infected RBCs that underwent invasion in the 
presence of no antibody (panel A), 12.8 -AF633 (panel B), anti -Ym1 -AF633 (panel 
C) or DCHF -DA- loaded RBCs incubated for the same time period with 12.8 -AF633 
(panel D) or anti -Ym1 -AF633 (panel E). The gate displayed in red defines a region 
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Figure 4.6 Comparasion of the ability of different DNA -binding dyes to 
estimate ring -stage parasitaemia. 
Parasitaemia detected by flow cytometry when a highly synchronous early ring - 
stage culture was stained with (A) Coriphosphine O (2, 1, 0.5, 0.25, 0.125 or 0.0625 
pg mL -1; green bars), (B) Hoechst 33342 (10, 5, 2.5, 1.25, 0.625, 0.3125 pg mL -1; 
orange bars), (C) DAPI (1, 0.5, 0.25, 0.125, 0.625, 0.03125 pg mL -1; blue bars) or 
(D) DAPI and 0.017% Triton X -100 (1, 0.5, 0.25, 0.125 pg mL -1; purple bars). 
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4.3.3 Antibody titration 
In the preliminary ACWO experiments it had not been possible to gate 12.8 -AF633 
positive iRBCs as anti -Yml -AF633 positive staining was also observed. As 
discussed above positive anti -Yml -AF633 staining appeared to be due to a non- 
specific association of anti -Ym 1 -AF633 with the RBC surface. We reasoned that 
this could be due to the high antibody concentration used in these experiments, 
namely 1 mg mL -1. 
To determine whether this was the case, late stage iRBCs were allowed to undergo 
invasion in the presence of a mixture of 12.8 -AF633 and Alexa Fluor 488 -labelled 
anti-Yml (anti -Ym 1 -488) at equal concentrations, the concentration of each antibody 
ranging from 1000 µg mL -' to 0.0625 gg mL-1. If anti -Yml staining were due to a 
non -specific interaction with the RBC at high concentrations, one would expect to 
see this staining gradually lost as the concentration of anti -Yml lowers. Figure 4.7 
displays flow cytometry histogram overlays of 12.8 -AF633 and anti-Yml-AF488 
fluorescence of iRBCs 21, 40 and 46 h post invasion. As expected, at all time points 
AF488 fluorescence decreased as the anti -Yml -AF488 concentration decreased. In 
contrast, as the concentration of 12.8 -AF633 lowered, AF633 fluorescence splits into 
two distinct peaks leading to the formation of a valley in the histogram overlays. 
This valley demarcates the boundary between specific antibody binding and non- 
specific antibody binding. For uninfected RBCs AF633 fluorescence did not 
separate into two peaks and was indistinguishable from AF488 fluorescence (data 
not shown). Hence, a range of antibody concentrations at which 12.8- AF633, but not 
anti -Yml -AF488 was specifically associated with the iRBC following invasion 
could be defined. 
4.3.4 In vitro ACWO assay at lower antibody concentration 
Given that a range of antibody concentration at which 12.8 but not anti -YM1 
associated with iRBCs post invasion had now been defined, the in vitro ACWO 
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Figure 4.7 12.8 but not an irrelevant control antibody (anti -Ym1) is associated 
with newly infected RBCs following merozoite invasion. 
Highly synchronous late -stage iRBCs were incubated with a mixed antibody solution 
containing 12.8 (AF633) and anti -Ym1 (AF488) at equal concentrations. Flow 
cytometry histograms of parasites sampled from assay wells at 21, 40 and 46 hours 
after assay set up. Anti -Ym1 fluorescence, detected in the FITC channel, is 
displayed in the left hand panels. 12.8 fluorescence, detected in the Alexa -633 
channel, is displayed in the right hand panels. The concentration of 12.8 (AF633) 
and anti -Ym1 (AF488) was titrated two -fold from 1000 pg mL -1 to 0.0625 pg mL -1. 
Antibody concentration is indicated by histogram colour. Histograms are from 
individual assay wells and are representative of three triplicate assay wells. 
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125 pg mL -', 31.25 gg mL"' and 3.9 pg mL -1. DCFH -DA staining was carried out 
both pre and post treatment. Samples were acquired 13, 20, 37 and 44 hours after 
assay setup. A quadrant gate was applied to both infected and uninfected RBCs, 
which defined regions of high Alexa633 and low FITC fluorescence (gate Q1), high 
Alexa633 and high FITC fluorescence (gate Q2), low Alexa633 and high FITC 
fluorescence (gate Q3), and low Alexa633 and low FITC fluorescence (gate Q4). 
Representative plots illustrating this gating strategy for parasites that had undergone 
invasion into RBCs pre -loaded with DCFH -DA are shown in Figure 4.8 Panel A. In 
this experiment a unique population of Alexa633h'ghFITCh'gh parasites were identified 
in parasites that had undergone invasion in the presence of 12.8 -AF633 but not in 
those that had undergone invasion in the presence of anti- Yml -AF63. This 
population was present across all three mAb concentrations at the 13 h and 20 h time 
points, however, at the 37 h and 44 h time points there was no significant difference 
between the percentage of events in Q2 in 12.8 -AF633 and anti -Yml -AF633 treated 
samples (Figure 4.8 panel B). 
4.3.4.1 Re-titrating DCFH-DA 
In the previous experiment there were a significantly higher number of 
Alexa633h'ghFITCh'gh -gated parasites in cultures that had undergone invasion in the 
presence of 12.8 -AF633 than cultures that had undergone invasion in the presence of 
anti -Yml- AF633. However, the actual percentages of 12.8 -AF633 treated parasites 
within this gate were still low and raised into question whether the effect being seen 
was a robust one. Given that these parasites displayed DCF fluorescence at the 
higher end of detection limits, we reasoned that lowering the concentration of 
DCFH -DA used in the experiment might increase our ability to detect parasites 
within this gate. 
Synchronous schizont stage cultures were incubated with 31.25 µg mL-' 12.8 -AF633 
or anti -Yml -AF633 and allowed to undergo invasion into RBCs pre -loaded with 
DCFH -DA at a concentration of 100 µM, 50 µ, 25 µM, 12.5.11M, 6.25 µ, 3.125 
µM or 1.56 µM. 13 hours after assay set up, samples were stained with Hoechst 
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Figure 4.8 A unique population of antibody associated iRBCs displaying high 
DCF fluorescence is observed when P. falciparum undergoes invasion in the 
presence of the anti -MSP -119- specific mAb 12.8. 
Synchronous schizont stage cultures were incubated with either 12.8 -AF633 or anti - 
Ym1 -AF633 and allowed to undergo invasion into DCFH -DA- loaded RBCs. At 13, 
20, 37 and 44 hours after assay set -up, samples were acquired by flow cytometry. 
Samples were gated as infected or uninfected RBCs based on Hoechst staining. 
(A) A quadrant gate was applied to delineate four gates: Q1 (Alexa633h'ghFITC1 °W) 
Ab- associated iRBCs with low ROS level; Q2 (Alexa633h'ghFITCh'gh) Ab- associated 
iRBCs with high ROS level; Q3 (Alexa633b °WFITCh'gh), Non Ab- associated iRBCs 
with high ROS level; Q4 (Alexa633b°WFITCb°W), Non Ab- associated iRBCs with low 
ROS level. (B) Graphs display the percentage of iRBCs in gate Q2 expressed as 
the mean of two duplicate wells. Error bars indicate the standard error of the mean. 
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the ACWO experiment (at lower antibody concentrations) described above. Figure 
4.9 displays the percentage of parasites in gate Q2 for 12.8 -AF633 and anti -Yml- 
AF633 treated samples over the range of DCFH -DA concentrations used. At all 
concentrations of DCFH -DA there were more iRBCs in gate Q2 in 12.8 -AF633 
treated samples than anti -Yml -AF633 treated samples. However, the percentage of 
iRBCs in gate Q2 was still low. 
4.3.5 Dihydrorhodamine 123 
Lowering the concentration of DCFH -DA had not resulted in an increase in the 
number of iRBCs in the FITChigh633high gate. We reasoned that the small percentage 
of iRBC events in gate Q2 might be due to DCFH not being prevalent in the 
subcellular compartment where 12.8 was located. Anti -MSP -119 antibodies 
internalised inside the RBC during invasion localise to the food vacuole (Dluzewski 
et al., 2008), an acidic compartment (pH 5.4 -5.5) (Klonis et al., 2007). The main 
monoanion -dianion transition of DCF has a pKa of 5 (Leonhardt et al., 1971), hence 
DCF fluorescence will be affected by pH and in the case of the food vacuole would 
be expected to quench DCF fluorescence by a factor of -2 (Fu et al., 2010). We 
therefore decided to use the ROS probe DHR 123 to investigate the potential 
catalytic ACWO activity of internalised 12.8. DHR 123 is a lipid soluble ROS 
indicator that is oxidised to cationic rhodamine 123 inside the cell. Given that the 
fluorescence spectrum of Rhodamine 123 is pH- independent from pH 4 to 10, one 
would not expect an acidic location of 12.8 to influence the ability of DHR 123 to 
detect ROS. 
Synchronous schizont -stage cultures were incubated with no antibody, 12.8 -AF633 
or anti -Yml -AF633 and allowed to undergo invasion into RBCs pre -loaded with 
DHR 123 at a range of concentrations. Figure 4.10 displays the median rhodamine 
123 fluorescence intensity of iRBCs 23 hours after assay set up. The presence of 
12.8 or anti -Yml antibody over this period did not appear to affect parasite ROS 
levels when compared to cultures incubated with no antibody. ' 
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Figure 4.9 The proportion of iRBCs that are associated with the anti -MSP -119 
mAb 12.8 and display high DCF fluorescence remains low at lower 
concentrations of DCFH -DA. 
Synchronous schizont stage cultures were incubated with either 12.8 -AF633 or 
Ym1 -AF633 and allowed to undergo invasion into RBCs pre -loaded with DCFH -DA 
at 3.125, 12.5, 25, 100 pM. At 13 hours after assay set up, 
samples were acquired by flow cytometry. Samples were gated as infected or 
uninfected RBCs based on Hoechst staining. A quadrant gate was applied to 
delineate four gates: Q1 (Alexa633h'9hFITCb °W), Q2 (Alexa633h'9hFITCh'9h) Q3 
(Alexa633b°WFITCh'9h) and Q4 (Alexa633b °WFITCb °W). The graph display the 
percentage of iRBCs in gate Q2 expressed as the mean of two duplicate wells. 
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Figure 4.10 The intracellular ROS probe DHR 123 does not detect differences 
in the ROS level of iRBCs that have undergone invasion in the presence of no 
Ab, the anti -MSP -119 mAb 12.8 or an anti -Ym1 mAb. 
Synchronous schizont stage cultures were allowed to undergo invasion into RBCs 
pre -loaded with 0.19, 0.39, 0.78, 1.56, 3.13, 6.25, 12.5, 25, 50 or 100 pM DHR123 
in the presence of anti -Ym1 -AF633 (green line), 12.8 -AF633 (blue) or no antibody 
(red line). The median rhodamine 123 fluorescence intensity of iRBCs 23 hours 
after assay set up is shown. 
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4.4 Discussion 
This chapter set out to test the hypothesis that during merozoite invasion MSP -119 
specific antibodies are internalised inside the RBC and produce ROS via the 
ACWOP, which are detrimental to the intraerythrocytic development of the parasite. 
Production of ROS by the MSP -119 specific mAb 12.8, following RBC 
internalisation during invasion, was not reliably detected despite extensive repeated 
efforts to optimise an assay to detect this effect. There was, however, some evidence 
in the in vitro ACWO experiments carried out at a lower Ab concentration that 
iRBCs specifically associated with 12.8 had a higher ROS level than iRBCs that had 
undergone invasion in the presence of the non -specific anti -Yml Ab. It is interesting 
to note that the effect seen was only discerable at time points that occurred early on 
in the IDC. 
From the data presented here it is not possible to determine if the effect seen, namely 
increased iRBC ROS levels in the presence of specifically associated 12.8, is a real 
effect by which MSP -119 specific Abs inhibit P. falciparum in vitro growth. The 
following possibilites exist (i) a more robust effect was not detected due to an 
inability to detect ACWO under the assay conditions used or (ii) ACWO by MSP -119 
specific antibodies is not the mechanism by which these antibodies inhibit the 
intraerythrocytic development of the parasite. Possibility (i) will be discussed first. 
The aforementioned ACWO hypothesis was developed to attempt to explain the 
mechanism responsible for intraerythrocytic inhibition by MSP -119 specific 
antibodies that had been observed both by our lab (Arnot et al., 2008) and other 
groups (Bergmann -Leitner et al., 2009; Moss et al., 2012). This inhibition had been 
observed using polyclonal anti -MSP -119 antibodies purified from the serum of 
rabbits immunised with recombinant MSP -119. For the in vitro ACWO assay, the 
mAb 12.8 was chosen as the source of MSP -119 specific antibody. The use of a 
mouse mAb over polyclonal antibodies was deemed advantageous as it provided a 
non -variable, continuous supply of antibody of defined specificity. Additionally, on 
a practical level there were not sufficient quantities of the polyclonal anti -MSP -119 
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IgG - that the intraerythrocytic growth inhibitiory effect had originally been 
detected with - left to carry out IgG hungry in vitro ACWO assays. 
In hindsight 12.8 may not have been the most appropriate source of antibody to use. 
This is because the intraerythrocytic growth inhibition exerted by polyclonal anti - 
MSP -119 antibodies is not replicated in GIAs carried out using 12.8. It therefore 
follows that the inability to convincingly detect ROS production by 12.8 in the in 
vitro ACWO assay may be because this antibody does not function via this 
mechanism. Given that anti -MSP -119 specific Abs are known to inhibit P. 
falciparum growth through a number of different mechanisms in vitro (Blackman et 
al., 1994; Guevara Patiño et al., 1997), this does not preclude the possibility that 
other anti -MSP -119 specific Abs exert intraerythrocytic growth inhibition by 
activation of the ACWOP. It has in fact been reported that 12.8 inhibits merozoite 
invasion by preventing proteolytic processing of MSP -142 by SUB2 (Blackman et al., 
1990; Blackman et al., 1994; Guevara Patiño et al., 1997). However, this result has 
not been replicated when attempted by members of our lab or the GIA reference 
laboratory at the NIH (David Cavanagh, personal communication). Furthermore, in 
the experiments carried out with the Amplex red reagent, the level of H202 
production was lower in Alexa Fluor- labelled Abs than in unlabelled Abs. This may 
have lowered the ability of the in vitro ACWO assay to detect an effect. 
The most common in vitro assay used to measure in vitro growth inhibition by Abs is 
the GIA. The GIA is a crude measure of in vitro growth inhibition, requiring large 
quantities of Ab and lacking in the ability to distinguish inhibition of merozoite 
invasion from inhibition of the intraerythrocytic development of the parasite. It is 
unlikely that the GIA has the required sensitivity to detect an effect as specific as 
activation of the ACWOP. Here, we developed an assay with increased sensitivity 
relative to the GIA as we were looking for an effect that be quite transient and occur 
quite early on in the sequence of events that lead to intraerythrocytic growth 
inhibition. The detection of specific differences between treatment and control 
cultures in this assay required using low Ab concentrations at which one would not 
expect to see a growth inhibitory effect. In hindsight it is possible that this resulted 
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in the assay being carried out at a concentration of Ab that was too low to affect the 
oxidative stress levels of the parasite. A future avenue of research would be look for 
a correlation between intraerythrocytic growth inhibition by anti -MSP -119 Abs and 
an increase in the level of oxidative stress experienced by the parasite. If such a 
correlation were detected one could then investigate whether increased ROS 
production was a cause or consequence of the intraerythrocytic inhibition observed 
In order for antibodies to carry out ACWO they require a source of 102. A potential 
biological source of this molecule is that generated by activated polymorphonuclear 
neutrophils (PMNs) and it has been hypothesised that PMN -bound antibodies use 
this 'O2 to produce ozone via the ACWOP (Babior et al., 2003). It has recently been 
demonstrated that opsonised P. falciparum merozoites can trigger PMN respiratory 
bursts (Joos et al., 2010) and one can envisage several scenarios in which ACWO 
might facilitate or amplify this response: (i) merozoite bound antibody might activate 
PMNs and then intercept the 102 produced during their respiratory burst to catalyse 
the production of H202/O3, (ii) neutrophil bound antibody could carry out the same 
function and (ii) ROS generated via mechanisms (i) or (ii) could be detrimental to 
nearby intraerythrocytic parasites, given that ROS metabolites are known to be 
distinctly toxic for intraerythrocytic parasites (Allison and Eugui, 1983; Clark and 
Hunt, 1983; Greve et al., 1999). Investigation of these possibilities would be 
particularly interesting given that antibody respiratory burst activity by PMN has 
been correlated with clinical protection to P. falciparum malaria in vivo (Joos et al., 
2010). As with any in vitro model, the ACWO assay developed here is likely to be 
an oversimplification of what might occur in vivo and perhaps the inclusion of other 
cells types, for example PMN, is required for ACWO by MSA- specific antibodies to 
occur in vitro. 
It is possible that internalised 12.8 did carry out ACWO but that the ROS probes we 
used failed to detect it. Given that MSP -119 and anti- MSP -119 antibodies locate to 
the developing digestive vacuole (DV) following merozoite invasion, it is reasonable 
to assume that internalised 12.8 may also localise there. The level of DCFH (the de- 
esterified form of DCFHA) that is present in the digestive vacuole will be a function 
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of the level and activity of intracellular esterases present in that subcellular 
compartment. Hypothetically, one would expect the DV to display the highest level 
of DCF fluorescence (ROS level) given that this is the site of haemoglobin digestion. 
However, Fu et al. (Fu et al., 2010) did not detect accumulation of DCF fluorescence 
in the DV, implying that there is not a sufficient quantity of DCFH present in this 
organelle or that there may be quenching of DCF fluorescence. The acidic pH of the 
DV could be responsible for quenching of DCF fluorescence but this would not 
explain our inability to detect rhodamine 123 fluorescence during the in vitro ACWO 
assay. The possibility exists that haematin in the DV could be responsible for 
quenching of both ROS indicators. The in vitro ACWO experiments presented in 
this chapter were carried out in complete medium that contained phenol red. It has 
subsequently come to my attention that the presence of phenol red greatly attenuates 
the DCF signal. Consequently, any future in vitro ACWO experiments should be 
carried out in phenol red -free medium. Use of a fluorogenic ROS probe that could 
be targeted to a particular subcellular compartment may prove useful is this regard. 
Additionally, it has been reported that DCFH -DA lacks specificity and can be auto - 
oxidised (Bonini et al., 2006; Pal et al., 2012). In future studies of in vitro ACWO 
activity fluorogenic probes which exhibit a greater degree of specificity, similar to 
those recently developed for detection of 03 (Garner et al., 2009) or H202 (Dickinson 
and Chang, 2008) may prove useful. 
P. falciparum lacks catalase and a genuine glutathione peroxidase system and 
therefore might be considered vulnerable to ROS. Inded it is thought that the 
antimalarial actions of primaquine, chloroquine and artemisinin are mediated, at least 
in part, by increasing the oxidative stress level in the iRBC (Becker et al., 2004). 
However, it has emerged that P. falciparum imports a number of human proteins 
involved in antioxidant defence, including the antioxidant enzymes peroxiredoxin II 
(Koncarevic et al., 2009), superoxide dismutase and catalase (Foth et al., 2011). It 
therefore follows that P. falciparum may not be as vulnerable to ROS as previously 
thought. Indeed, Fu et al. (Fu et al., 2010) found that inactivation of RBC catalase 
did not result in a significant increase in the oxidative stress level experienced by P. 
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falciparum thus implying that glutathione peroxidase and other antioxidants may be 
sufficient to protect the parasite from oxidative stress. 
The identification of ACWO in a seminal paper in 2000 by Wentworth and 
colleagues (Wentworth et al., 2000) spawned a flurry of research publications in this 
area. However, it remains to be determined how important this mechanism of 
antibody function is to immune defence in vivo and whether it plays any role in 
antibody mediated immunity to P. falciparum infection. 
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5 Investigation of the functional activity of 
MSP3.3- specific antibodies 
5.1 Introduction 
A novel gene, PF10 0347, was identified whilst searching the P. falciparum genome 
sequence for open reading frames containing homology to MSP3 (Pearce et al., 
2005; Singh et al., 2009). The product of this gene, recently re- designated as 
MSP3.3, is one of six members of a family of proteins defined by the presence of a 
NLRNA/NLRNG signature motif. Additionally, all family members contain an N- 
terminal signature sequence and share a high degree of sequence conservation in 
their C- terminal halves (Singh et al., 2009). The MSP3.3 protein sequence, 424 
amino acids in length, contains glycine -rich and leucine- zipper like motifs, in 
addition to two SUB 1 processing sites (Figure 5.1). 
MSP3.3 is unique to P. falciparum and displays a high degree of intraspecies amino 
acid sequence conservation; in one study, of 14 P. falciparum isolates sequenced, 
only four non -synonymous single nucleotide polymorphisms (SNPs) were identified, 
whilst another study located three non -synonymous SNPs in sequences encoding the 
C- terminal region of MSP3.3 from 36 P. falciparum isolates of disparate 
geographical origin (Singh et al., 2009; Tetteh et al., 2009). MSP3.3 is recognised 
by Abs elicited in response to P. falciparum infection in malaria endemic regions 
(Pearce et al., 2005) and is reported to be a target of ADCI (Singh et al., 2009). 
In our lab, an intrinsically unstructured region from the C- terminal half of MSP3.3, 
designated MSP3.3C, has been expressed and purified as a recombinant antigen (K. 
Dhanasarnsombut, PhD thesis, University of Edinburgh; Dhanasarnsombut et al., 
manuscript in preparation). Immunisation of rabbits with recombinant MSP3.3C 
elicited Abs specific to this antigen that were found to be remarkably effective at 
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inhibiting the in vitro growth of P. falciparum (Dhanasarnsombut). Light 
microscopic analysis of Giemsa -stained smears indicated that the intraerythrocytic 
development of P. falciparum might be compromised during these assays. 
The mechanisms by which Abs to P. falciparum antigens inhibit the growth of the 
parasite are not fully understood, particularly when it comes to elucidating how these 
Abs may interfere with the biochemical and physiological development of the 
parasite inside the RBC. Dissecting these mechanisms would prove useful, both in 
terms of informing vaccine design to elicit functional immune responses and in 
developing an in vitro assay that can serve as a functional readout of an effective 
immune response, whether naturally acquired or vaccine induced. Thus this chapter 
aims to characterise the mechanism by which Abs to MSP3.3C inhibit the growth of 
P. falciparum parasites in vitro. 
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MxxIVNIIFY ILYLYIYKRN LVQNENVNKS NLRKGLSTNN SENGIKSLKD 
EDEHINII SAFSYGGY PIYETTGSLG TGVESVKAID GE MDSK 
PKENKISTEP GADQVSIGLV NESDSSLEND KKKKENVKKE MLEGSP 
DSHDSSKEKL NLNDNSKWSD FLKNIVTFGG FGPTVVHDVS DTLSDISKDE 
VTQKTTKDIG STLLDFFLPL PTKNTNTYEK KNENKNVSNV DSKTKSNEKG 
RPPTYSPILD DGIEFSGGLY FNEKKSTEEN KQKNVLESVN LTSWDKEDIV 
KENEDVKDEK DEDDEEEEEK YENEIIKQPE DILDEEEVLE EEILEENKND 
TVDTSDLEKK NIPDLSNDNN YYSLIYKNYK DNDKSEKTAQ TLITALISLL 
NGKNELDATI RRLKHRFMEF FTYN 
Figure 5.1 Amino acid sequence of MSP3.3 
The N- terminal signal sequence (light blue residues), within which lies a PEXEL motif (red 
residues), in addition to the NLRNA/NLRNG signature motif (green residues), a glycline 
rich motif (orange residues) and a leucine- zipper like sequence (dark blue residues). The 
MSP3.3C region, comprised of residues 229 to 360, is marked with a shaded background. 
SUB 1 processing sites are demarcated by downward arrows. 
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5.2 Materials and methods 
Routine culturing of P. falciparum parasites is described in Chapter 2. 
5.2.1 Rabbit immunisations and production of anti- MSP3.3C 
antibodies 
As part of this earlier study in our lab, on the anti- parasite effects of antibodies to 
MSP3.3, two rabbits (coded 6066 and 6067) were immunised intramuscularly using 
100 µg per dose of recombinant MSP3.3C antigen formulated with Freund's 
complete /incomplete adjuvant. Each animal was immunised on days 0, 7, 14, 28 and 
42, with blood samples collected for serum on days 0, 8 and 49. Rabbits were 
housed and immunised at BioGenes GmbH (Berlin, Germany). 
Total IgG from immunised rabbit sera was purified by affinity chromatography as 
detailed in Chapter 2. In order to obtain MSP3.3C- specific IgG, a MSP3.3C- coupled 
affinity column was prepared. 1 mL of a 7 mg mL-' solution of recombinant MSP3.3 
in coupling buffer (0.2 M NaHCO3, 0.5 M NaC1, pH 8.3) was added to a 1 mL Hi- 
Trap N- hydroxy -succinimide (NHS)- activated Sepharose column (GE Healthcare) 
and the coupling reaction carried out according to the manufacturer's instructions 
(GE Healthcare). Purified total rabbit IgG was passed through this column. The 
column was washed extensively with PBS prior to eluting bound MSP3.3C- specific 
IgG with 0.1 M glycine -HC1 pH 2.7 into tubes containing 1 M Tris pH 9.0 
neutralisation buffer. Purification of MSP3.3C- specific IgG from total IgG was 
carried out by Kelwalin Dhanasarnsombut. 
5.2.2 Growth inhibition assay with multiple time points 
The GIA is used to test the ability of Abs against blood -stage P. falciparum antigens 
to inhibit parasite invasion and growth in vitro. The Ab treatments were anti - 
MSP3.3C IgG (total IgG from rabbit 6066), in addition to anti -AMA1 IgG and NR 
IgG, which served as positive and negative controls, respectively. Each Ab sample, 
at a stock concentration of 12 mg mL-1, was serially diluted across four 
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concentrations; 6, 3, 1.5 and 0.75 mg mL -1. 50 µL of each antibody dilution in RPMI 
1640 (Invitrogen, 21870) was dispensed in duplicate into the wells of a flat -bottomed 
microtitre plate (Costar, 3598). An equal volume (50 µL) of parasite culture at 0.5% 
parasitaemia and 4% haematocrit, consisting predominantly of mid -stage schizonts in 
twofold- concentration complete medium, was dispensed into each well. Therefore, 
at the onset of the assay parasites were present at 0.5% parasitaemia in complete 
culture medium at 2% haematocrit. Plates were incubated at 37 °C, 5% CO2. At 
three time points, 16 h, 27 h and 44 h after the start of the assay, (i.e. when negative 
control cultures were predominantly at ring, trophozoite and schizont stage, 
respectively), cells within each well were resuspended. Following this, 10 µL of 
cells from each well were dispensed into 290 µL of 3.47 µM Coriphospine O in 
RPMI 1640 and stained in the dark at RT for 15 mins. The data from these samples 
were acquired on a Becton Dickinson FACScan fluorescence -activated cell analyser. 
Data from 50, 000 cells were acquired for each sample. 
5.2.3 Stage specific growth inhibition assay 
A stage -specific growth inhibition assay (SSGIA) was developed from the standard 
GIA. In the SSGIA, immune IgG is added to highly synchronous cultures of mid - 
ring stage, mid -trophozoite stage or mid -schizont stage parasites, termed the 
SSGIA(R), SSGIA(T) or SSGIA(S), respectively. Unlike the standard GIA, where 
parasitaemia is measured 42 h after incubation with immune IgG, in the SSGIA 
parasites are sampled at 3 time points over one erythrocytic cycle, each time point 
corresponding to the next stage of parasite intraerythrocytic development. For 
example, in the SSGIA(R) immune IgG is added to parasites at mid -ring stage, then 
parasites are sampled at the subsequent life -cycle time points corresponding to 
trophozoite, schizont and (following re- invasion), ring stage. For clarity, assay set 
up and sampling time points for each assay are displayed in Table 5.1. 
Parasites were synchronised by sorbitol treatment in order to yield a -0 -18 h post - 
invasion culture of ring stage parasites. A second sorbitol treatment was carried out 
34 h later in order to obtain a 0 -4 h post- invasion ring stage culture. Synchrony of 
this 0 -4 h culture was maintained by sorbitol treatment every 48 hours until assay set 
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up. Ab added to cultures consisted of two separate anti- MSP3.3C IgG preparations, 
one being total IgG from rabbit 6066 and the other total IgG from rabbit 6067. In 
addition, anti -AMAI IgG and NR IgG, served as positive and negative controls 
respectively. Each IgG was serially diluted across four concentrations; 12mg mL-I, 
6mg mL"', 3mg mL"' and 1.5 mg mL-' . Then, 50 pL of each antibody dilution in 
RPMI 1640 was dispensed in duplicate into the wells of a flat -bottomed microtitre 
plate (Costar, 3598). Following this, 50 µL of parasite culture at 0.8% parasitaemia 
and 4% haematocrit, in twofold- concentration complete medium, was dispensed into 
each well. Therefore, at the start of the assay parasites were present at 0.8% 
parasitaemia in complete culture medium at 2% haematocrit. Plates were incubated 
at 37 °C, 5% CO2 for the duration of the assay. 
In the SSGIA two methods are used to measure parasite growth inhibition: (i) flow 
cytometric measurement of parasitaemia and parasite DNA content and (ii) 
microscopically determined measurements of intraerythrocytic growth stage. At 
each sampling time point, cells were resuspended and 10 µL of culture from each 
assay well was dispensed into 300 µL RPMI 1640 containing 0.31 µg mL-' Hoechst 
33342 (Invitrogen, H3570). Cells were stained for 30 mins at 37 °C in a FACs tube. 
The data from these samples were then acquired on a BD LSR II flow cytometer. 
Data from 150,000 cells were acquired for each sample. 
In addition, at each sampling time point 3 µL of culture from duplicate wells 
containing the highest concentration (6 mg mL-1) of each Ab treatment were placed 
onto a microscope slide, spread thinly with a clean microscope slide, allowed to air 
dry and stained for 20 minutes with 10% Giemsa solution. These smears were 
examined by light microscopy and 100 parasites per smear scored into four classes: 
ring stage, trophozoite stage (haemozoin evident, single nucleus unless a multiple 
invasion event), schizont (multiple nuclei, with or without segmentation) and pynotic 
(condensed nuclei, parasite rounded in shape and densely stained). 
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Time point Assay Hours post (initial) invasion Stage of negatve control culture 
Assay set up SSGIA(R) 12 -16 Mid ring 
Time point 1 SSGIA(R) 30 -34 Mid trophozoite 
Time point 2 SSGIA(R) 40 -44 Mid schizont 
Time point 3 SSGIA(R) 60 -64 Mid ring 
Assay set up SSGIA(T) 30 -34 Mid trophozoite 
Time point 1 SSGIA(T) 40 -44 Mid schizont 
Time point 2 SSGIA(T) 60 -64 Mid ring 
Time point 3 SSGIA(T) 78 -82 Mid trophozoite 
Assay set up SSGIA(S) 40 -44 Mid schizont 
Time point 1 SSGIA(S) 60 -64 Mid ring 
Time point 2 SSGIA(S) 78 -82 Mid trophozoite 
Time point 3 SSGIA(S) 88 -92 Mid schizont 
Table 5.1 Table 5.1 Assay set up and sampling time points of the SSGIA. 
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5.2.4. Immunofluorescence assay 
Immunofluorescence assay (IFA) is a technique used to visualise parasite antigens 
using an antigen -specific primary antibody followed by a secondary antibody 
conjugated to a fluorochrome. Parasite cultures were washed with RPMI 1640 and 
resuspended at 20% haematocrit in RPMI 1640. Approximately 3 gL of this culture 
was placed onto a microscope slide, spread thinly with a clean microscope slide and 
allowed to air dry. Smears were fixed with 2% paraformaldehyde /PBS for 2 minutes 
at 4 °C and then with 90% acetone /10% methanol for 2 minutes at 4 °C. Smears 
were air -dried, blocked with 1% BSA/PBS for 1 h at RT and then reacted with 5 µg 
mL -' of anti -EXP -2 mouse mAb 7.7 and 31.5 pg mL-' of MSP3.3C- specific, affmity 
purified IgG for 1 h at RT in 1% BSA/PBS. Slides were washed 3 times in PBS and 
incubated with FITC- conjugated goat anti -mouse IgG (DakoCytomation) and 12.5 
µg mL"' Alexa Fluor 568 goat anti -rabbit IgG (Invitrogen, A- 11036) in 1% BSA/PBS 
for 1 h at RT. Slides were washed a further 3 times in PBS, stained with 0.5 µg mL-' 
DAPI /PBS and mounted in Citifluor (Citifluor Ltd). Single stained slides of each 
primary and each secondary Ab were prepared as controls. Parasites were viewed 
using on an Olympus BX50 fluorescence microscope with a 100 x oil -immersion 
objective lens. 
5.2.5 IgG uptake 
Parasites were synchronised by 3 rounds of sorbitol treatment in order to obtain a 0 -4 
h post invasion culture as detailed for the SSGIA assay. Treatments included 
MSP3.3C- specific, affinity purified IgG from rabbit 6066, anti -AMA1 IgG, NR IgG 
and RPMI 1640 alone (see section 5.3 for details of exact treatments used in each 
experiment). 50 µL of each antibody treatment at a concentration of 1 mg mL-' or 
RPMI alone was dispensed in duplicate into the wells of a flat -bottomed microtitre 
plate. 50 µL of a 12 h post invasion parasite culture at 0.5% parasitaemia and 4% 
haematocrit, in twofold- concentration complete medium, was dispensed into each 
well. Therefore, at the start of the assay parasites were present at 0.5% parasitaemia 
in complete medium at 2% haematocrit. Plates were incubated at 37 °C, 5% CO2 for 
the duration of the assay. 
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At sampling time points (30 h, 40 h and 60 h post initial invasion) 3 of 
resuspended culture was placed onto a microscope slide, spread thinly with a clean 
microscope slide and allowed to air dry. Smears were fixed with 2% 
paraformaldehyde /PBS for 2 minutes at 4 °C and then with 90% acetone /10% 
methanol for 2 minutes at 4 °C. Smears were air -dried, blocked with 1% BSA/PBS 
for 1 h at RT and then reacted with 5 µg mL -' of the anti -EXP -2 mouse mAb 7.7 for 
1 h at RT in 1% BSA/PBS. Slides were washed three times in PBS, and incubated 
with FITC- conjugated goat anti -mouse IgG and 12.5 µg mL -' AlexaFluor 568 goat 
anti- rabbit IgG (Invitrogen, A- 11036) in 1% BSA/PBS for 1 h at RT. Slides were 
washed a further 3 times in PBS, stained with 0.5 µg mL -' DAPI /PBS and mounted 
in Citifluor (Citifluor Ltd.). Single stained slides for mAb 7.7 and each secondary 
Ab were prepared as controls. In order to determine whether IgG could be detected 
inside iRBCs, parasites were viewed using a Olympus BX50 fluorescence 
microscope with a 100 x oil- immersion objective lens. 
5.2.6 Confocal microscopy 
For confocal microscopy experiments looking at MSP3.3 expression, slides were 
prepared as detailed under the IFA section above with the following modification; 
sampling time points were at 30 h and 40 h post invasion and not 60 h post invasion. 
For confocal microscopy experiments looking at IgG uptake, slides were prepared as 
detailed in the IgG uptake section above with the following modifications; anti - 
AMA1 IgG was included as a treatment and sampling time points were 30h and 40h 
post invasion. In both experiments, slides were viewed on a Leica SP5II confocal 
microscope (Leica Microsystems) with the 63 x objective using LAS AP software 
(Leica). Dianne Murray assisted with data acquisition. Data were analysed using 
Volocity software (Improvision). 
5.2.7 JC -1 assays 
Parasites were synchronised by three rounds of sorbitol treatment in order to obtain a 
0 -4 h post invasion culture as detailed for the SSGIA assay. Ab treatments included 
MSP3.3C- specific, affinity purified IgG from rabbit 6066 and NR IgG. Each IgG 
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treatment was serially diluted across four concentrations; 12mg mL"', 6mg mL "', 
3mg mL"' and 1.5 mg mL-I. Then, 50 µL of each antibody dilution in RPMI 1640 
was dispensed in duplicate into the wells of a flat -bottomed microtitre plate. 
Additionally, 50 µL of the following treatments were dispensed in duplicate into 
wells; 60 µM chloroquine, 0.2% sodium azide and RPMI 1640. Following this, 50 
µL of a 10 h parasite culture at 0.5% parasitaemia and 4% haematocrit, in twofold - 
concentration complete medium, was dispensed into each well. Therefore, at the 
start of the assay parasites were present at 0.5 %. parasitaemia in complete culture 
medium at 2% haematocrit. Plates were incubated at 37 °C, 5% CO2 for the duration 
of the assay. 
Sampling time points, unless stated otherwise, were 10 h (immediately after assay set 
up), 22 h, 30 h and 36 h post invasion. At each time -point 10 µL of resuspended 
cells were taken from each assay well and dispensed into 300 µL of 6 JC -1/0.5 
µM Hoechst 33342, and stained in the dark at 37 °C for 30 minutes. Subsequently, 
all samples were washed once with RPMI 1640, resuspended in 300 µL RPMI 1640 
and 150,000 cells from each sample acquired on a BD LSR II flow cytometer. 
Flow cytometry data acquried from JC -1 assays were analysed using FlowJo 
software (Tree Star Inc) to determine the co- ordinates of a gate, which on an FSC 
versus Hoescht axis, would only include iRBCs. This gate was applied to JC -1 assay 
flow cytometry data in R(R, 2005). A ratio was derived for each gated fluorescence 
event (i.e. each iRBC acquired by flow cytometry) by dividing JC -1 red fluorescence 
by JC -green fluorescence. The R code used to carry out this computation was 
written by Graeme Cowan. 
5.2.8 DHCF -DA assays 
Parasites were synchronised by 3 rounds of sorbitol treatment in order to obtain a 0 -4 
h post invasion culture as detailed for the SSGIA assay. Ab treatments included 
MSP3.3C- specific, affinity purified IgG from rabbit 6066 and NR IgG. Each IgG 
treatment was serially diluted across four concentrations; 12 mg mL"', 6 mg mL"', 3 
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mg mL "1 and 1.5 mg mL "I. Then, 50 µL of each antibody dilution in RPMI 1 640 was 
dispensed in duplicate into the wells of a flat -bottomed microtitre plate. Following 
this, 50 µL of a 10 h parasite culture at 0.5% parasitaemia and 4% haematocrit, in 
twofold- concentration complete medium, was dispensed into each well. Therefore, 
at the start of the assay parasites were present at 0.5% parasitaemia in complete 
culture medium at 2% haematocrit. Plates were incubated at 37 °C, 5% CO2 for the 
duration of the assay. 
Sampling time points, unless stated otherwise, were 10 h (immediately after assay set 
up), 22 h, 30 h and 36 h post invasion. At each time point 10 µL of resuspended 
cells were taken from each assay well and dispensed into 300 µL of 5 DCFH -DA 
(Invitrogen, C2938)/0.5 µM Hoechst 33342 and stained in the dark at 37 °C for 30 
minutes. Subsequently, all samples were washed once with RPMI 1640, 
resuspended in 300 µL RPMI 1640 and 150,000 cells from each sample acquired on 
a BD LSR II flow cytometer. 
5.2.9 Statistical anlayses: SSGIA data 
For each of the 3 types of SSGIA, namely SSGIA(R), SSGIA(T) and SSGIA(S), data 
from 3 independent experiments were analysed together. For each of these 3 sets of 
data, one analysis was carried out to explain variation in the outcome parasitaemia 
and another carried out to explain variation in the outcome DNA content. Therefore, 
a total of 6 statistical analyses were carried out. 
"Well" was the independent statistical unit and as repeated sampling from wells had 
taken place, data were treated as repeated measures data. A covariance mixed model 
analysis was carried out by Margo Chase -Topping in SAS version 9.3. `Well' was 
treated as a random effect. The advantage of using a covariance pattern mixed 
model instead of a regular mixed model with a random effect is that it does not 
assume there is a constant correlation between all time points(Brown and Prescott, 
2006). A variety of covariance patterns were tested prior to each analysis and the 
one that provided the best fit was used in the final model . Analysis was performed 
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on all data and then on each treatment (antibody) separately. To examine the nature 
of any statistically significant effects within each treatment (antibody), the 
differences in least square means were examined, after carrying out a Bonferroni 
adjustment for the number of comparisons made. Analyses were carried out on log 
transformed raw parasitaemias and median fluorescence intensities of the Hoescht 
channel, for parasitaemia and DNA content analyses, respectively. 
5.2.10 Statistical analyses: JC -1 data 
Statistical analyses of JC -1 red to green ratios were carried out by Liam Herbert in R. 
Preliminary analysis showed that the range of ratios obtained in each of the 3 
experimental replicates were statistically significantly different from one another. 
Therefore, analysing the data from all 3 replicates in 1 statistical analysis was not 
possible. Therefore, one experimental replicate was taken to be representative used 
for statistical analysis. Linear mixed models were fitted separately for each of the 4 
sampling time points. Treatment and concentration were treated as fixed effects and 
well as a random effect. 
5.3 Results 
5.3.1 Stage- specific growth inhibition assay: method 
development 
Dhanasarnsombut et al. (Dhanasarnsombut) observed numerous parasites with 
abnormal morphology during GIAs carried out in the presence of anti- MSP3.3C IgG, 
which were reminiscent of unhealthy parasites that had been observed in cultures 
treated with anti- MSP1 -19 IgG (Arnot et al., 2008; Bergmann -Leitner et al., 2009) 
and indicated that the development of post invasion intraerythrocytic forms might be 
inhibited or disrupted. 
In a standard GIA, Abs are added to synchronous late stage cultures (trophozoites 
and schizonts) and growth inhibition is measured 42 hours later, by comparing the 
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parasitaemia of the experimental culture to that of a control culture. In order to 
investigate whether abnormal development of intraerythrocytic parasites was 
occurring in anti- MSP3.3C IgG treated cultures, and in particular to determine at 
which morphological stage of parasite development these abnormalities might 
become apparent, the temporal resolution of the GIA was increased by sampling 
from treatment wells at multiple time points over the course of the GIA. 
MSP3.3C specific IgG was added to a synchronous schizont stage culture, and 
parasitaemia and parasite DNA content measured at three time points post invasion 
(16, 27 and 44 hours after assay set up), corresponding to the ring, trophozoite and 
schizont stages of healthy NR IgG treated control cultures. The level of growth 
inhibition observed at the highest concentration of anti- MSP3.3C IgG at each of 
these time points was 41 %, 43 %, and 40 %, respectively (Figure 5.2e). This was 
approximately half the level of growth inhibition exhibited by the positive control, 
anti -AMA 1 IgG and differed from the results of GIAs carried out by 
Dhanasarnsombut et al. (Dhanasamsombut) where the strong inhibitory activity of 
anti- MSP3.3C IgG and anti-AMAI IgG had been comparable. 
In this experiment parasitaemia and DNA content were determined using the acridine 
derivative Coriphosphine O, a dual colour stain that emits red fluorescence when 
bound to RNA and green fluorescence when bound to DNA and subcellular vesicles. 
Based on these dual fluorescence properties, coriphosphine O staining can 
distinguish between ring, trophozoite and schizont stages. Figure 5.2b displays red 
(FL3 channel) versus green (FL1 channel) fluorescence of iRBCs from healthy 
control cultures 16, 27 and 44 hours after assay set up. The progression of the 
culture through the IDC is reflected by the predominance of rings, rings and 
trophozoites, and schizonts, respectively, at each of these time points. 
Surprisingly, comparison of plots of red (FL3 channel) versus green (FL1 channel) 
fluorescence of iRBCs treated with the highest concentration. (6 mg mL-1) of anti - 
MSP3.3C IgG to iRBCs treated with the same concentration of NR IgG revealed that 
a whole population of cells, namely schizonts, were completely absent from 
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MSP3.3C IgG treated cultures (Figure 5.2c). This inhibitory effect was dose - 
dependent, with the proportion of schizonts detected increasing as the concentration 
of MSP3.3C IgG decreased. This striking effect was quantified by determining the 
median fluorescence intensity (MFI) of the FL1 channel, as a measure of parasite 
DNA content, for each sample (Figure 5.2e). At the 16 and 27 h time points, parasite 
DNA replication has not occurred yet and there is no difference between parasite 
DNA content in MSP3.3C IgG and NR IgG treated cultures. However, at the 44 h 
time point, it is clear that the ability of MSP3.3C IgG cultures to develop to schizonts 
and undergo DNA replication is severely inhibited. 
This stage -specific growth inhibition by anti- MSP3.3C IgG may explain the 
surprisingly lower level of growth inhibitory activity seen in this GIA compared to 
those of Dhanasarnsombut et al. in our laboratory (Dhanasarnsombut). In the GIA 
carried out by Dhanasarnsombut et al., Ab treatments were added to synchronous 
trophozoite stage cultures, as is standard practice in GIA, whereas in this experiment 
Ab treatments had been applied to schizont stage cultures. I therefore reasoned that 
the parasite stage at which Ab is added might be critical to the level and nature of 
growth inhibition observed. 
In order to determine if this was the case, a GIA was carried out, adding Ab 
treatments to a trophozoite stage culture and measuring parasitaemia and DNA 
content at four time points post- invasion. The temporal resolution of the GIA was 
further from the one described above by (i) using a highly synchronous 4 hour post 
invasion culture of parasites and (ii) monitoring when merozoite invasion was 
complete so that time points were measured as hours post merozoite invasion instead 
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Figure 5.2 Anti- MSP3.3C IgG inhibits the intraerythrocytic development of P. 
falciparum 
Anti- MSP3.3 IgG, anti -AMA1 IgG or NR IgG were serially diluted across four 
concentrations; 6 mg mL -1 (circle), 3 mg mL -1 (square), 1.5 mg mL"1 (upward 
triangle) and 0.75 mg mL -1 (downward triangle) and added to synchronous schizont 
stage cultures. At three time points, 16h , 27h and 44h after assay set up, 
corresponding to ring, trophozoite and schizont stages of development in NR IgG 
control cultures, parasitaemia and parasite DNA content measured by flow 
cytometry after Coriphosphine O staining of parasites. A, Gating strategy for 
determining parasitaemia. RBCs were gated by forward and side scatter (left hand 
panel). Infected RBCs were then gated by comparison of red (FL3 channel) and 
green (FL1 channel) fluorescence in uninfected RBC (middle panel) and infected 
RBC (right hand panel) samples. B, Representative bivariate scatterplots of red 
fluorescence (FL3 channel) versus green fluorescence (FL1 channel) of iRBCs in 
the absence of antibody 16, 27 and 44 h after assay set up. The gates R, T and S, 
define areas of FL3 and FL1 fluorescence of rings, trophozoite and schizonts, 
respectively. The percentage of iRBCs in R, T and S gates are displayed. C, 
Representative bivariate scatter plots of red (FL3 channel) versus green (FL1 
channel) fluorescence of anti- MSP3.3C IgG treated samples 44 h after the addition 
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of Ab. For comparison, representative plots of samples treated with 6 mg mL -1 of 
the positive control, anti -AMA1 IgG, and 6 mg mL -1 of the negative control, NR IgG, 
at the same time point, are displayed. Parasitaemia (bottom right hand corner) and 
percentage of iRBCs in R, T and S gates are shown. D, Parasite growth inhibition 
(percentage) in the presence of anti- MSP3.3C IgG (left hand panel) or anti -AMA1 
IgG (right hand panel). E, Parasite DNA content (MFI of the FL -1 channel) of iRBCs 
treated with anti- MSP3.3C IgG (left hand panel) or naive rabbit IgG (right hand 
panel). Data points represent the mean of two duplicate samples and error bars 
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Figure 5.3 Growth inhibition by anti- MSP3.3C IgG added to trophozoite stage 
cultures. 
Percentage growth inhibition of cultures treated with anti- MSP3.3C IgG (total IgG 
from rabbit 6066 or rabbit 6067) or anti -AMA1 IgG relative to control cultures treated 
with the same concentration of naive rabbit IgG. Treatment IgG, serially diluted 
across four concentrations (6 mg mL -1, 3 mg mL -1, 1.5 mg mL -1 and 0.75 mg mL -1), 
was added to trophozoite stage cultures and parasitaemia measured by flow 
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Figure 5.4 Growth inhibition by anti- MSP3.3C IgG added to ring stage stage 
cultures. 
Percentage growth inhibition of cultures treated with anti- MSP3.3C IgG (total IgG 
from rabbit 6066 or rabbit 6067) or anti -AMA1 IgG relative to control cultures treated 
with the same concentration of NR IgG. Treatment IgG, serially diluted across four 
concentrations (6 mg mL -1, 3 mg mL 1, 1.5 mg mL"' and 0.75 mg mL-1), was added to 
ring stage cultures and parasitaemia measured by flow cytometry of Hoechst 33342 
stained samples 48 hours later. 
124 
In the first GIA with multiple time points, carried out using anti- MSP3.3C IgG, the 
dye Coriphosphine O was used to enumerate iRBCs by flow cytometry. 
Discrimination of ring infected RBCs from uninfected RBCs had proved difficult in 
some samples. This could be due to quenching of the dye upon binding nucleic acids 
or staining of parasite vesicles interfering with measurements of DNA content. 
Hoechst 33342 is a minor groove DNA -binding dye with AT selectivity (Müller and 
Gautier, 1975) and thus lends itself well to studying P. falciparum, a parasite whose 
genome is greater than 80% AT rich (Gardner et al., 2002). Given that reproducible, 
precise measurements of DNA content and merozoite invasion inhibition can be 
made with this dye (Dent et al., 2008), Hoechst 33342 was employed in all 
subsequent experiments investigating the functional activity of anti- MSP3.3C IgG. 
The advantages of measuring GIA outcomes via flow cytometry, as opposed to the 
standard method employed, parasite specific enzyme lactate dehydrogenase, which is 
generated by active parasite metabolism (Malkin et al., 2005), are twofold. Firstly, 
given that levels of PfLDH mRNA and enzymatic activity vary significantly 
throughout the intraerythrocytic cycle of the parasite (Vivas et al., 2005), this 
detection method does not allow comparative measures of growth inhibition when 
stage -specific effects are involved, whereas flow cytometry does. Secondly, analysis 
of the flow cytometric data from each parasite infected can accurately determine 
DNA content, providing information about the stage of intraerythrocytic 
development of the parasite, whereas pLDH assays do not. 
When anti- MSP3.3C IgG was added to trophozoite stage cultures, the level of 
growth inhibition detected was comparable to that of Dhanasarnsombut et al.(K. 
Dhanasarnsombut, PhD thesis, University of Edinburgh; Dhanasarnsombut et al., 
manuscript in preparation); i.e. - 80% at the highest concentration of anti- MSP3.3C 
IgG, and of a comparable magnitude to that seen with the positive anti -AMA 1 
control (Figure 5.3). Light microscopic examination of Giemsa- stained smears taken 
at the first time point (1 h post invasion) revealed that anti- MSP3.3C IgG treated 
cultures contained a high proportion of schizonts relative to NR IgG treated cultures, 
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indicating that these cultures had developed into schizonts, but having had their 
development blocked during this stage, had not been able to undergo invasion. 
Finally, I investigated the effect of adding anti- MSP3.3C IgG to ring stage cultures. 
Ab treatments were added to mid -ring stage cultures and parasitaemia, DNA content 
and parasite morphology examined at 3 time points corresponding to subsequent 
trophozoite, schizont and ring stages of control cultures. The level of growth 
inhibition observed in anti- MSP3.3C IgG treated cultures 48 hours after the addition 
of antibody was - 90 %, higher than the level of inhibition observed with the anti - 
AMA 1 positive control (Figure 5.4). Furthermore, using 6 mg mt» IgG, at the 
timepoint when corresponding negative control cultures were predominantly 
schizonts, cultures treated with anti- MSP3.3C IgG had not developed beyond the 
trophozoite stage, and this inhibitory effect was dose -dependent (Figure 5.5). 
Data from the preliminary experiments described above were put together to develop 
the stage specific growth inhibition assay ( SSGIA) in order to dissect in finer detail 
the mechanism of action of MSP3.3C specific Abs in GIAs. This assay, depicted 
schematically in Figure 5.6, involves the addition of immune IgG to highly 
synchronous mid -ring, mid -trophozoite and mid -schizont stage cultures. In each 
case, at the following three stages of intraerythrocytic development, parasitaemia and 
parasite DNA content are measured by flow cytometry, and parasite morphology 
examined by light microscopy of Giemsa stained smears. For example, after the 
addition of immune IgG to a mid -ring stage culture, samples are taken at two pre - 
invasion time points, corresponding to when healthy control cultures are at the 
trophozoite and schizont stage of development, respectively, and at one post -invasion 
time point, when control cultures have undergone merozoite invasion and are at ring 
stage. All SSGIA time points are given relative to hours since the initial merozoite 
invasion event, as shown in Figure 5.6. In the SSGIA, anti -AMA1 IgG is used as a 
positive GIA control, and also as an example of an Ab whose functional activity is to 
block the ability of merozoites to invade erythrocytes. NR IgG was used to control 
for any non -specific growth inhibitory or growth promoting effects of rabbit IgG. 
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Figure 5.5 Intraerythrocytic growth inhibition by anti- MSP3.3C IgG added to 
ring stage stage cultures. 
Treatment IgG was added to synchronous ring stage cultures 9 hours post invasion 
and the DNA content of Hoechst 33342 -stained parasites measured by flow 
cytometry 22 and 40 hours after invasion, in addition to 9 hours into the next 
invasion cycle. A, Bivariate scatter plots of forward scatter (FSC -A) versus Hoechst 
fluorescence (Hoechst -A) of uRBC (left) and iRBC samples were compared in order 
to gate iRBCs. Hoescht staining of iRBCs in the absence of antibody 9 h (middle, 
left), 22 h (middle, right) and 40 h (right) post invasion, when parasites are 
predominantly, rings, trophozoites and schizonts, respectively, are displayed. Note 
the shift along Hoescht -A axis between trophozoite and schizont samples. B, 
Bivariate scatter plots of FSC -A versus Hoechst -A staining of RBCs at 40 hours post 
invasion, when control cultures (NR IgG treated) were schizonts. For comparison, 
representative plots of samples treated with the highest concentration of anti -AMA1 
IgG and NR IgG are displayed. Uninfected RBCs are shown in black and gated 






















Figure 5.6 Schematic outline of the SSGIA 
Schematic timelines of the SSGIA(R), SSGIA(T) and SSGIA(S). On each time line, 
the time at which antibody was added (upward red arrow), sampline time point 1 
(downward red arrow 1), sampling time point 2 (downward red arrow 2), sampling 
time point 3 (downward red arrow 3) and merozoite invasion events (red line) are 
depicted. The time in hours since the first merozoite invasion event and 
intraerythrocytic parasite stages are depicted at the top of the figure. 
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and merozoite invasion inhibitory effects, to delineate at which stages of parasite 
development inhibitory effects become apparent, and to account for any effects due 
to the stage of development at which immune IgG is added. 
5.3. Stage- specific growth assay results 
The results of three independent SSGIA experiments carried out with total IgG, 
purified from each of two rabbits immunised with recombinant MSP3.3C, are 
displayed in Figures 5.7 -5.10. For each sample, parasitaemia was calculated as the 
percentage of total RBC gated events in the iRBC gate and mean parasitaemia 
computed for each set of duplicate wells. Relative parasitaemia was calculated 
according to the equation RP = Pt/Pc where RP = relative parasitaemia, Pt = mean 
parasitaemia in the presence of test antibody and Pc = mean parasitaemia in the 
presence of naive rabbit IgG at the same concentration as the test antibody. 
Therefore, an RP value of 1 indicates no difference from the negative control, RP 
values > 1 denote increased parasitaemia relative to the negative control and RP 
values < 1 indicate parasitaemias lower than the negative control. Calculating 
relative parasitaemia in this way controls for any non -specific growth promoting or 
growth- inhibitory effects of rabbit IgG, however significant differences between 
parasitaemias in the presence or absence of NR IgG were not observed (data not 
shown). This data normalisation was carried out in order to allow comparison 
between the three independent experiments carried out. 
For each sample, the Hoechst median fluorescence intensity (MFI) of iRBC gated 
events was calculated as a measure of DNA content. Relative DNA content was 
calculated according to the equation RDC = RDCt/RDCc where RDC = relative 
DNA content, RDCt = mean DNA content of two independent wells in the presence 
of test antibody and RDCc = mean DNA content of two independent wells in the 
presence of naive rabbit IgG at the same concentration as the test antibody. RDC 
values greater than or less than 1, signify a higher and lower DNA content than 
controls, respectively. 
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At all time points in the SSGIA assays, Giemsa- stained blood smears were prepared 
from duplicate wells of the highest concentration of each IgG treatment. These 
smears were scored by light microscopy to determine the proportion of each 
intraerythrocytic parasite stage present in each sample. In addition, pycnotic 
parasites were scored, defined as those parasites with condensed nuclei that were 
rounded in shape and densely stained. 
5.3.2. SSGIA(R) 
The statistical models fitted to explain variation in parasitaemia and DNA content in 
the SSGIA(R) are displayed in Tables 5.2 and 5.7, respectively. For parasitaemia the 
effects of Ab concentration and time point within each treatment are displayed in 
Tables 5.3 -5.6 and for DNA content in Tables 5.8 -5.11. For the outcome 
parasitaemia the concentration of anti -AMA1 IgG (p <0.001), anti- MSP3.3C (6066) 
IgG (p <0.001) and anti- MSP3.3C (6067) IgG (p <0.001) significantly affected 
parasitaemia. The concentration of NR IgG had no affect on parasitaemia 
(p= 0.9292). For the outcome DNA content the concentration of anti- MSP3.3C 
(6066) IgG (p <0.001) and anti- MSP3.3C (6067) IgG (p= 0.0007) significantly 
affected DNA content. The concentration of anti -AMA 1 IgG (p= 0.9727) and NR 
IgG (p= 0.7740) did not affect DNA content. 
At 30 h post invasion RPs and RDCs are - 1 in anti -AMA1 IgG and both anti - 
MSP3.3C IgG treated cultures (Figure 5.7, panels A and B). At 40 h post invasion, 
two effects are noticeable in anti- MSP3.3C IgG treated cultures: (i) RP values start to 
fall below 1 at higher concentrations of the Ab (Figure 5.7, panel A) and (ii) RDC 
values are strikingly reduced at higher concentrations of the Ab (Figure 5.7, panel 
B). Effect (i) is due to a drop in DNA content of iRBCs such that they no longer sit 
within the confines of the iRBC gate. At 30 h post invasion, a proportion of 
pycnotic, densely stained trophozoites were observed and these forms persisted for 
the duration of the assay (Figure 5.7, panel C and Figure 5.10, contrast plates A and 
B with plates C and D). Between 30 h and 40 h post invasion control cultures have 
developed from the trophozoite stage to the schizont stage. This is exemplified by a 
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statistically significant increase in DNA content between these two time points at all 
concentrations of anti -AMA 1 IgG and NR IgG. This statistically significant increase 
is not seen in anti- MSP3.3C IgG (6066) at 6, 3 and 1.5 mg mL"' and anti- MSP3.3C 
IgG (6067) at 6 and 3 mg mL"'. This could be explained by anti- MSP3.3C IgG 
treated parasites being inhibited during either the ring stage or the trophozoite stage. 
Examination of Giemsa- stained smears reveals that these parasites stall at the 
trophozoite stage of development and that development from the ring to trophozoite 
stage is not inhibited (Figure 5.7, panel C). 
Merozoite invasion occurs between the 40 h and 60 h time points and consequently 
there is a statistically significant increase in parasitaemia in NR IgG treated cultures 
between these two time points. As anti- MSP3.3C IgG treated parasites have at this 
stage not developed beyond the trophozoite stage of the previous cycle (Figure 5.7, 
panel C), their ability to undergo invasion is severely inhibited and this is reflected in 
the low RP values at 60h in Figure 5.7, panel A. At 6, 3 and 1.5 mg mL-' of both 
anti- MSP3.3C IgG treatments, there is no statistically significant increase in 
parasitaemia between 40 h and 60 h. 
Between 40 h and 60 h the DNA content of anti -AMA1 IgG and NR IgG treated 
cultures decreases statistically significantly as parasites undergo invasion and move 
from the schizont stage to the ring stage. In anti- MSP3.3C (6066) IgG at 6, 3 and 1.5 
mg mL-' there is no statistically significant decrease in DNA content (at 0.75 mg 
mL"' there is) and the same is true for anti- MSP3.3C (6067) at 6 and 3 mg mL-1. 
This explains the shape of the titration seen at 60 h in Figure 5.7, panel B. It also 
exemplifies an effect seen in all the SSGIAs, namely that the inhibitory activity of 
anti- MSP3.3C IgG from rabbits 6066 and 6067 is very similar, with the effect of IgG 




The statistical models fitted to explain variation in parasitaemia and DNA content in 
the SSGIA(T) are displayed in Tables 5.12 and 5.17, respectively. For parasitaemia 
the effects of Ab concentration and time point within each treatment are displayed in 
Tables 5.13 -5.16 and for DNA content in Tables 5.18 -5.21. For the outcome 
parasitaemia the concentration of anti -AMA1 IgG (p <0.001), anti- MSP3.3C (6066) 
IgG (p <0.001) and anti- MSP3.3C (6067) IgG (p <0.001) significantly affected 
parasitaemia. The concentration of NR IgG had no affect on parasitaemia 
(p= 0.9147). For the outcome DNA content the concentration of anti- MSP3.3C 
(6066) IgG (p <0.001) and anti- MSP3.3C (6067) IgG (p <0.001) significantly affected 
DNA content. The concentration of anti -AMA1 IgG (p= 0.1547) and NR IgG 
(p= 0.1702) did not affect DNA content. 
At 40 h post invasion RP (Figure 5.8, panel A) and RDA (Figure 5.8, panel B) values 
in anti- MSP3.3C IgG treated cultures are - 1 with the exception of 6 mg mL-1 of Ab, 
where they fall slightly below 1. Hence, progression into S phase is not inhibited 
and the majority of parasites develop into schizonts by 40 h post invasion (Figure 
5.8, panel C). Following merozoite invasion, at the 60 h and 78 h time points, RPs 
are substantially reduced in anti- MSP3.3C IgG treated cultures, to a similar extent as 
that seen with the positive anti-AMA1 control (Figure 5.8 panel A). At 6 mg mL-1 
there is no statistically significant difference between parasitaemias at the 40 h and 
60 h time points in anti-AMA1 and anti- MSP3.3C treatments, despite merozoite 
invasion having occurred between these two time points. This is in contrast to all 
other concentrations of anti -AMA1 and anti- MSP3.3C treatments, in addition to all 
concentrations of NR IgG, where statistically significant differences between 
parasitaemias detected at 40 h and 60 h were detected. 
This inhibition of increase in parasitaemia between 40 h and 60 h in anti- MSP3.3C 
IgG treated cultures could be due to inhibition of merozoite invasion or it could be 
due to inhibition of intraerythrocytic schizont development. The latter is the case as 
exemplified by the persistence of schizonts in anti- MSP3.3C IgG treated cultures at 
60 h and 78 h (Figure 5.8, panel C). At 6 mg mL -1 of either anti- MSP3.3C IgG 
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treatment there was no statistically significant decrease in DNA content between 40 
h (where control cultures are schizonts) and 60 h (where control cultures are rings). 
This is in contrast to anti -AMA 1 and NR IgG where there was a statistically 
significant decrease in DNA content between these two time points. Graphically, 
this effect is exemplified by RDC values substantially above 1 at the highest 
concentration of MSP3.3C specific IgG (Figure 5.8b). At 60 h many of these 
schizonts had disintegrated to the point that it was no longer possible to distinguish 
whether they were trophozoites or schizonts without prior knowledge of their 
developmental stage at the previous time point (Figure 5.10, contrast plates E and F 
with plates G and H). By 78 h a very high proportion of the parasites scored lacked 
their RBC and appeared to be extracellular (Figure 5.10, plates M and N). 
It is not possible to discern from this data whether or not these stalled schizonts have 
undergone fewer mitotic divisions than control cultures prior to schizont rupture. 
RDC values fall slightly below 1 at the 40 h time point for the highest concentration 
of anti- MSP3.3C IgG, when control cultures were at mid -schizont stage, thus a 
greater difference in DNA content may have been detected if sampling had occurred 
just prior to schizont rupture (Figure 5.8b). 
5.3.2. SSGIA(S) 
The statistical models fitted to explain variation in parasitaemia and DNA content in 
the SSGIA(T) are displayed in Tables 5.22 and 5.26, respectively. For parasitaemia 
the effects of Ab concentration and timepoint within each treatment are displayed in 
Tables 5.23 -5.55 and for DNA content in Tables 5.27 -5.30. For the outcome 
parasitaemia the concentration of anti -AMA1 IgG (p <0.001), anti- MSP3.3C (6066) 
IgG (p= 0.0003) and NR IgG (p= 0.0286) significantly affected parasitaemia. The 
significant affect of the concentration of NR IgG, although only weakly statistically 
significant, is likely to be due to a slight inhibition of parasitaemia following 
merozoite invasion at 6 mg mL-I. For the outcome DNA content the concentration 
of anti- MSP3.3C (6066) IgG (p <0.001), anti- MSP3.3C (6067) IgG (p <0.001) and 
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anti -AMA 1 IgG (p <0.001) significantly affected DNA content. The concentration of 
NR IgG (p= 0.1702) did not affect DNA content (p= 0.70781). 
The addition of anti- MSP3.3C IgG to mid -schizont stage cultures results in 
noticeably reduced RPs at all sampling time points (Figure 5.9a). This reduction in 
RP is less than that seen when anti- MSP3.3C IgG is added to mid -ring (Figure 5.7a) 
or mid -schizont (Figure 5.8a) stage cultures. This inhibitory effect of anti- MSP3.3C 
IgG is due to partial inhibition of parasite development during the schizont stage 
preceding the 60 h time point, as evidenced by the persistence of schizonts in anti - 
MSP3.3C treated cultures at this time point, which is not seen in anti -AMA1 or NR 
treated control cultures (Figure 5.9, panel C). 
At the 88 h time points, two effects are noticeable: (i) the drop in RP values in anti - 
MSP3.3C IgG treated cultures becomes more substantial and effects a wider range of 
concentrations of the Ab (Figure 5.9, panel A) and (ii) RDC values are substantially 
reduced. In NR IgG and anti -AMA1 treated cultures there is a statistically 
significant increase in DNA content between 78 h and 88 h as parasites develop from 
the trophozoite stage to the schizont stage. At 6, 3 and 1.5 mg mL "' of both anti - 
MSP3.3C IgG treatments there was no statistically significant increase in DNA 
content from 78 h to 88 h. Analysis of Giemsa- stained smears revealed that this was 
due to the inhibitory action of these antibodies blocking development beyond the 
trophozoite stage. Trophozoites in 78h post invasion cultures treated with anti - 
MSP3.3C IgG appeared to have not formed properly; they were lightly stained, 
wispy in appearance and frequently lacking a cytoplasm. By the final assay time 
point the majority of parasites scored were deformed or visible only as small, densely 
stained dots (Figure 5.10, contrast plates I and J with plates K and L). As for 
SSGIA(T), apparently extracellular parasites were observed, which may explain the 
drop in forward scatter of iRBCs observed by flow cytometry in cultures treated with 
anti- MSP3.3C IgG. Overall, the developmental stage at which anti- MSP3.3C IgG is 
added significantly affects relative parasitaemia at post invasion time points, with 
much lower relative parasitaemias observed when Ab addition occurs at ring or 
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trophozoite stages than at stages. The stage of Ab addition has no effect on RP 
values in anti -AMA1 IgG treated samples. 
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Figures 5.7 -5.9 Anti- MSP3.3C IgG inhibits the in vitro growth of P. falciparum 
by blocking its intraerythrocytic development. The degree of this inhibition 
and the stage at which it occurs is dependent upon the developmental stage 
at which the inhibitory IgG is added. 
A panels, Changes in relative parasitaemia of parasites cultured in the presence 
anti- MSP3.3C IgG (total IgG purified from each of two rabbits, 6066 and 6067) or a 
standard pool of purified rabbit a -AMA1 IgG added at different stages of parasite 
development; ring stage (Figure 5.7a), trophozoite stage (Figure 5.8a) or schizont 
stage (Figure 5.9a). Each IgG preparation was serially diluted across four 
concentrations; 6mg mL -1, 3mg mL -1, 1.5 mL -1 and 0.75 mL "1. At the time points 
indicated on the graphs parasitaemia of anti- MSP3.3C IgG /anti -AMA1 IgG treated 
samples was determined by flow cytometry and compared to RBCs cultured in the 
presence of control naive rabbit IgG of the same concentration (parasitaemia = 1). 
Three independent experiments were performed and individual bars display the 
mean relative parasitaemia for IgG preparations from the three assays, with error 
bars indicating the standard error of the mean (SEM). B panels, Changes in 
relative DNA content of parasites cultured in the presence of anti- MSP3.3C IgG 
(total IgG purified from each of two rabbits, 6066 and 6067) or a standard pool of 
purified rabbit anti -AMA1 IgG added at different stages of parasite development; 
ring stage (Figure 5.7b), trophozoite stage (Figure 5.8b) or schizont stage (Figure 
5.9b). Each IgG preparation was serially diluted across four concentrations; 6mg 
mL 1, 3mg mL -1, 1.5 mL»1 and 0.75 mL 1. At the time points indicated on the graphs 
infected RBCs were stained with Hoechst 33342 and their DNA content measured 
by flow cytometry and compared to parasitised RBCs cultured in the presence of 
control naive rabbit IgG of the same concentration (DNA content = 1). Three 
independent experiments were performed and individual bars show the mean 
relative DNA content for IgG preparations from the three assays, with error bars 
indicating the SEM. C panels, Changes in the intraerythrocytic developmental 
stage of parasites cultured in the presence of anti- MSP3.3C IgG (total IgG purified 
from each of two rabbits, 6066 and 6067), NR IgG, a standard pool of purified rabbit 
anti -AMA1 IgG (A) or no IgG (Inf). Treatments were added at different stages of 
parasite development; ring stage (Figure 5.7c), trophozoite stage (Figure 5.8c) or 
schizont stage (Figure 5.9c). At the time points indicated on the graph, giemsa- 
stained smears were prepared and the proportion of ring (white), trophozoite (light 
grey), schizont (dark grey) and pycnotic (black) parasites enumerated by light 
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microscopy. Percentages shown are the mean of two independent wells from one 











Figure 5.10 An abundance of pycnotic and abnormally developing forms is 
present in anti- MSP3.3C IgG treated cultures. 
Light microscopic comparison of healthy P. falciparum parasites from cultures 
treated with NR IgG, or abnormally developing forms observed in cultures treated 
with anti- MSP3.3C IgG. Plates A and B: pycnotic trophozoites 28 hours after the 
addition of anti- MSP3.3C IgG to ring stage cultures, compared to healthy schizonts 
at the same assay time point in cultures treated with NR IgG (plate D) and healthy 
trophozoites treated with NR IgG from the previous assay time point (plate C). 
Plates E and F, deformed schizonts 40 hours after the addition of anti- MSP3.3C IgG 
to trophozoite stage cultures, whereas at the same assay time point NR IgG treated 
cultures are healthy rings (plate H) and were healthy schizonts at the previous 
assay time point (plate G). Plates I and J, deformed and pycnotic parasites, 48 
hours after the addition of anti- MSP3.3C IgG to schizont stage cultures, contrasted 
to healthy schizonts at the same assay time point from cultures treated with NR IgG 
(plates K and L). Plates M -O, pycnotic and extracellular /collapsedparasites 48 
hours after the addition of anti- MSP3.3C Abs to trophozoite stage cultures. 
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Effect DF f p 
Treatment 3,106 128.44 <0.001 
Concentration 3,106 75.32 <0.001 
Time 2,134 269.68 <0.001 
Treatment *concentration 9,106 11.25 <0.001 
Treatment *time 6,148 62.43 <0.001 
Concentration *time 6,148 46.16 <0.001 
Treatment *concentration *time 18,153 5.75 <0.001 
Table 5.2 Statistical model fitted to explain variation in parasitaemia for all 
treatments in the SSGIA(R). 
Effect DF f p 
Concentration 3,25 30.81 <0.001 
Time 2,32.6 164.64 <0.001 
Concentration *time 6,35.3 18.38 <0.001 
Table 5.3 Statistical model fitted to explain variation in parasitaemia for the 
anti -AMA1 IgG treatment in the SSGIA(R) 
Effect DF f p 
Concentration 3,16.6 0.17 0.9292 
Time 2,36.1 2777.40 <0.001 
Table 5.4 Statistical model fitted to explain variation in parasitaemia for the NR 
IgG treatment in the SSGIA(R) 
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Effect DF f p 
Concentration 3,25.8 35.78 <0.001 
Time 2,34 3.11 0.0574 
Concentration *time 6,36.6 19.33 <0.001 
Table 5.5 Statistical model fitted to explain variation in parasitaemia for the 
anti- MSP3.3C IgG (6066) treatment in the SSGIA(R) 
Effect DF f p 
Concentration 3,23.3 39.57 <0.001 
Time 2,33.5 14.36 <0.001 
Concentration *time 6,36 21.86 <0.001 
Table 5.6 Statistical model fitted to explain variation in parasitaemia for the 
anti- MSP3.3C IgG (6067) treatment in the SSGIA(R). 
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Effect DF f p 
Treatment 3,153 5.55 0.0012 
Concentration 3,153 9.06 <0.001 
Time 2,139 122.53 <0.001 
Treatment *concentration 9,153 3.01 0.0025 
Treatment *time 6,154 16.55 <0.001 
Concentration *time 6,154 7.52 <0.001 
Treatment *concentration *time 18,161 1.99 0.0127 
Table 5.7 Statistical model fitted to explain variation in parasite DNA content 
for all treatments in the SSGIA(R). 
Effect DF f p 
Concentration 3,21.3 0.08 0.9727 
Time 2,37.9 86.66 <0.001 
Concentration *time NS 
Table 5.8 Statistical model fitted to explain variation in parasite DNA content 
for the anti -AMA1 IgG treatment in the SSGIA(R). 
Effect DF f p 
Concentration 3,17.8 0.37 0.7740 
Time 2,36.8 163.91 <0.001 
Concentration *time NS 
Table 5.9 Statistical model fitted to explain variation in parasite DNA content 
for the NR IgG treatment in the SSGIA(R). 
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Effect DF f p 
Concentration 3,51.4 9.61 <0.001 
Time 2,34.6 1.34 0.2758 
Concentration *time 6,38 3.95 0.0037 
Table 5.10 Statistical model fitted to explain variation in parasite DNA content 
for the anti- MSP3.3C IgG (6066) treatment in the SSGIA(R). 
Effect DF f p 
Concentration 3,38.1 7.03 0.0007 
Time 2,34.4 7.08 0.0027 
Concentration *time 6,37.5 6.20 <0.001 
Table 5.11 Statistical model fitted to explain variation in parasite DNA content 
for the anti- MSP3.3C IgG (6067) treatment in the SSGIA(R). 
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Effect DF f p 
Treatment 3,89.4 262.69 <0.001 
Concentration 3,89.4 465.43 <0.001 
Time 2,163 2791.44 <0.001 
Treatment *concentration 9,89.4 57.87 <0.001 
Treatment *time 6,167 106.26 <0.001 
Concentration *time 6,167 220.95 <0.001 
Table 5.12 Statistical model fitted to explain variation in parasitaemia for all 
treatments in the SSGIA(T). 
Effect DF f p 
Concentration 3,28 336.06 <0.001 
Time 2,43.2 16.49 <0.001 
Concentration *time 6,44.5 75.15 <0.001 
Table 5.13 Statistical model fitted to explain variation in parasitaemia for the 
anti -AMAI IgG treatment in the SSGIA(T). 
Effect DF f p 
Concentration 3,24.4 0.17 <0.9147 
Time 2,39.9 2777.40 <0.001 
Table 5.14 Statistical model fitted to explain variation in parasitaemia for the 
NR IgG treatment in the SSGIA(T). 
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Effect DF f p 
Concentration 3,16.8 189.26 <0.001 
Time 2,36.7 306.63 <0.001 
Concentration *time 6,37.3 94.80 <0.001 
Table 5.15 Statistical model fitted to explain variation in parasitaemia for the 
anti- MSP3.3C IgG (6066) treatment in the SSGIA(T). 
Effect DF f p 
Concentration 3,22.4 308.84 <0.001 
Time 2,41.7 651.50 <0.001 
Concentration *time 6,42.4 123.64 <0.001 
Table 5.16 Statistical model fitted to explain variation in parasitaemia for the 
anti- MSP3.3C IgG (6067) treatment in the SSGIA(T). 
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Effect DF f p 
Treatment 3,88 9.96 <0.001 
Concentration 3,88 59.79 <0.001 
Time 2,149 2130.81 <0.001 
Treatment *concentration 9,88 21.27 <0.001 
Treatment *time 6,158 20.33 <0.001 
Concentration *time 6,158 45.85 <0.001 
Treatment *concentration *time 18,160 11.38 <0.001 
Table 5.17 Statistical model fitted to explain variation in parasite DNA content 
for all treatments in the SSGIA(T). 
Effect DF f p 
Concentration 3,22.9 1.92 0.1547 
Time 2,38.5 703.84 <0.001 
Concentration *time NS 
Table 5.18 Statistical model fitted to explain variation in parasite DNA content 
for the anti -AMAI IgG treatment in the SSGIA(T). 
Effect DF f p 
Concentration 3,25 1.81 0.1702 
Time 2,39.1 1114.82 <0.001 
Concentration *time NS 
Table 5.19 Statistical model fitted to explain variation in parasite DNA content 
for the NR IgG treatment in the SSGIA(T). 
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Effect DF f p 
Concentration 3,20.2 43.9 <0.001 
Time 2,39.5 301.42 <0.001 
Concentration *time 6,40.3 46.19 <0.001 
Table 5.20 Statistical model fitted to explain variation in parasite DNA content 
for the anti- MSP3.3C IgG (6066) treatment in the SSGIA(T). 
Effect DF f p 
Concentration 3,21.6 46.21 <0.001 
Time 2,36.4 419.01 <0.001 
Concentration *time 6,38.3 27.38 <0.001 
Table 5.21 Statistical model fitted to explain variation in parasite DNA content 
for the anti- MSP3.3C IgG (6067) treatment in the SSGIA(T). 
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Effect DF f p 
Treatment 3,78 33.35 <0.001 
Concentration 3,78 25.80 <0.001 
Time 2,122 71.37 <0.001 
Treatment *concentration 9,78 3.27 0.0020 
Treatment *time 6,145 15.38 <0.001 
Table 5.22 Statistical model fitted to explain variation in parasitaemia for all 
treatments in the SSGIA(S). 
Effect DF f p 
Concentration 3,18 17.12 <0.001 
Time 2,29.6 20.85 <0.001 
Table 5.23 Statistical model fitted to explain variation in parasitaemia for the 
anti -AMAI IgG treatment in the SSGIA(S). 
Effect DF f p 
Concentration 3,15.9 3.92 0.0286 
Time 2,34.6 36.74 <0.001 
Table 5.24 Statistical model fitted to explain variation in parasitaemia for the 
NR IgG treatment in the SSGIA(S). 
Effect DF f p 
Concentration 3,18 10.77 0.0003 
Time 2,29.8 76.72 <0.001 
Table 5.25 Statistical model fitted to explain variation in parasitaemia for the 
anti- MSP3.3C IgG (6066) treatment in the SSGIA(S). 
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Effect DF f p 
Treatment 3,78 303.84 <0.001 
Concentration 3,78 17.46 <0.001 
Time 2,178 374.78 <0.001 
Treatment *concentration 9,78 2.75 0.0076 
Treatment *time 6,178 86.12 <0.001 
Concentration *time 6,178 8.45 <0.001 
Treatment *concentration *time NS 
Table 5.26 Statistical model fitted to explain variation in parasite DNA content 
for all treatments in the SSGIA(S). 
Effect DF f p 
Concentration 3,18 13.11 <0.001 
Time 2,40 139.10 <0.001 
Concentration *time 6,40 3.08 0.0141 
Table 5.26 Statistical model fitted to explain variation in parasite DNA content 
for the anti -AMAI IgG treatment in the SSGIA(S). 
Effect DF f p 
Concentration 3,18 2.68 0.70781 
Time 2,46 249.34 <0.001 
Concentration *time NS 
Table 5.27 Statistical model fitted to explain variation in parasite DNA content 
for the NR IgG treatment in the SSGIA(S). 
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Effect DF f p 
Concentration 3,18 14.55 <0.001 
Time 2,40 16.69 <0.001 
Concentration *time 6,40 15.20 <0.001 
Table 5.28 Statistical model fitted to explain variation in parasite DNA content 
for the anti- MSP3.3C IgG (6066) treatment in the SSGIA(S). 
Effect DF f p 
Concentration 3,18 27.66 <0.001 
Time 2,40 19.99 <0.001 
Concentration *time 6,40 17.30 <0.001 
Table 5.29 Statistical model fitted to explain variation in parasite DNA content 
for the anti- MSP3.3C IgG (6067) treatment in the SSGIA(S). 
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5.3.3 MSP3.3 expression 
The SSGIA results demonstrated that P. falciparum is only susceptible to growth 
inhibition by anti- MSP3.3C Abs over a specific time window of its development 
within the host erythrocyte. Thus ascertaining where MSP3.3 is located at the 
different stages of the erythrocytic cycle may provide some insight into how anti - 
MSP3.3C Abs inhibit parasite development. 
The subcellular localisation of MSP3.3 at each stage of the erythrocytic cycle was 
determined by IFA; parasites were probed with MSP3.3C- specific, affinity purified 
IgG and the mouse mAb 7.7, which recognises the PVM antigen EXP -2. MSP3.3 is 
expressed in the intraerythrocytic ring, trophozoite and schizont stages, and on free 
merozoites (Figure 5.11). IFAs of young trophozoite stages revealed that MSP3.3 is 
located outside of the PV, in the erythrocyte cytoplasm (Figure 5.11, 2nd column of 
rows 3 and 4). This was highly surprising given that up until this point MSP3.3 was 
thought to only localise to the merozoite surface. The identification of this novel 
MSP3.3 location was made possible by the examination of young trophozoite stages, 
which occupy a small area of the RBC and thus MSP3.3 export is visible. By the 
schizont stage, the parasite occupies the majority of the RBC cytoplasm and the 
exported MSP3.3 is no longer visible (Figure 5.11, 
3rd column of rows 3 and 4). A 
short peptide sequence, known as the Plasmodium export element (PEXEL), is 
frequently found in parasite proteins that are exported outside of the PV (Haase and 
de Koning -Ward, 2010). A search of the MSP3.3 protein sequence revealed a 
PEXEL motif from amino acid positions 19 -23 (Figure 5.1) and this may explain the 
staining pattern observed in IFAs with trophozoite stage cultures. 
In order to investigate the subcellular location of MSP3.3 at a higher resolution, IFAs 
were repeated on trophozoite and schizont stage cultures and examined via confocal 
microscopy. These IFAs confirmed the localisation patterns observed in the first 
experiment. In young trophozoites anti- MSP3.3 staining occurs in a particulate 
pattern outside of the PVM, in the RBC cytoplasm (Figure 5.12a). In mature 
schizonts, the anti- MSP3.3 staining pattern is consistent with a merozoite surface 
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location and appears to co- localise with anti -EXP2 staining at some areas of the 
merozoite surface, as indicated by the partial overlap of red and green (yellow 
staining, Figure 5.12b, panels in the 6th column). This partial co- localisation may 
result from the punctate staining pattern of EXP -2 (Figure 5.12 panels A and B, 2nd 
column). 
For all IFAs the following controls were carried out: (i) single stain slides to check 
that EXP -2 and MSP3.3 single stain patterns were the same as that on double stain 
slides and (ii) parasites were probed with secondary Abs alone in order to confirm 
their specificity. 
5.3.4 IgG uptake 
The observation that MSP3.3C specific Abs can inhibit intraerythrocytic parasite 
development in the absence of merozoite invasion, for example as seen during the 
SSGIA(R) assay, indicates that these Abs may be able to access the intraerythrocytic 
parasite post invasion. To test this hypothesis ring stage parasites were incubated 
with MSP3.3C specific, affinity purified rabbit IgG or NR IgG and evaluated by 
fluorescence microscopy for the presence of internalised IgG. At 30h (Figure 5.13, 
panels in column 1, rows 3 and 4) 40h (Figure 5.13, panels in column 2, rows 3 and 
4) and 60h post invasion (Figure 5.13, panels in column 3, rows 3 and 4), MSP3.3 
specific IgG was detected within trophozoite, schizont and ring infected RBCs, 
respectively. The panels in the 5th row of Figure 5.13 display merged images of 
DAPI, anti -EXP -2 and anti -NR IgG staining in NR IgG treated samples. NR IgG 
was not dected within trophozoite, schizont or ring infected RBCs. 
In order to investigate this IgG uptake at higher resolution, a similar experiment was 
performed using confocal microscopy. In this experiment anti -AMAI IgG was 
included as an experimental treatment to determine whether Abs recognising other 
target antigens are also able to access the intraerythrocytic parasite post invasion. 
Anti -AMA1 IgG was detected in schizont iRBCs 40h post invasion (Figure 5.14b, 
panels in the 2 "d row of columns 3 and 4) and MSP3.3C- specific IgG was detected in 
161 
trophozoite and schizont iRBCs 30h (Figure 5.14a, 1st row of columns 3 and 4) and 
40h post invasion (Figure 5.14b, 1st row of columns 3 and 4), respectively. High 
background staining in some NR IgG treated samples (Figure 5.14b, 4th row, 
columns 3 and 4) meant that it was not possible to define whether or not NR IgG was 
located inside iRBCs in this experiment, however, no staining colocalising with 
iRBCs was above background and no specific staining pattern was observed in these 
samples. 
5.3.5 JC -1 assays 
The ability of Abs to disrupt the intraerythrocytic development of P. falciparum and 
cause deterioration of the parasite was first noted by Jensen (Jensen et al., 1982). 
These "crisis forms" have since been observed in cultures treated with Abs specific 
to MSP -1 (Arnot et al., 2008; Woehlbier et al., 2006), Pf332 (Ahlborg et al., 1996) 
and MSP3.3 (Dhanasarnsombut). To date, the fate of these Ig- induced crisis forms 
has not been investigated. Similar "crisis forms ", observed in cultures exposed to 
antimalarial drugs (Ch'ng et al., 2010; Meslin et al., 2007), febrile temperatures 
(Oakley et al., 2007) and steroids (López et al., 2010), have been shown to be 
undergoing parasite death. It therefore follows that the unhealthy forms observed in 
response to anti- MSP3.3C IgG treatment may similarly be undergoing parasite death. 
To explore this hypothesis, the lipophilic dye JC -1 was used to determine if any loss 
of mitochondrial membrane potential (MMP), a marker of parasite death, was 
occurring in cultures treated with anti- MSP3.3C IgG. In healthy cells, JC -1 exists in 
two different forms; the negative charge across the mitochondrial membrane enables 
the dye to accumulate as aggregates in the mitochondrial matrix, which emit a red 
fluorescence, whereas in the cell cytoplasm JC -1 exists as a monomer, which emits a 
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Figure 5.11 MSP3.3 is expressed in blood stage parasites and exported 
outside of the parasitophorous vacuole. 
Representative IFA photomicrographs of rings (1St column), trophozoites (2nd 
column), schizonts (3`d column) and free merozoites (4th column) probed with 
MSP3.3C specific, affinity purified rabbit IgG (red) and the anti -EXP -2 mouse mAb 
7.7 (green), which served as a marker for the PVM of the intracellular parasite. 
Nuclear staining (DAPI) is whosn in blue. Single channels and a merged image are 
shown for each stage. 
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Figure 5.12 Confocal microscopy images of MSP3.3C staining in trophozoites 
and schizonts. 
Representative confocal microscopy images of trophozoites (panel A) and schizonts 
(panel B) probed with MSP3.3C specific, affinity purified IgG (red) and the anti -EXP- 
2 mouse mAb 7.7 (green), which marks the PVM of the intraerythrocytic parasite. 
Parasite nuclei were visualised with DAPI (blue). Single channels and merged 
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Figure 5.13 MSP3.3C specific IgG enters the iRBC post invasion. 
MSP3.3C specific, affinity purified rabbit IgG or NR IgG was added to synchronous 
ring stage cultures 12 hours post invasion. At 30h, 40h and 60h post invasion IFA 
slides were prepared from treatment wells. Parasites were probed with the anti - 
EXP-2 mouse mAb 7.7 and DAPI and visualised by fluorescence microscopy. 
Representative images from anti- MSP3.3C IgG treated cultures of single channel 
DAPI (first row), FITC (anti -EXP2, second row), Alexa 568 (anti- MSP3.3, third row) 
fluorescence, in addition to merged images from all three channels (fourth row) at 
30h (1st column), 40h (2nd column) and 60h (3rd column) post invasion. In the fifth 
row a representative merged image of DAPI, FITC (anti -EXP2) and Alexa 568 (anti - 
MSP3.3C) at 30h (1St column), 40h (2nd column) and 60h (3`d column) is displayed. 
Anti- MSP3.3 IgG but not NR IgG could be detected inside iRBCs 30 h, 40 h and 60 
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Figure 5.14 MSP3.3C and AMAI specific IgG enters the iRBC post invasion. 
Confocal microscopy of P. fa/ciparum treated with MSP3.3C- specific, affinity purified 
rabbit IgG or anti -AMA1 IgG or NR IgG added to synchronous ring stage cultures 12 
h post invasion. At 30 h post invasion, MSP3.3C- specific IgG, but not NR IgG could 
be detected by confocal microscopy inside trophozoite iRBCs (panel A). Single 
channel DAPI (column 1), FITC (anti -EXP -2, column 2) and Alexa 568 (anti- mouse, 
column 3) fluorescence or a merged image from all 3 channels (column 4) for 
cultures treated with anti- MSP3.3C IgG (1st row), no antibody (2nd row) or NR IgG 
(3rd row) is displayed. 40 h post invasion MSP3.3C- specific IgG and AMA1 specific 
IgG could be detected by confocal microscopy inside schizont iRBCs (panel B). 
Single channel DAPI (column 1), FITC (anti -EXP -2, column 2) and Alexa 568 (anti - 
mouse, column 3) fluorescence or a merged image from all 3 channels (column 4) 
for cultures treated with anti- MSP3.3C IgG (1st row), anti -AMA1 (2nd row), no Ab (31-d 
row) or NR IgG is displayed. The anti -EXP -2 mouse mAb 7.7 and DAPI were used 
to demarcate the PVM and parasite nuclei, respectively. 
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to the collapse of the electrochemical gradient across the mitochondrial membrane, 
resulting in a loss of JC1 -red fluorescence but not JC1 -green fluorescence. 
An initial experiment was carried out to determine: (i) that JC -1 could be used to 
detect MMP loss under the conditions tested, (ii) whether there was any indication 
that loss of parasite MMP was occurring in response to anti- MSP3.3C IgG treatment 
and (iii) the time of onset and duration of any such loss detected. NR IgG served as 
a negative control and the antimalarial drug chloroquine (CQ) as a positive control, 
as loss of MMP has been shown to occur when parasites undergo programmed cell 
death in response to CQ treatment (Ch'ng et al., 2010). The standard method used by 
researchers to analyse JC -1 flow data is to define JC -1 red and JC -1 green - positive 
gates based on an arbitrarily defined level of fluorescence intensity. In order to 
circumvent the subjectivity required by this method of analysis, in the analyses 
presented below I have calculated the ratio of JC -1 red fluorescence to JC -1 Green 
fluorescence for each individual infected RBC. The data are presented as the 
distribution of these ratios for the entire iRBC population of each sample. 
In the preliminary experiment, treatments were added to highly synchronous ring 
stage cultures and MMP measured at three time points over the following 48h 
replication cycle. Eight hours after treatments had been applied (20h post invasion), 
loss of MMP could be detected at the highest concentration of anti- MSP3.3C IgG 
and in the CQ- treated positive control (Figure 5.15). By 32 h post invasion anti - 
MSP3.3C IgG treated parasites displayed a highly significant loss of MMP relative 
to controls, and this effect was dose -dependent. 
Interpretation of the results at the next time point (60h post invasion), which occurs 
after control cultures have undergone merozoite invasion, becomes more difficult. 
This is because the JC 1 red fluorescence to JC1 green fluorescence ratio (R:G) 
increases throughout the intraerythrocytic cycle of the parasite, with ring stage 
parasites having a significantly lower R:G that trophozoites, which in turn have a 
lower R:G than schizonts. Hence, at this time point "parasite stage" becomes a 
confounding factor making any meaningful interpretation of the results extremely 
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difficult. Due to this, the JC -1 assay was adapted so that sampling occurred at 
shorter intervals and only covered the developmental period over which parasite 
stage is the same in both experimental and control cultures. In this assay MSP3.3C 
specific IgG or NR IgG were added to highly synchronous ring stage cultures 10 h 
post invasion and sampling time points were immediately after assay set up (10h), 
22h, 30h and 36h post invasion. 
Three independent replicates of this experiment were carried out. The range of JC -1 
R:G ratios were statistically significantly different between these experiments, 
possibly due to the fact that different voltage settings were used on the flow 
cytometer for each experiment. Therefore, all three experiments were not combined 
for statistical analysis. The general trends were the same in all three experiments and 
representative results from one of them are displayed in Figure 5.16. 
For the 10 h post invasion time point, samples were taken immediately after 
treatments were applied and as expected there is no statistical significant difference 
between treatments (p= 0.18). At 22 h and 36 h JC -1 R:G ratios obtained with anti - 
MSP3.3C IgG and NR IgG treated samples were statistically significantly different 
from one another (p <0.05 and p <0.001, respectively). At 30 h post invasion 
treatment was not a significant risk factor in the statistical model fitted to explain the 
data (p= 0.93). The loss of statistical significance at this time point is likely due to 
the higher R:G ratios observed in the second set of anti- MSP3.3C IgG treated wells 
(Figure 5.16, bottom left -hand graph, box plots 5 -8). MMP loss was detected for CQ 
and sodium azide positive control treatments, as expected. 
5.3.6 DCFH -DA assays 
Chapter 4 of this thesis explored the hypothesis that Abs to MSP -119 are able to 
inhibit the intraerythrocytic growth of P. falciparum by carrying out ACWO inside 
the RBC. Given that Abs to MSP3.3C can access the intraerythrocytic parasite and 
inhibit the development of the parasite inside the RBC, it seemed logical to examine 















































































Figure 5.15 JC -1 red:gree ratios of iRBCs after treatment with MSP3.3C- 
specific IgG. 
MSP3.3C specific IgG (6 mg mL 1, 3 mg mL 1, 1.5 mg mL 1, 0.75 mg RIC), NR IgG 
(6 mg mL 1, 3 mg mL "1, 1.5 mg mL -1, 0.75 mg mL -1), no Ab or 30 pM chloroquine 
(CQ) was added to highly synchronous ring stage cultures 12 hours post invasion. 
20h, 32h and 60h post invasion, samples were taken from each treatment well, 
stained with JC -1 and Hoechst, and Hoechst, JC -1 green and JC -1 red fluorescence 
measured by flow cytometry. Infected RBCs were gated on hoecsht fluorescence. 
Following this, the ratio of JC -1 red fluorescence to JC -1 green fluorescence of each 
individual infected red blood cell in each sample was calculated using the R 
statistical language. The box plots depict the distribution of ratios for each sample 
with the 25th percentile, median and the 75th percentile displayed. The whisker range 
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Figure 5.16 JC -1 staining of iRBCs reveals loss of MMP in P. falciparum 
parasites in the presence of MSP3.3C specific Abs. 
MSP3.3C specific IgG (6 mg mL -1, 3 mg mL-1, 1.5 mg mL -1, 0.75 mg mL-1), NR IgG 
(6 mg mL -1, 3 mg mL-1, 1.5 mg mL-1, 0.75 mg mL-1), no Ab, 30 pM chloroquine (CQ) 
or sodium azide was added to highly synchronous ring stage cultures 10 hours post 
invasion. Immediately after assay set up (10h), 22h, 30h and 36h post invasion, 
samples were taken from each treatment well, stained with JC -1 and Hoechst, and 
JC -1 green, JC -1 red and Hoechst fluorescence measured by flow cytometry. A, An 
illustration of the gating strategy employed. For all samples, infected RBCs were 
gated on hoecsht fluorescence (left hand plot). The JC -1 red fluorescence and JC -1 
green fluorescence of the total iRBC population can then be viewed (right hand plot) 
B, Bivariate scatter plots of JC -1 red fluorescence versus JC -1 green fluorescence 
of iRBCs from MSP3.3C and NR IgG treated samples at time point 2. C, The ratio 
of JC -1 red fluorescence to JC -1 green fluorescence of each individual infected red 
blood cell in each sample was calculated using the R statistical language. The box 
plots depict the distribution of ratios for each sample with the 25th percentile, median 
and the 75th percentile displayed. The whisker range is between the 10th and 90th 
percentiles. Data from two duplicate wells of each sample is shown, from one of 
three independent experiments. 
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Variable P value Relative Risk 95% CI 
Treatment 0.18 1.07 0.97 - 1.17 
Concentration 2 0.11 1.12 0.97- 1.28 
Concentration 3 0.49 1.05 0.91 - 1.2 
Concentration 4 <0.001 1.27 1.11 - 1.45 
Table 5.30 The results of the statistical model fitted to explain variation in JC -1 
R:G 10 h post invasion. 
Variable P value Relative Risk 95% CI 
Treatment 0.038 1.21 1.01 - 1.45 
Concentration 2 0.43 0.90 0.7 - 1.16 
Concentration 3 0.92 1.01 0.78 - 1.31 
Concentration 4 0.57 1.08 0.83 - 1.39 
Table 5.31 The results of the statistical model fitted to explain variation in JC -1 
R:G 22 h post invasion. 
Variable P value Relative Risk 95% CI 
Treatment .93 0.99 0.87 -1.14 
Concentration 2 0.1 1.18 0.97 -1.43 
Concentration 3 0.35 1.1 0.9 -1.33 
Concentration 4 0.05 1.21 1.00 - 1.48 
Table 5.32 The results of the statistical model fitted to explain variation in JC -1 
R:G 30 h post invasion. 
Variable P value Relative Risk 95% CI 
Treatment <0.001 1.34 1.16 -1.54 
Concentration 2 0.41 1.09 0.89 -1.32 
Concentration 3 0.52 1.07 0.88 -1.30 
Concentration 4 0.81 1.03 0.84 - 1.25 
Table 5.33 The results of the statistical model fitted to explain variation in JC -1 
R:G 36 h post invasion. 
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To this end, a preliminary experiment was carried out to determine whether an 
increased level of ROS could be detected in iRBCs cultured in the presence of 
MSP3.3C specific IgG relative to those cultured in the presence of NR IgG. Two 
different assays were carried out in parallel, in the first assay Ab treatments were 
applied to a parasite culture pre -loaded with DCFH -DA, where as in the second 
assay, Ab treatments were applied to a standard parasite culture and at each sampling 
time point parasites were stained with DCFH -DA in order to measure the DCF signal 
at the particular time point. In both assays, anti- MSP3.3C IgG or NR IgG was added 
to highly synchronous ring stage cultures 10h post invasion and sampling time points 
were immediately after the addition of treatments to the assay culture (10 h time 
point), 22h and 30h post invasion. 
Figure 5.17 displays the DCF fluorescence of iRBCs, expressed as the median 
fluorescence intensity in the FITC channel, in the assay where the cumulative DCF 
signal over time was measured i.e. Ab treatments had been applied to a culture pre - 
loaded with DCFH -DA. At 22 h and 30 h post invasion, at the higher concentrations 
of anti- MSP3.3C IgG, there is some indication that the ROS level inside the iRBC up 
until these time points is slightly higher than in untreated samples. This is, however, 
unlikely to be a specific effect of anti- MSP3.3C Abs, as a similar effect can be seen 
in NR IgG treated samples. 
Figure 5.18 displays the normalised DCF fluorescence when the DCF signal is 
measured at specific time -points during the assay i.e. parasites stained with DHCF- 
DA at sampling time points. For each sample, iRBCs were gated on the basis of 
Hoechst fluorescence. The DCF signal of the total iRBC population was determined, 
expressed as the median fluorescence intensity of the FITC channel. The arithmetic 
mean DCF signal was computed for each set of duplicate wells and normalised by 
dividing it by the mean DCF signal of duplicate wells treated with the same 
concentration of NR IgG at the same time point. Therefore, a normalised DCF 
fluorescence of 1 indicates no difference from the negative control, normalised DCF 
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Figure 5.17 Cumulative DCF signals in cultures treated with MSP3.3C specific 
IgG. 
MSP3.3C specific IgG, NR IgG, chloroquine (CQ), sodium azide (NaN3) or no 
treatment was added to iRBCs pre -loaded with the ROS probe DHCF -DA. 10h, 22h 
and 30h post invasion samples were taken, stained with Hoechst 33342 and the 
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Figure 5.18 DCF signals detected at specific time points in the presence of 
MSP3.3C specific IgG. 
MSP3.3C specific IgG or naive rabbit IgG was added to highly synchronous ring 
stage cultures 10 h after invasion and the ROS level of iRBCs measured at 10 h 
(circles), 22 h (squares) and 30 h (triangles) post invasion with the intracellular ROS 
probe DCFH -DA. The DCF signal (median fluorescence intensity) of the total iRBC 
population was determined prior to normalising the data to the DCF signal (median 
fluorescence intensity) detected at that time time point at the same concentration of 
NR IgG. 
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Figure 5.19 The effect of MSP3.3C specific Abs on parasite ROS levels. 
MSP3.3C specific IgG or NR IgG was added to highly synchronous ring stage 
cultures 10h post invasion and the ROS level of iRBCs measured at 10h, 22h, 30h 
and 36h post invasion using the intracellular ROS probe, DCFH -DA. The DCF 
signal (median fluorescence intensity) of the total iRBC population was determined 
prior to normalising the data to the DCF signal detected at the same concentration 
of NR IgG. Two independent experiments were performed and individual bars 
display the mean normalised DCF fluorescence from these two experiments, with 
error bard indicating the standard error of the mean. 
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and normalised DCF fluorescence values < 1 indicate DCF signals lower than the 
negative control. 
In contrast to the higher level of ROS in the presence of anti- MSP3.3C IgG that one 
would expect to see if ACWO were occurring, at 22h and 30h post invasion, iRBCs 
treated with anti- MSP3.3C IgG exhibited normalised DCF fluorescence significantly 
below this level and this effect was dose -dependent (Figure 5.18). It appears that this 
effect may occur within minutes of Ab addition as, at the highest concentration of 
anti- MSP3.3C IgG, a reduced DCF signal is detected at the 10 h post invasion time 
point i.e. immediately after antibodies had been added to the assay culture (Figure 
5.18). 
In order to confirm the reduced level of ROS detected in MSP3.3C IgG treated 
cultures, two further independent experiments were carried out, adding MSP3.3C 
specific IgG or NR IgG 10 h post -invasion and measuring the ROS level of iRBCs, 
immediately after treatments had been added to the assay culture (i.e at 10h), and at 
22h, 30h and 36h post invasion. Samples taken immediately after treatments were 
added to wells did not display a normalised DCF fluorescence ratio significantly 
different from 1. At all later sampling time points, at 6 and 3 mg mL-' of anti - 
MSP3.3C IgG the normalised DCF fluorescence falls far below 1. This effect 
appears to decline at 1.5 and 0.75 mg mL "' anti- MSP3.3C IgG at 30 and 36 h post 
invasion (Figure 5.19). 
5.4 Discussion 
The activity of Abs in parasite GlAs can result from inhibition of merozoite invasion 
or inhibition of the intraerythrocytic development of the parasite. The terminology 
used is confusing; the word "growth" in GIA refers to the increase in parasitaemia 
that occurs over successive invasion cycles, yet "growth" is also used in reference to 
the physiological and biochemical development of the parasite inside the RBC. For 
the purpose of clarity, I will refer to the latter as parasite development and the former 
as parasite growth. A common misconception by some authors (Bergmann -Leitner 
et al., 2009; Duncan and Hill, 2012) is that functional GIA readouts which detect 
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both live and dead parasites, measure inhibition of merozoite invasion, where as read 
outs detecting only live parasites measure both inhibition of merozoite invasion and 
parasite development. While the latter statement is correct, the former is not; 
inhibition of merozoite invasion can result from development inhibition earlier in the 
erythrocytic cycle. For example, if Abs block development of the parasite at the 
schizont stage, merozoite invasion will not occur, yet this does not directly result 
from Abs interfering with merozoite invasion. 
By using a modified GIA, the stage -specific GIA ( SSGIA), which measures the 
effect of adding Ab to each intraerythrocytic parasite stage, and then monitors the 
intraerythrocytic development of the parasite over one invasion cycle, I have shown 
that the GIA activity of MSP3.3C specific Abs is due to developmental inhibition of 
the parasite. P. falciparum is only susceptible to this inhibition over a limited time 
period of its development inside the RBC; the formation of ring forms and their 
maturation into trophozoite forms was not inhibited in the SSGIA, whereas the 
further development of trophozoite and schizont stages was. It took some hours from 
the time of Ab addition until development of the parasite was retarded or halted. 
This is seen most clearly during the SSGIA(T), where MSP3.3C specific Abs are 
added to a synchronous culture 30 -34 h P.I. We know from the SSGIA(R) data that 
trophozoites are vulnerable to growth retardation by MSP3.3C specific Abs, however 
in the SSGIA(T), the intraerythrocytic development of the parasite is not halted until 
the schizont stage. 
1 cannot rule out the possibility that MSP3.3C specific Abs are able to carry out a 
small level of merozoite invasion inhibition, as inhibition assays were not carried out 
using purified merozoites, which would be the only way to defmitively rule out this 
possibility. However, the data presented here supports the proposal that the 
predominant mode of action of MSP3.3C specific Abs is to block the development of 
the intraerythrocytic trophozoite and schizont stages. This is in contrast to Abs to 
well- characterised antigens such as AMA -1 and Rh5, which work by preventing the 
ability of extracellular merozoite to invade the RBC (Douglas et al., 2011; Kocken et 
al., 1998). 
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The ability of Abs to disrupt the intraerythrocytic development of P. falciparum in 
vitro has been recognised for many years (Jensen et al., 1982; Jensen et al., 1984). 
Abs to antigenically distinct regions of MSP -1 display development inhibitory 
activity in GIAs (Arnot et al., 2008; Bergmann -Leitner et al., 2009; Woehlbier et al., 
2006), and in the case of anti -MSP -119 Abs this may be due to interference of the Ab 
with food vacuole formation (Moss et al., 2012). Additionally, in GIAs Abs to Pf332 
can inhibit the development of mature asexual blood stages (Balogun et al., 2011). 
These cases of development inhibition occur in the absence of immune effector cells, 
however, Abs can also act in cooperation with monocytes to inhibit the growth of P. 
falciparum in vitro. This process is called antibody- dependent cellular inhibition 
(ADCI) and results in intraerythrocytic inhibition of the parasite at the trophozoite 
stage (Bouharoun -Tayoun et al., 1995; Jafarshad et al., 2007). In all of the 
aforementioned cases of development inhibition, and in the SSGIA assays carried out 
in the presence of anti- MSP3.3C IgG, parasites displaying abnormal morphology and 
resembling "crisis forms" were observed. However, to date no one has investigated 
the phenotype of these unhealthy forms. 
Here, I have demonstrated that in response to treatment with MSP3.3C specific Abs, 
P. falciparum undergoes parasite death, as demonstrated by loss of parasite MMP. 
Recently, a CQ induced programmed cell death (PCD) pathway has been described 
in P. falciparum (Ch'ng et al., 2010; Ch'ng et al., 2011). In these studies MMP loss 
was used as a marker for parasite PCD and distinguished from unregulated necrotic 
death seen in response to heat or sodium azide treatment. I included CQ and sodium 
azide treatments, at the same concentration as these researchers, in my JC -1 
experiments and also observed loss of MMP in response to CQ treatment. However, 
contrary to the Tan group, I also observed a similar magnitude of MMP loss in 
response to sodium azide treatment. This is not surprising as sodium azide blocks 
the mitochondrial electron transport chain and decreases MMP in rat cells (Sato et 
al., 2008). Jogdand et al. (Jogdand et al., 2012) demonstrated loss of MMP in dying 
parasites treated with hyperimmune IgG and anti -GLURP Abs during ADCI assays. 
These researchers also detected loss of parasite MMP in response to medium 
starvation and temperature fluctuation, further indicating that loss of MMP may be a 
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general indicator of parasite death, not just PCD. It is therefore not possible to 
determine from my data whether a- MSP3.3C IgG treated parasites are undergoing 
parasite PCD or necrotic death. The measurement of other PCD markers during 
SSGIAs might prove useful in this regard. However, measurement of P. falciparum 
PCD has been inconsistent among different research groups (Meslin et al., 2007; 
Nyakeriga et al., 2006; Totino et al., 2008). It would be interesting to investigate 
whether MMP loss, and parasite death occur in response to treatment with Abs of 
different specificities, such as those to MSP -1 and Pf332, where unhealthy parasites 
have been observed microscopically in response to Ab treatment. RBCs undergo 
eryptosis in response to a variety of treatments (Lang and Qadri, 2012) and it is 
possible that parasites are dying in response to a- MSP3.3C IgG treatment because 
the RBCs they inhabit are undergoing eryptosis. This hypothesis is consistent with 
the large number of extracellular intraerythrocytic forms observed in MSP3.3C 
treated cultures. A high proportion of extracellular intraerythrocytic forms have also 
been observed in a -Pf332 Ab treated cultures. 
GIAs fulfil two primary roles in malaria research. Firstly, they are used to 
comparatively test between different asexual vaccine candidate antigens and 
platforms (Arnot et al., 2008; Douglas et al., 2011; Reed et al., 2009). Secondly, 
they are used to assess the functional activities of antimalarial Abs and thereby 
provide insight into what effector mechanisms might govern human immunity to P. 
falciparum infection. There are several limitations to both of these approaches; in 
vitro mechanisms of antibody action may not operate in vivo and it has yet to be 
demonstrated that GIAs are of any value in predicting vaccine efficacy (Duncan and 
Hill, 2012). 
The research presented here highlights the importance of ensuring that the assay 
techniques used in GIAs are relevant to the mode of action of the Abs in question. 
For example the National Institute of Health GIA reference centre uses biochemical 
measurement of pLDH as its functional readout in GIAs. However, the enzymatic 
activity of pLDH is higher in more mature intraerythrocytic parasite stages (Vivas et 
al., 2005), therefore comparing the comparative efficiency of two different Abs via 
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this readout, if one Ab were to block intraerythrocytic development at the ring stage, 
and the other were to block development at the schizont stage, would not be an 
accurate comparison. 
It is paramount that where functional GIA readouts vary naturally according to 
parasite stage, this must be taken into account as a potentially confounding factor 
when interpreting results. For example, both I and Jogdand et al. (Jogdand et al., 
2012) have shown that parasite MMP varies naturally over the intraerythrocytic 
developmental cycle. Where Abs work by blocking parasite intraerythrocytic 
development, as is possibly the case during ADCI (Bouharoun -Tayoun et al., 1995), 
this could easily lead one to erroneously conclude that parasites are undergoing 
parasite death, where the effect is in fact simply due to a difference in parasite stage. 
The JC -1 assay presented in this chapter was developed so that parasite stage was not 
a confounding factor. 
I also investigated the hypothesis that anti- MSP3.3C Ab treated parasites were 
exposed to oxidative stress. Contrary to this, I found that MSP3.3C specific Ab 
treated cultures had a lower ROS level than controls treated with NR IgG. Parasite 
ROS levels increase in mature intraerythrocytic parasite stages (see Chapter 4) and 
Fu et al. (Fu et al., 2010) have suggested that this is consistent with the increased 
metabolic activity of the parasite that occurs at this time. It is possible that the lower 
parasite ROS levels I observed are due to a decreased metabolic activity in parasites 
that are undergoing parasite death. 
Singh et al. (Singh et al., 2009) reported a merozoite surface location for MSP3.3 in 
mature schizonts and free merozoites. The IFA data presented here are in agreement 
with a merozoite surface location of MSP3.3 in schizonts but further colocalisation 
studies would be needed in order to confirm whether MSP3.3 is located on the 
surface of free merozoites. I detected expression of MSP3.3 in ring stage parasites, 
contrary to Pearce et al. 2005 (Pearce et al., 2005) who did not detect MSP3.3 in 
parasite protein extracts prepared from ring stage cultures. This discrepancy could 
be due to differing sensitivities of the techniques used, or due to differences in the 
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antibody epitope specificities induced by immunisation with the respective 
constructs used. 
Given that inhibition by MSP3.3C- specific Abs occurs in the absence of merozoite 
invasion, it follows that these Abs must be accessing their cognate antigen at some 
time other than during merozoite invasion. Initial IFA data indicated that MSP3.3C- 
specific, affinity purified IgG could access the intraerythrocytic parasite when added 
to ring stage cultures i.e. after merozoite invasion had occurred. The MSP3.3 
specific IgG could be detected in trophozoite, schizont and following an invasion, 
ring stage parasites. The IgG could have accessed the ring stage iRBC following 
invasion, or the IgG could have bound to free merozoites and been carried into the 
iRBC during invasion. In the initial IFA, I could not detect NR IgG inside the iRBC, 
however, a further experiment using confocal microscopy identified a non -specific 
pattern in the iRBC, although this was no higher than background staining. In the 
latter experiment I found that anti -AMA1 IgG is also able to access intraerythrocytic 
schizonts. This raises the possibility that any Ig can access the intraerythrocytic 
parasite but that only those binding their epitopes remain specifically within the 
iRBC. This notion is supported by Bergmann -Leitner et al. (Bergmann -Leitner et 
al., 2009) who found that fluorescent beads could access the iRBC but showed only a 
non -specific staining pattern. 
Initially, the ability of Ig to access the intraerythrocytic parasite post invasion may 
seem surprising given the relatively large size of the Ab molecule, and the selective 
uptake pathways that exist in the malaria parasite (Desai et al., 2000; Staines et al., 
2007). This is, however, not a new phenomenon; Pouvelle et al. (Pouvelle et al., 
1991) demonstrated that intraerythrocytic P. falciparum can endocytose protein A, 
dextran and IgG Ab without these macromolecules passing through the erythrocytic 
and PV membranes. This lead these authors to propose the `parasitophorous duct' 
hypothesis, postulating that the TVN extends to the RBC membrane, thereby 
forming an aqueous channel that enables direct access of macromolecules to the 
intraerythrocytic parasite. Although the presence of such a duct remains a bone of 
contention (Sherman and Zidovetzki, 1992; Taraschi et al., 1992), it has been 
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demonstrated that labelled polypeptides ranging up to 206 kDa in size can gain direct 
access to the intraerythrocytic parasite through a membrane network. Furthermore, 
MSP -142- specific Abs are able to access late trophozoite /early schizont stage 
parasites post invasion (Bergmann -Leitner et al., 2009). A number of human RBC 
proteins are imported into the parasite cytoplasm (Foth et al., 2011; Koncarevic et 
al., 2009), possibly through the same mechanisms that IgG uses to access the 
intraerythrocytic parasite. 
The possibility exists, although it is unlikely, that the intraerythrocytic access of 
MSP3.3C- specific IgG post invasion is an artefact of the fixation and 
permeabilisation steps used in the IFA. Carrying out a live IFA, 4D- imaging 
experiments tracking labelled -Ab in individual live parasites and detection of the 
intraerythrocytic IgG via biochemical means would help to address this concern. 
MSP3.3, lacking either a transmembrane domain or a consensus sequence for the 
attachment of a GPI membrane anchor, is presumed to locate to the merozoite 
surface through protein -protein interactions with neighbouring ligands. Microarray 
analysis has identified two low -level peaks of transcription at 14 and 36 hours post 
invasion in the parasite strain HB3 (Bozdech et al., 2003a), with similar transcription 
profiles also observed in the Dd2 and 3D7 strains (Bozdech et al., 2003b; Le Roch et 
al., 2003). However, how this correlates with the actual MSP3.3 protein abundance 
levels over the intraerythrocytic cycle is not known. A large scale proteomic study 
recently found that many P. falciparum protein abundance profiles over the 
erythrocytic cycle exhibited a significant time delay relative to their mRNA 
transcript abundance profiles (Foth et al., 2011), challenging the "just in time" 
induction of gene expression hypothesis and the assumption that transcription 
profiles can be read as protein expression profiles. 
The IFA data presented here indicates that MSP3.3 is exported outside of the PV into 
the erythrocyte cytosol and this proposition is supported by the presence of a PEXEL 
motif in the MSP3.3 protein sequence. However, MSP3'.3 does not occur in 3 
predicted P. falciparum secretomes (Hiller et al., 2004; Sargeant et al., 2006; van 
Ooij et al., 2008). It is tempting to speculate that MSP3.3 is a bifunctional protein, 
188 
one function occurring after its first expression peak and involving its spatial location 
in the erythrocyte cytosol, the second occurring during its second expression peak 
and involving its merozoite surface location. Alternatively, MSP3.3 bifunctionality 
may result from engagement with multiple interaction partners; IUPs employ a 
template- induced folding process, which can result in the protein adopting different 
conformations, and thereby potentially different functions, when binding to different 
interaction partners(Jeffery, 2009; Tompa et al., 2005). 
MSP3.3C specific Abs may prevent the export of MSP3.3, thereby disrupting a 
critical function of the protein or may disturb a metabolic pathway that is essential to 
the development of the intraerythrocytic parasite. Consistent with this first 
hypothesis, I did not detect export of MSP3.3 in the IgG uptake experiments. 
However, partial disruption of the PF10 0347 locus does not significantly affect 
parasite survival in vitro (Pearce et al., 2005), suggesting that one would not expect 
disruption of MSP3.3 protein function by Abs to result in the drastic inhibition levels 
seen during SSGIAs. Alternatively, an evident phenotype upon gene disruption may 
only become apparent in vivo through host -parasite interactions. MSP3.3 has also 
been identified as a target of ADCI (Singh et al., 2009), although this inhibition 
occurs via a different mechanism than the developmental inhibition presented here. 
The P. falciparum MSP3.3 family of proteins contains shared or cross -reactive C- 
terminal epitopes (Singh et al., 2009). MSP3.3C specific Abs do not cross react with 
MSP3 or MSP6 in Western blots of parasite extracts, suggesting that MSP3.3C 
contains unique epitopes (Dhanasarnsombut), as does MSP3.4 (Sakamoto et al., 
2012). However, a -100 kDa protein was also detected in these Western blots, 
raising the possibility that these Abs may cross -react with another antigen. 
Sakamoto et al. similarly detected a -100 kDa band when probing schizont extracts 
with Abs raised against recombinant MSP3.4 but found that this was not due to 
cross -reactivity with other MSP3 family members. 
As MSAs are directly exposed to the immune system whilst the merozoite is 
extracellular, research investigating the modus operandi of these Abs, has, to a large 
189 
extent, focused on growth inhibition that results from Abs binding to free merozoites 
(Bouharoun -Tayoun et al., 1995; Jafarshad et al., 2007; Moss et al., 2012). Here, I 
have shown that Abs to MSP3.3C are able to access the intraerythrocytic parasite 
after merozoite invasion has occurred and induce parasite death. To my knowledge 
this is the first demonstration that MSA- specific Abs can induce parasite death in 
vitro. This challenges the prevailing view that once the parasite is under the 
protective cover of the RBC, intracellular Ags such as MSAs are physically 
separated from, and therefore no longer vulnerable to, immune attack by serum Abs. 
This may have implications for both our understanding of naturally acquired Ab- 
mediated immunity to asexual P. falciparum stages and for effective vaccine design 
against this deadly pathogen. Further dissection of the mechanism by which 
MSP3.3C specific Abs kill intraerythrocytic P. falciparum, in addition to 
investigation of whether Abs to other antigenic targets known to induce development 
inhibition operate in this manner, will be informative to both of these research 
avenues. 
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6 General discussion 
The overall aim of this thesis was to further the understanding of how merozoite 
surface antigen -specific antibodies inhibit the in vitro growth of P. falciparum. This 
aim has been successfully achieved. Specifically, in this thesis, I have: i) generated 
polyclonal B cell lines producing MSP -1 Block 2 RO33- specific mAbs and 
determined the light chain isotype, IgG subclass and epitope specificity of these 
mAbs, ii) developed an in vitro functional assay to detect oxidative stress levels 
during the intraerythrocytic cycle and presented data which suggests that internalised 
MSP -1 -19 specific Abs may carry out ACWO in vitro and iii) developed novel 
functional in vitro inhibition assays, which I have utilised to dissect the mechanism 
by which Abs to hte novel merozoite surface antigen MSP3.3C kill P. falciparum 
parasites in vitro. A detailed discussion of these findings with respect to the relevant 
literature is presented at the end of each chapter. Instead of repeating these here, the 
potential significance and relevance of these findings will be discussed, in the 
broader context of understanding the mechanisms of antibody mediated immunity to 
blood stage P. falciparum infection, and the development of therapeutic interventions 
against this parasite stage. In addition, I pinpoint areas where there are still 
significant gaps in understanding and suggest avenues for future research. 
When this project was conceived, it was intended that in the first instance human 
mAbs to MSAs would be generated, which would then be utilised in both existing 
and novel in vitro inhibition assays, such as the GIA and the in vitro ACWO assays. 
Although I was not able to generate sufficient quantities of human mAbs for use in in 
vitro functional assays, the arguments presented in Chapter 3 for the generation of 
MSA- specific human mAbs as useful tools with which to investigate mechanisms of 
antibody action in vitro still apply. This is illustrated by the fact that a human mAb 
specific to MSP -2 has recently proved a highly informative reagent with which to 
investigate strain -transcending Ab responses in Fc- dependent in vitro functional 
assays such as ADCI (Stubbs et al., 2011). 
The limitations of using polyclonal non -human Abs as reagents in functional in vitro 
assays, which formed part of the rationale for the development of MSA -specific 
191 
human mAbs in the first place, are applicable to the research detailed in Chapters 4 
and 5 of this thesis. For example, mAbs specific to MSP3.3C would allow 
investigation of the epitopes recognised by growth inhibitory anti- MSP3.3C Abs. 
The region of MSP3.3 identified as a target of ADCI (amino acids 228 -424) (Singh 
et al., 2009) almost entirely covers the MSP3.3C antigen (amino acids 229 -360 of 
MSP3.3). It would be therefore be interesting to investigate whether the epitopes 
recognised by Abs active in ADCI overlapped with, or were entirely different from 
the inhibitory MSP3.3 Abs described in Chapter 5. Such an analysis would require 
MSP3.3- specific human mAbs, as the Fc- dependent effects necessary for ADCI 
might not be replicated with murine mAbs. However, given that MSP3.3 appears to 
be only weakly and infrequently recognised by Abs elicited in response to P. 
falciparum infection (Pearce et al., 2005), isolating low- frequency anti- MSP3.3 
human mAbs from human PBMC samples may prove difficult. 
It has been argued that there is a need for the development of high throughput 
standardised in vitro Ab inhibition assays to act as surrogate endpoints with which to 
assess the efficacy of blood stage vaccines in clinical trials (Ockenhouse et al., 2006; 
Polhemus et al., 2007; Withers et al., 2006). Given that we have a limited 
understanding of the different mechanisms by which Abs can inhibit P. falciparum 
growth in vitro, such assays may ignore the significance of Abs whose function have 
not yet been fully characterised in vitro. Additionally, whilst the scalability of in 
vitro assays is an important consideration, it is worth noting that full interpretation of 
the flow cytometry data from the SSGIA required relatively time- intensive gathering 
of semi -quantitative and arguably subjective data by examination of stained blood 
smears using light microscopy. It is hoped that the in vitro functional assays 
presented in this thesis, such as the SSGIA and JC -1 assay, may prove useful in 
uncovering some of the mechanisms by which other inhibitory Abs act. For example 
it would be interesting to investigate whether intraerythrocytic growth inhibition by 
anti -MSP -119 and Pf332 antibodies results in parasite death. 
Understanding the mechanisms of Ab- mediated in vitro growth inhibition may 
provide insight into how antibody mediated immunity is brought about in natural 
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P. falciparum infections. However, it is important to note that any mechanisms of 
Ab action identified in an in vitro assay are a model of what may be functional 
mechanisms of immunity that operate in vivo. In particular, the large quantities of 
Ab required to observe GIA effects calls into question its relevance as a functional 
correlate of immunity. Furthermore, GIAs are frequently carried out using well - 
characterised laboratory strains of P. falciparum, which may not represent the 
characteristics of parasite strains circulating in endemic populations. Studies which 
have identified correlations between in vitro functional assays and clinical immunity 
(Crompton et al., 2010; Dent et al., 2008; Druilhe and Khusmith, 1987; Jensen et al., 
1983; John et al., 2004; Joos et al., 2010) offer some encouragement that these in 
vitro assays may have some relevance to what occurs in vivo. It is important to 
recognise that both innate and cell- mediated immunity are thought to contribute to 
acquired protective immunity to blood stage P. falciparum infection (McCall and 
Sauerwein, 2010; McMorran et al., 2009; Spence and Langhorne, 2012), and 
potential mechanisms of Ab- mediated immunity identified in vitro should be 
considered in light of their potential interactions with these processes. For example, 
MSP -119- specific Abs can inhibit SUB2- mediated processing of MSP -142 (Blackman 
et al., 1994; Harris et al., 2005). It would be interesting to explore whether this 
inhibition of proteolytic processing blocks the recently identified interaction between 
MSP -l33 and the human pro -inflammatory protein S l OOP (Waisberg et al., 2012). 
Data in chapter 4 of this thesis suggest that MSP -119- specific Abs may carry out 
ACWO inside the parasite, which could harm the intraerythrocytic development of 
the parasite. Although this research was not able to determine whether this is a 
realistic mechanism by which in vitro growth inhibition operates. Given that Abs 
can function directly as bactericidal, fungicidal and parasiticidal agents (Brena et al., 
2011; Connolly et al., 2004; Vouldoukis et al., 2011) the investigation of other 
mechanisms by which MSA- specific Abs may directly kill P. falciparum parasites is 
worthy of further investigation. 
The research presented in Chapter 5 of this thesis describes a novel mechanism of 
antibody mediated in vitro growth inhibition, and would not have been possible 
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without the research carried out in Chapter 4. During the development of the in vitro 
ACWO assay it was not known at what stage of the intraerythrocytic developmental 
cycle ACWO might occur. Therefore, repeated sampling across the intraerythrocytic 
developmental cycle using a highly synchronous parasite culture was employed to 
increase the likelihood of detecting any such effects. Within this context, the idea of 
carrying out a GIA with multiple time points was first formed. When data that 
intraerythrocytic parasite development might be compromised during anti- MSP3.3C 
IgG GIAs arose in earlier studies by other lab members, it was the fortuitous addition 
of anti- MSP3.3C IgG to GIA assays using multiple time -point sampling as part of 
the ACWO assays that lead to the first evidence of the mechanism by which anti - 
MSP3.3C Abs might exert their effect. 
One of the assumptions of this project was that understanding the mechanisms by 
which MSA- specific Abs act is significant because MSAs are thought to be targets of 
protective immunity. However, sero -epidemiological studies linking Ab responses 
to particular antigens with prospective protection to P. falciparum infection only 
demonstrate associative correlations, which may disappear once confounding factors 
such as age or exposure are controlled for. A parasite -specific Ab response, 
predictive of protection against malaria in a diverse range of transmission settings 
remains elusive. 
One of the arguments that has been used in support of MSAs as targets of protective 
immunity is that they are directly accessible to anibodies whilst the merozoite is 
extracellular. The research presented here and by others (Bergmann -Leitner et al., 
2009; Pouvelle et al., 1991) suggests that antibodies can access the intraerythrocytic 
parasite, and raises the possibility that other antigens hidden under the "protective 
cover of the RBC" may also be vulnerable to antibody- mediated immune attack and 
there worthy of consideration as vaccine candidate antigens. 
Whilst efforts have been made to dissect which components of the inhibitory 
response to MSAs are due to inhibition of merozoite invasion and which are due to 
intraerythrocytic development inhibition, there is little information regarding the 
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molecular mechanisms of this inhibition. It is known that some Abs to MSP -1 and 
AMA -1 inhibit merozoite invasion by blocking proteolytic processing by SUB -2 
(Woehlbier et al., 2010). In the case of the mechanism of action of MSP3.3C Abs, 
and Abs of other antigen specificities that inhibit intraerythrocytic development of 
the parasite, an analysis of how the addition of immune IgG to asexual P. falciparum 
cultures effects stage -specific mRNA transcript and protein abundance levels over 
the course of the IDC may prove informative. However, the interpretation of such 
information against a background in which the functions of MSP3.3, in addition to 
other MSAs are unknown remains challenging. To quote "we may not know enough 
about malaria to make an effective vaccine" (Pierce and Miller, 2009). 
195 
7 References 
Adisa, A., Rug, M., Klonis, N., Foley, M., Cowman, A. F. and Tilley, L. (2003). 
The signal sequence of exported protein -1 directs the green fluorescent protein to 
the parasitophorous vacuole of transfected malaria parasites. JBiol Chem 278, 
6532 -6542. 
Ahlborg, N., Iqbal, J., Björk, L., Stáhl, S., Perlmann, P. and Berzins, K. (1996). 
Plasmodium falciparum: differential parasite growth inhibition mediated by 
antibodies to the antigens Pf332 and Pf155/RESA. Exp Parasitol 82, 155 -163. 
Ahlborg, N., Ling, I. T., Howard, W., Holder, A. A. and Riley, E. M. (2002). 
Protective immune responses to the 42- kilodalton (kDa) region of Plasmodium 
yoelii merozoite surface protein 1 are induced by the C- terminal 19 -kDa region 
but not by the adjacent 33 -kDa region. Infect Immun 70, 820 -825. 
Aikawa, M., Hepler, P. K., Huff, C. G. and Sprinz, H. (1966). The feeding 
mechanism of avian malarial parasites. J. Cell Biol 28, 355 -373. 
Akpogheneta, O. J., Duah, N. O., Tetteh, K. K. A., Dunyo, S., Lanar, D. E., 
Pinder, M. and Conway, D. J. (2008). Duration of naturally acquired antibody 
responses to blood -stage Plasmodium falciparum is age dependent and antigen 
specific. Infect Immun 76, 1748 -1755. 
al- Yaman, F., Genton, B., Anders, R., Taraika, J., Ginny, M., Mellor, S. and 
Alpers, M. P. (1995). Assessment of the role of the humoral response to 
Plasmodium falciparum MSP2 compared to RESA and SPf66 in protecting 
Papua New Guinean children from clinical malaria. Parasite Immunol 17, 493- 
501. 
al- Yaman, F., Genton, B., Kramer, K. J., Chang, S. P., Hui, G. S., Baisor, M. 
and Alpers, M. P. (1996). Assessment of the role of naturally acquired antibody 
levels to Plasmodium falciparum merozoite surface protein -1 in protecting Papua 
New Guinean children from malaria morbidity. Am J Trop Med Hyg 54, 443- 
448. 
Allison, A. C. and Eugui, E. M. (1983). The role of cell- mediated immune 
responses in resistance to malaria, with special reference to oxidant stress. Annu 
Rev Immunol 1, 361 -392. 
Amaratunga, C., Lopera -Mesa, T. M., Brittain, N. J., Cholera, R., Arie, T., 
Fujioka, H., Keefer, J. R. and Fairhurst, R. M. (2011). A role for fetal 
hemoglobin and maternal immune IgG in infant resistance to Plasmodium 
falciparum malaria. PLoS ONE 6, e14798. 
Amer, J., Goldfarb, A. and Fibach, E. (2003). Flow cytometric measurement of 
reactive oxygen species production by normal and thalassaemic red blood cells. 
Eur . Haematol 70, 84-90. 
196 
Anders, R. F., Adda, C. G., Foley, M. and Norton, R. S. (2010). Recombinant 
protein vaccines against the asexual blood stages of Plasmodium falciparum. 
Hum Vaccin 6, 39 -53. 
Arnot, D. E., Cavanagh, D. R., Remarque, E. J., Creasey, A. M., Sowa, M. P. K., 
Morgan, W. D., Holder, A. A., Longacre, S. and Thomas, A. W. (2008). 
Comparative testing of six antigen -based malaria vaccine candidates directed 
toward merozoite -stage Plasmodium falciparum. Clin Vaccine Immunol 15, 
1345 -1355. 
Babior, B. M., Takeuchi, C., Ruedi, J., Gutierrez, A. and Wentworth, P. (2003). 
Investigating antibody- catalyzed ozone generation by human neutrophils. Proc 
Nall Acad Sci USA 100, 3031 -3034. 
Baird, J. K. (1995). Host age as a determinant of naturally acquired immunity to 
Plasmodium falciparum. Parasitol Today 11, 105 -111. 
Baird, J. K., Jones, T. R., Danudirgo, E. W., Annis, B. A., Bangs, M. J., Basri, 
H., Purnomo and Masbar, S. (1991). Age- dependent acquired protection 
against Plasmodium falciparum in people having two years exposure to 
hyperendemic malaria. Am J Trop Med Hyg 45, 65 -76. 
Balogun, H. A., Awah, N. W., Farouk, S. E. and Berzins, K. (2011). Pf332 -C231- 
reactive antibodies affect growth and development of intra- erythrocytic 
Plasmodium falciparum parasites. Vaccine 30, 21 -28. 
Bannister, L. H. and Mitchell, G. H. (1995). The role of the cytoskeleton in 
Plasmodium falciparum merozoite biology: an electron- microscopic view. Ann 
Trop Med Parasitol 89, 105 -111. 
Bannister, L. H., Hopkins, J. M., Dluzewski, A. R., Margos, G., Williams, I. T., 
Blackman, M. J., Kocken, C. H., Thomas, A. W. and Mitchell, G. H. (2003). 
Plasmodium falciparum apical membrane antigen 1 (PfAMA -1) is translocated 
within micronemes along subpellicular microtubules during merozoite 
development. J Cell Sci 116, 3825 -3834. 
Bannister, L. H., Hopkins, J. M., Fowler, R. E., Krishna, S. and Mitchell, G. H. 
(2000a). Ultrastructure of rhoptry development in Plasmodium falciparum 
erythrocytic schizonts. Parasitology 121, 273 -287. 
Bannister, L. H., Hopkins, J. M., Fowler, R. E., Krishna, S. and Mitchell, G. H. 
(2000b). A brief illustrated guide to the ultrastructure of Plasmodium falciparum 
asexual blood stages. Parasitol. Today 16, 427 -433. 
Bannister, L. H., Hopkins, J. M., Margos, G., Dluzewski, A. R. and Mitchell, G. 
H. (2004). Three- dimensional ultrastructure of the ring stage of Plasmodium 
falciparum: evidence for export pathways. Microsc Microanal 10, 551 -562. 
197 
Barfod, L., Bernasconi, N. L., Dahlbäck, M., Jarrossay, D., Andersen, P. H., 
Salanti, A., Ofori, M. F., Turner, L., Resende, M., Nielsen, M. A., et al. 
(2007). Human pregnancy- associated malaria -specific B cells target 
polymorphic, conformational epitopes in VAR2CSA. Mol Microbiol 63, 335- 
347. 
Barfod, L., Dobrilovic, T., Magistrado, P., Khunrae, P., Viwami, F., Bruun, J., 
Dahlbäck, M., Bernasconi, N. L., Fried, M., John, D., et al. (2010). 
Chondroitin sulfate A- adhering Plasmodium falciparum- infected erythrocytes 
express functionally important antibody epitopes shared by multiple variants. 
The Journal of Immunology 185, 7553 -7561. 
Baruch, D. I., Pasloske, B. L., Singh, H. B., Bi, X., Ma, X. C., Feldman, M., 
Taraschi, T. F. and Howard, R. J. (1995). Cloning the P. falciparum gene 
encoding PfEMP1, a malarial variant antigen and adherence receptor on the 
surface of parasitized human erythrocytes. Cell 82, 77 -87. 
Baum, J., Papenfuss, A. T., Baum, B., Speed, T. P. and Cowman, A. F. (2006). 
Regulation of apicomplexan actin -based motility. Nat Rev Microbiol 4, 621 -628. 
Becker, K., Rahlfs, S., Nickel, C. and Schirmer, R. H. (2003). Glutathione - 
functions and metabolism in the malarial parasite Plasmodium falciparum. Biol 
Chem 384, 551 -566. 
Becker, K., Tilley, L., Vennerstrom, J. L., Roberts, D., Rogerson, S. and 
Ginsburg, H. (2004). Oxidative stress in malaria parasite- infected erythrocytes: 
host -parasite interactions. Int J Parasitol 34, 163 -189. 
Bergmann -Leitner, E. S., Duncan, E. H. and Angov, E. (2009). MSP -1p42- 
specific antibodies affect growth and development of intra- erythrocytic parasites 
of Plasmodium falciparum. Malar J 8, 183 -195. 
Bergmann -Leitner, E. S., Duncan, E. H., Mullen, G. E., Burge, J. R., Khan, F., 
Long, C. A., Angov, E. and Lyon, J. A. (2006). Critical evaluation of different 
methods for measuring the functional activity of antibodies against malaria blood 
stage antigens. Am J Trop Med Hyg 75, 437 -442. 
Blackman, M. J. and Holder, A. A. (1992). Secondary processing of the 
Plasmodium falciparum merozoite surface protein -1 (MSP1) by a calcium - 
dependent membrane -bound serine protease: shedding of MSP133 as a 
noncovalently associated complex with other fragments of the MSP1. Mol 
Biochem Parasitol 50, 307-315. 
Blackman, M. J., Heidrich, H. G., Donachie, S., McBride, J. S. and Holder, A. 
A. (1990). A single fragment of a malaria merozoite surface protein remains on 
the parasite during red cell invasion and is the target of invasion -inhibiting 
antibodies. JExp Med 172, 379 -382. 
198 
Blackman, M. J., Ling, I. T., Nicholls, S. C. and Holder, A. A. (1991). Proteolytic 
processing of the Plasmodium falciparum merozoite surface protein -1 produces 
a membrane -bound fragment containing two epidermal growth factor -like 
domains. Mol Biochem Parasitol 49, 29 -33. 
Blackman, M. J., Scott- Finnigan, T. J., Shai, S. and Holder, A. A. (1994). 
Antibodies inhibit the protease- mediated processing of a malaria merozoite 
surface protein. JExp Med 180, 389 -393. 
Blisnick, T., Morales Betoulle, M. E., Barale, J. C., Uzureau, P., Berry, L., 
Desroses, S., Fujioka, H., Maffei, D. and Braun Breton, C. (2000). Pfsbpl, a 
Maurer's cleft Plasmodium falciparum protein, is associated with the erythrocyte 
skeleton. Mol Biochem Parasitol 111, 107 -121. 
Boddey, J. A., Hodder, A. N., Günther, S., Gilson, P. R., Patsiouras, H., Kapp, 
E. A., Pearce, J. A., de Koning -Ward, T. F., Simpson, R. J., Crabb, B. S., et 
al. (2010). An aspartyl protease directs malaria effector proteins to the host cell. 
Nature 463, 627 -631. 
Bonini, M. G., Rota, C., Tomasi, A. and Mason, R. P. (2006). The oxidation of 
2 ",7- "dichlorofluorescin to reactive oxygen species: a self -fulfilling prophesy? 
Free Radic Biol Med 40, 968 -975. 
Bouharoun -Tayoun, H. and Druilhe, P. (1992). Plasmodium falciparum malaria: 
evidence for an isotype imbalance which may be responsible for delayed 
acquisition of protective immunity. Infect Immun 60, 1473 -1481. 
Bouharoun -Tayoun, H., Attanath, P., Sabchareon, A., Chongsuphajaisiddhi, T. 
and Druilhe, P. (1990). Antibodies that protect humans against Plasmodium 
falciparum blood stages do not on their own inhibit parasite growth and invasion 
in vitro, but act in cooperation with monocytes. JExp Med 172, 1633 -1641. 
Bouharoun -Tayoun, H., Oeuvray, C., Lunel, F. and Druilhe, P. (1995). 
Mechanisms underlying the monocyte -mediated antibody -dependent killing of 
Plasmodium falciparum asexual blood stages. JExp Med 182, 409 -418. 
Bozdech, Z., Llinás, M., Pulliam, B. L., Wong, E. D., Zhu, J. and DeRisi, J. L. 
(2003a). The transcriptome of the intraerythrocytic developmental cycle of 
Plasmodium falciparum. PLoS Biol 1, E5. 
Bozdech, Z., Zhu, J., Joachimiak, M. P., Cohen, F. E., Pulliam, B. and DeRisi, J. 
L. (2003b). Expression profiling of the schizont and trophozoite stages of 
Plasmodium falciparum with a long -oligonucleotide microarray. Genome Biol 4, 
R9. 
Brena, S., Cabezas- Olcoz, J., Moragues, M. D., Fernández de Larrinoa, I., 
Domínguez, A., Quindós, G. and Pontón, J. (2011). Fungicidal monoclonal 
antibody C7 interferes with iron acquisition in Candida albicans. Antimicrob 
Agents Chemother 55, 3156 -3163. 
199 
Brown, H. and Prescott, R. (2006). Applied Mixed Models in Medicine. Wiley. 
Bryce, J., Boschi- Pinto, C., Shibuya, K., Black, R. E.WHO Child Health 
Epidemiology Reference Group (2005). WHO estimates of the causes of death 
in children. Lancet 365, 1147 -1152. 
Bullen, H. E., Charnaud, S. C., Kalanon, M., Riglar, D. T., Dekiwadia, C., 
Kangwanrangsan, N., Torii, M., Tsuboi, T., Baum, J., Ralph, S. A., et al. 
(2012). Biosynthesis, localisation and macromolecular arrangement of the 
Plasmodium falciparum translocon of exported proteins; PTEX. JBiol Chem 
287, 7871 -7884. 
Cao, J., Kaneko, O., Thongkukiatkul, A., Tachibana, M., Otsuki, H., Gao, Q., 
Tsuboi, T. and Torii, M. (2009). Rhoptry neck protein RON2 forms a complex 
with microneme protein AMA1 in Plasmodium falciparum merozoites. Parasitol 
Int 58, 29 -35. 
Cavanagh, D. R. and McBride, J. S. (1997). Antigenicity of recombinant proteins 
derived from Plasmodium falciparum merozoite surface protein 1. Mol Biochem 
Parasitol 85, 197 -211. 
Cavanagh, D. R., Dobaflo, C., Elhassan, I. M., Marsh, K., Elhassan, A., Hviid, 
L., Khalil, E. A., Theander, T. G., Arnot, D. E. and McBride, J. S. (2001). 
Differential patterns of human immunoglobulin G subclass responses to distinct 
regions of a single protein, the merozoite surface protein 1 of Plasmodium 
falciparum. Infect Immun 69, 1207 -1211. 
Cavanagh, D. R., Dodoo, D., Hviid, L., Kurtzhals, J. A. L., Theander, T. G., 
Akanmori, B. D., Polley, S., Conway, D. J., Koram, K. and McBride, J. S. 
(2004). Antibodies to the N- terminal block 2 of Plasmodium falciparum 
merozoite surface protein 1 are associated with protection against clinical 
malaria. Infect Immun 72, 6492 -6502. 
Cavanagh, D. R., Elhassan, I. M., Roper, C., Robinson, V. J., Giha, H., Holder, 
A. A., Hviid, L., Theander, T. G., Arnot, D. E. and McBride, J. S. (1998). A 
longitudinal study of type -specific antibody responses to Plasmodium falciparum 
merozoite surface protein -1 in an area of unstable malaria in Sudan. Jlmmunol 
161, 347 -359. 
Ch'ng, J.-H., Kotturi, S. R., Chong, A. G.-L., Lear, M. J. and Tan, K. S.-W. 
(2010). A programmed cell death pathway in the malaria parasite Plasmodium 
falciparum has general features of mammalian apoptosis but is mediated by clan 
CA cysteine proteases. Cell Death and Disease 1, e26 -13. 
Ch'ng, J.-H., Liew, K., Goh, A. S. -P., Sidhartha, E. and Tan, K. S.-W. (2011). 
Drug- induced permeabilization of parasite's digestive vacuole is a key trigger of 
programmed cell death in Plasmodium falciparum. Cell Death and Disease 2, 
e216. 
200 
Chang, H. H., Falick, A. M., Carlton, P. M., Sedat, J. W., DeRisi, J. L. and 
Marietta, M. A. (2008). N- terminal processing of proteins exported by malaria 
parasites. Mol Biochem Parasitol 160, 107 -115. 
Chang, S. P., Case, S. E., Gosnell, W. L., Hashimoto, A., Kramer, K. J., Tam, L. 
Q., Hashiro, C. Q., Nikaido, C. M., Gibson, H. L., Lee -Ng, C. T., et al. 
(1996). A recombinant baculovirus 42- kilodalton C- terminal fragment of 
Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys 
against malaria. Infect Immun 64, 253 -261. 
Chasis, J. A., Prenant, M., Leung, A. and Mohandas, N. (1989). Membrane 
assembly and remodeling during reticulocyte maturation. Blood 74, 1112 -1120. 
Chauhan, V. S., Yazdani, S. S. and Gaur, D. (2010). Malaria vaccine development 
based on merozoite surface proteins of Plasmodium falciparum. Hum Vaccin 6, 
757 -762. 
Chen, Q., Fernandez, V., Sundström, A., Schlichtherle, M., Datta, S., Hagblom, 
P. and Wahlgren, M. (1998). Developmental selection of var gene expression 
in Plasmodium falciparum. Nature 394, 392 -395. 
Cheng, Q., Cloonan, N., Fischer, K., Thompson, J., Waine, G., Lanzer, M. and 
Saul, A. (1998). stevor and rif are Plasmodium falciparum multicopy gene 
families which potentially encode variant antigens. Mol Biochem Parasitol 97, 
161 -176. 
Cheresh, P., Harrison, T., Fujioka, H. and Haldar, K. (2002). Targeting the 
malarial plastid via the parasitophorous vacuole. JBiol Chem 277, 16265- 
16277. 
Child, M. A., Epp, C., Bujard, H. and Blackman, M. J. (2010). Regulated 
maturation of malaria merozoite surface protein -i is essential for parasite 
growth. Mol Microbiol78, 187 -202. 
Chizzolini, C., Dupont, A., Akue, J. P., Kaufmann, M. H., Verdini, A. S., Pessi, 
A. and Del Giudice, G. (1988). Natural antibodies against three distinct and 
defined antigens of Plasmodium falciparum in residents of a mesoendemic area 
in Gabon. Am J Trop Med Hyg 39, 150 -156. 
Clark, I. A. and Hunt, N. H. (1983). Evidence for reactive oxygen intermediates 
causing hemolysis and parasite death in malaria. Infect Immun 39, 1-6. 
Clark, J. T., Donachie, S., Anand, R., Wilson, C. F., Heidrich, H. G. and 
McBride, J. S. (1989). 46 -53 kilodalton glycoprotein from the surface of 
Plasmodium falciparum merozoites. Mol Biochem Parasitol 32, 15 -24. 
Cohen, S., McGregor, I. A. and Carrington, S. (1961). Gamma- globulin and 
acquired immunity to human malaria. Nature 192, 733 -737. 
201 
Collins, C. R., Withers- Martinez, C., Hackett, F. and Blackman, M. J. (2009). 
An inhibitory antibody blocks interactions between components of the malarial 
invasion machinery. PLoS Pathog 5, e 1000273. 
Connolly, S. E., Thanassi, D. G. and Benach, J. L. (2004). Generation of a 
complement- independent bactericidal IgM against a relapsing fever Borrelia. J 
Immunol 172, 1191 -1197. 
Conway, D. J. (1997). Natural selection on polymorphic malaria antigens and the 
search for a vaccine. Parasitol. Today 13, 26-29. 
Conway, D. J., Cavanagh, D. R., Tanabe, K., Roper, C., Mikes, Z. S., Sakihama, 
N., Bojang, K. A., Oduola, A. M., Kremsner, P. G., Arnot, D. E., et al. 
(2000). A principal target of human immunity to malaria identified by molecular 
population genetic and immunological analyses. Nat Med 6, 689 -692. 
Conway, D. J., Greenwood, B. M. and McBride, J. S. (1992). Longitudinal study 
of Plasmodium falciparum polymorphic antigens in a malaria- endemic 
population. Infect Immun 60, 1122 -1127. 
Cooke, B. M., Lingelbach, K., Bannister, L. H. and Tilley, L. (2004). Protein 
trafficking in Plasmodium falciparum- infected red blood cells. Trends Parasitol 
20, 581 -589. 
Cooke, B. M., Mohandas, N. and Coppel, R. L. (2001). The malaria -infected red 
blood cell: structural and functional changes. Adv Parasitol 50, 1 -86. 
Cooper, J. A. (1993). Merozoite surface antigen -I of Plasmodium. Parasitol Today 
9, 50-54. 
Corti, D., Langedijk, J. P. M., Hinz, A., Seaman, M. S., Vanzetta, F., Fernandez - 
Rodriguez, B. M., Silacci, C., Pinna, D., Jarrossay, D., Balla- 
Jhagjhoorsingh, S., et al. (2010). Analysis of memory B cell responses and 
isolation of novel monoclonal antibodies with neutralizing breadth from HIV -1- 
infected individuals. PLoS ONE 5, e8805. 
Counter, C. M., Botelho, F. M., Wang, P., Harley, C. B. and Bacchetti, S. (1994). 
Stabilization of short telomeres and telomerase activity accompany 
immortalization of Epstein -Barr virus -transformed human B lymphocytes. J. 
Virol. 68, 3410 -3414. 
Cowan, G. J. M., Creasey, A. M., Dhanasarnsombut, K., Thomas, A. W., 
Remarque, E. J. and Cavanagh, D. R. (2011). A malaria vaccine based on the 
polymorphic block 2 region of MSP -1 that elicits a broad serotype -spanning 
immune response. PLoS ONE 6, e26616. 
Cox -Singh, J. (2012). Zoonotic malaria: Plasmodium knowlesi, an emerging 
pathogen. Curr Opin Infect Dis 25, 530 -536. 
202 
Crompton, P. D., Miura, K., Traore, B., Kayentao, K., Ongoiba, A., Weiss, G., 
Doumbo, S., Doumtabe, D., Kone, Y., Huang, C.-Y., et al. (2010). In vitro 
growth- inhibitory activity and malaria risk in a cohort study in mali. Infect 
Immun 78, 737 -745. 
Daly, T. M. and Long, C. A. (1995). Humoral response to a carboxyl -terminal 
region of the merozoite surface protein -1 plays a predominant role in controlling 
blood -stage infection in rodent malaria. Jlmmunol 155, 236 -243. 
Datta, D., Vaidehi, N., Xu, X. and Goddard, W. A. (2002). Mechanism for 
antibody catalysis of the oxidation of water by singlet dioxygen. Proc Natl Acad 
Sci USA 99, 2636 -2641. 
de Koning -Ward, T. F., Gilson, P. R., Boddey, J. A., Rug, M., Smith, B. J., 
Papenfuss, A. T., Sanders, P. R., Lundie, R. J., Maier, A. G., Cowman, A. F., 
et al. (2009). A newly discovered protein export machine in malaria parasites. 
Nature 459, 945 -949. 
del Portillo, H. A., Nussenzweig, R. S. and Enea, V. (1987). Circumsporozoite 
gene of a Plasmodium falciparum strain from Thailand. Mol Biochem Parasitol 
24, 289 -294. 
Dent, A. E., Bergmann -Leitner, E. S., Wilson, D. W., Tisch, D. J., Kimmel, R., 
Vulule, J., Sumba, P. 0., Beeson, J. G., Angov, E., Moormann, A. M., et al. 
(2008). Antibody -mediated growth inhibition of Plasmodium falciparum: 
relationship to age and protection from parasitemia in Kenyan children and 
adults. PLoS ONE 3, e3557. 
Desai, S. A., Bezrukov, S. M. and Zimmerberg, J. (2000). A voltage- dependent 
channel involved in nutrient uptake by red blood cells infected with the malaria 
parasite. Nature 406, 1001 -1005. 
Dickinson, B. C. and Chang, C. J. (2008). A targetable fluorescent probe for 
imaging hydrogen peroxide in the mitochondria of living cells. JAm Chem Soc 
130, 9638 -9639. 
Dluzewski, A. R., Ling, I. T., Hopkins, J. M., Grainger, M., Margos, G., 
Mitchell, G. H., Holder, A. A. and Bannister, L. H. (2008). Formation of the 
food vacuole in Plasmodium falciparum: a potential role for the 19 kDa fragment 
of merozoite surface protein 1 (MSP1(19)). PLoS ONE 3, e3085. 
Douglas, A. D., Williams, A. R., Illingworth, J. J., Kamuyu, G., Biswas, S., 
Goodman, A. L., Wyllie, D. H., Crosnier, C. E. C., Miura, K., Wright, G. J., 
et al. (2011). The blood -stage malaria antigen PfRH5 is susceptible to vaccine - 
inducible cross -strain neutralizing antibody. Nature Communications 3, 601 -8. 
203 
Drakeley, C. J., Carneiro, I., Reyburn, H., Malima, R., Lusingu, J. P. A., Cox, 
J., Theander, T. G., Nkya, W. M. M. M., Lemnge, M. M. and Riley, E. M. 
(2005). Altitude- dependent and -independent variations in Plasmodium 
falciparum prevalence in northeastern Tanzania. Jlnfect Dis 191, 1589 -1598. 
Druilhe, P. and Khusmith, S. (1987). Epidemiological correlation between levels of 
antibodies promoting merozoite phagocytosis of Plasmodium falciparum and 
malaria -immune status. Infect Immun 55, 888 -891. 
Duah, N. 0., Miles, D. J. C., Whittle, H. C. and Conway, D. J. (2010). 
Acquisition of antibody isotypes against Plasmodium falciparum blood stage 
antigens in a birth cohort. Parasite Immunol 32, 125 -134. 
Duncan, C. J. A. and Hill, A. V. S. (2012). Can growth inhibition assays (GIA) 
predict blood -stage malaria vaccine efficacy? Hum Vaccin Immunother 8, 706- 
714. 
Dvorak, J. A., Miller, L. H., Whitehouse, W. C. and Shiroishi, T. (1975). 
Invasion of erythrocytes by malaria merozoites. Science 187, 748 -750. 
Egan, A. F., Morris, J., Barnish, G., Allen, S., Greenwood, B. M., Kaslow, D. C., 
Holder, A. A. and Riley, E. M. (1996). Clinical immunity to Plasmodium 
falciparum malaria is associated with serum antibodies to the 19 -kDa C- terminal 
fragment of the merozoite surface antigen, PfMSP -1. Jlnfect Dis 173, 765 -769. 
Eisen, D. P., Saul, A., Fryauff, D. J., Reeder, J. C. and Coppel, R. L. (2002). 
Alterations in Plasmodium falciparum genotypes during sequential infections 
suggest the presence of strain specific immunity. Am J Trop Med Hyg 67, 8 -16. 
Eisen, D., Billman- Jacobe, H., Marshall, V. F., Fryauff, D. and Coppel, R. L. 
(1998). Temporal variation of the merozoite surface protein -2 gene of 
Plasmodium falciparum. Infect Immun 66, 239 -246. 
Fenton, B., Clark, J. T., Khan, C. M., Robinson, J. V., Walliker, D., Ridley, R., 
Scaife, J. G. and McBride, J. S. (1991). Structural and antigenic polymorphism 
of the 35- to 48- kilodalton merozoite surface antigen (MSA -2) of the malaria 
parasite Plasmodium falciparum. Mol Cell Biol 11, 963 -971. 
Ferreira, M. U., Kimura, E. A., Katzin, A. M., Santos -Neto, L. L., Ferrari, J. 0., 
Villalobos, J. M. and de Carvalho, M. E. (1998). The IgG- subclass distribution 
of naturally acquired antibodies to Plasmodium falciparum, in relation to malaria 
exposure and severity. Ann Trop Med Parasitol 92, 245 -256. 
Fischer, K., Marti, T., Rick, B., Johnson, D., Benting, J., Baumeister, S., 
Helmbrecht, C., Lanzer, M. and Lingelbach, K. (1998). Characterization and 
cloning of the gene encoding the vacuolar membrane protein EXP -2 from 
Plasmodium falciparum. Mol Biochem Parasitol 92, 47 -57. 
204 
Flint, J., Harding, R. M., Boyce, A. J. and Clegg, J. B. (1998). The population 
genetics of the haemoglobinopathies. Baillieres Clin. Haematol 11, 1 -51. 
Flint, J., Hill, A. V., Bowden, D. K., Oppenheimer, S. J., Sill, P. R., Serjeantson, 
S. W., Bana -Koiri, J., Bhatia, K., Alpers, M. P. and Boyce, A. J. (1986). High 
frequencies of alpha -thalassaemia are the result of natural selection by malaria. 
Nature 321, 744 -750. 
Flueck, C., Frank, G., Smith, T., Jafarshad, A., Nebie, I., Sirima, S. B., Olugbile, 
S., Alonso, P., Tanner, M., Druilhe, P., et al. (2009). Evaluation of two long 
synthetic merozoite surface protein 2 peptides as malaria vaccine candidates. 
Vaccine 27, 2653 -2661. 
Foth, B. J., Zhang, N., Chaal, B. K., Sze, S. K., Preiser, P. R. and Bozdech, Z. 
(2011). Quantitative time- course profiling of parasite and host cell proteins in the 
human malaria parasite Plasmodium falciparum. Mol Cell Proteomics 10, 
M110.006411. 
Francis, S. E., Sullivan, D. J. and Goldberg, D. E. (1997). Hemoglobin 
metabolism in the malaria parasite Plasmodium falciparum. Annu Rev Microbiol 
51, 97 -123. 
Fu, Y., Tilley, L., Kenny, S. and Klonis, N. (2010). Dual labeling with a far red 
probe permits analysis of growth and oxidative stress in P. falciparum- infected 
erythrocytes. Cytometry A 77, 253 -263. 
Galamo, C. D., Jafarshad, A., Blanc, C. and Druilhe, P. (2009). Anti -MSP1 block 
2 antibodies are effective at parasite killing in an allele -specific manner by 
monocyte -mediated antibody- dependent cellular inhibition. J Infect Dis 199, 
1151 -1154. 
Galinski, M. R., Corredor- Medina, C., Povoa, M., Crosby, J., Ingravallo, P. and 
Barnwell, J. W. (1999). Plasmodium vivar merozoite surface protein -3 contains 
coiled -coil motifs in an alanine -rich central domain. Mol Biochem Parasitol 101, 
131 -147. 
Galinski, M. R., Ingravallo, P., Corredor- Medina, C., Al- Khedery, B., Povoa, 
M. and Barnwell, J. W. (2001). Plasmodium vivar merozoite surface proteins - 
3beta and- 3gamma share structural similarities with P. vivar merozoite surface 
protein- 3alpha and define a new gene family. Mol Biochem Parasitol 115, 41- 
53. 
Gardner, M. J., Hall, N., Fung, E., White, O., Berriman, M., Hyman, R. W., 
Carlton, J. M., Pain, A., Nelson, K. E., Bowman, S., et al. (2002). Genome 
sequence of the human malaria parasite Plasmodium falciparum. Nature 419, 
498 -511. 
205 
Garner, A. L., St Croix, C. M., Pitt, B. R., Leikauf, G. D., Ando, S. and Koide, 
K. (2009). Specific fluorogenic probes for ozone in biological and atmospheric 
samples. Nat Chem 1, 316 -321. 
Gilson, P. R. and Crabb, B. S. (2009a). Do apicomplexan parasite- encoded proteins 
act as both ligands and receptors during host cell invasion? F1000 Biol Rep 1, 
64. 
Gilson, P. R. and Crabb, B. S. (2009b). Morphology and kinetics of the three 
distinct phases of red blood cell invasion by Plasmodium falciparum merozoites. 
Int J Parasito139, 91 -96. 
Gilson, P. R., O'Donnell, R. A., Nebl, T., Sanders, P. R., Wickham, M. E., 
McElwain, T. F., de Koning -Ward, T. F. and Crabb, B. S. (2008). MSP1(19) 
miniproteins can serve as targets for invasion inhibitory antibodies in 
Plasmodium falciparum provided they contain the correct domains for cell 
surface trafficking. Mol Microbiol 68, 124 -138. 
Greve, B., Lehman, L. G., Lell, B., Luckner, D., Schmidt -Ott, R. and Kremsner, 
P. G. (1999). High oxygen radical production is associated with fast parasite 
clearance in children with Plasmodium falciparum malaria. J Infect Dis 179, 
1584 -1586. 
Grüring, C., Heiber, A., Kruse, F., Ungefehr, J., Gilberger, T.-W. and 
Spielmann, T. (2011). Development and host cell modifications of Plasmodium 
falciparum blood stages in four dimensions. Nature Communications 2, 165. 
Guevara Patiño, J. A., Holder, A. A., McBride, J. S. and Blackman, M. J. 
(1997). Antibodies that inhibit malaria merozoite surface protein -1 processing 
and erythrocyte invasion are blocked by naturally acquired human antibodies. J 
Exp Med 186, 1689 -1699. 
Gupta, S., Snow, R. W., Donnelly, C. A., Marsh, K. and Newbold, C. (1999). 
Immunity to non -cerebral severe malaria is acquired after one or two infections. 
Nat Med 5, 340 -343. 
Gysin, J., Moisson, P., Pereira da Silva, L. and Druilhe, P. (1996). Antibodies 
from immune African donors with a protective effect in Plasmodium falciparum 
human infection are also able to control asexual blood forms of the parasite in 
Saimiri monkeys. Res Immunol 147, 397 -401. 
Haase, S. and de Koning -Ward, T. F. (2010). New insights into protein export in 
malaria parasites. Cell Microbiol 12, 580 -587. 
Haldar, K., Samuel, B. U., Mohandas, N., Harrison, T. and Hiller, N. L. (2001). 
Transport mechanisms in Plasmodium -infected erythrocytes: lipid rafts and a 
tubovesicular network. Int JParasitol 31, 1393 -1401. 
206 
Hall, N., Karras, M., Raine, J. D., Carlton, J. M., Kooij, T. W. A., Berriman, M., 
Florens, L., Janssen, C. S., Pain, A., Christophides, G. K., et al. (2005). A 
comprehensive survey of the Plasmodium life cycle by genomic, transcriptomic, 
and proteomic analyses. Science 307, 82 -86. 
Harris, P. K., Yeoh, S., Dluzewski, A. R., O'Donnell, R. A., Withers -Martinez, 
C., Hackett, F., Bannister, L. H., Mitchell, G. H. and Blackman, M. J. 
(2005). Molecular identification of a malaria merozoite surface sheddase. PLoS 
Pathog 1, 241 -251. 
Hartmann, G. and Krieg, A. M. (2000). Mechanism and function of a newly 
identified CpG DNA motif in human primary B cells. Jlmmunol 164, 944 -953. 
Healer, J., Crawford, S., Ralph, S., McFadden, G. and Cowman, A. F. (2002). 
Independent translocation of two micronemal proteins in developing 
Plasmodium falciparum merozoites. Infect Immun 70, 5751 -5758. 
Henderson, K. A., Streltsov, V. A., Coley, A. M., Dolezal, O., Hudson, P. J., 
Batchelor, A. H., Gupta, A., Bai, T., Murphy, V. J., Anders, R. F., et al. 
(2007). Structure of an IgNAR -AMA1 complex: targeting a conserved 
hydrophobic cleft broadens malarial strain recognition. Structure 15, 1452 -1466. 
Hill, A. V., Allsopp, C. E., Kwiatkowski, D., Anstey, N. M., Twumasi, P., Rowe, 
P. A., Bennett, S., Brewster, D., McMichael, A. J. and Greenwood, B. M. 
(1991). Common west African HLA antigens are associated with protection from 
severe malaria. Nature 352, 595 -600. 
Hiller, N. L., Bhattacharjee, S., van Ooij, C., Liolios, K., Harrison, T., Lopez - 
Estraflo, C. and Haldar, K. (2004). A host -targeting signal in virulence 
proteins reveals a secretome in malarial infection. Science 306, 1934 -1937. 
Hinterberg, K., Schert, A., Gysin, J., Toyoshima, T., Aikawa, M., Mazie, J. C., 
da Silva, L. P. and Maffei, D. (1994). Plasmodium falciparum: the Pf332 
antigen is secreted from the parasite by a brefeldin A- dependent pathway and is 
translocated to the erythrocyte membrane via the Maurer's clefts. Exp Parasitol 
79, 279 -291. 
Hirunpetcharat, C., Tian, J. H., Kaslow, D. C., van Rooijen, N., Kumar, S., 
Berzofsky, J. A., Miller, L. H. and Good, M. F. (1997). Complete protective 
immunity induced in mice by immunization with the 19- kilodalton carboxyl - 
terminal fragment of the merozoite surface protein -1 (MSP 1 [ 19]) of Plasmodium 
yoelii expressed in Saccharomyces cerevisiae: correlation of protection with 
antigen- specific antibody titer, but not with effector CD4+ T cells. Jlmmunol 
159, 3400 -3411. 
Hogh, B., Petersen, E., Dziegiel, M., David, K., Hanson, A., Borre, M., Holm, A., 
Vuust, J. and Jepsen, S. (1992). Antibodies to a recombinant glutamate -rich 
207 
Plasmodium falciparum protein: evidence for protection of individuals living in 
a holoendemic area of Liberia. Am J Trop Med Hyg 46, 307 -313. 
Holder, A. A. and Freeman, R. R. (1982). Biosynthesis and processing of a 
Plasmodium falciparum schizont antigen recognized by immune serum and a 
monoclonal antibody. JExp Med 156, 1528 -1538. 
Holder, A. A. and Freeman, R. R. (1984). The three major antigens on the surface 
of Plasmodium falciparum merozoites are derived from a single high molecular 
weight precursor. J Exp Med 160, 621 629. 
Holder, A. A., Lockyer, M. J., Odink, K. G., Sandhu, J. S., Riveros- Moreno, V., 
Nicholls, S. C., Hillman, Y., Davey, L. S., Tizard, M. L. and Schwarz, R. T. 
(1985). Primary structure of the precursor to the three major surface antigens of 
Plasmodium falciparum merozoites. Nature 317, 270 -273. 
Holder, A. A., Sandhu, J. S., Hillman, Y., Davey, L. S., Nicholls, S. C., Cooper, 
H. and Lockyer, M. J. (1987). Processing of the precursor to the major 
merozoite surface antigens of Plasmodium falciparum. Parasitology 94, 199- 
208. 
Hopkins, J., Fowler, R., Krishna, S., Wilson, I., Mitchell, G. and Bannister, L. 
(1999). The plastid in Plasmodium falciparum asexual blood stages: a three - 
dimensional ultrastructural analysis. Protist 150, 283 -295. 
Howell, S. A., Hackett, F., Jongco, A. M., Withers -Martinez, C., Kim, K., 
Carruthers, V. B. and Blackman, M. J. (2005). Distinct mechanisms govern 
proteolytic shedding of a key invasion protein in apicomplexan pathogens. Mol 
Microbiol 57, 1342 -1356. 
Howell, S. A., Well, I., Fleck, S. L., Kettleborough, C., Coffins, C. R. and 
Blackman, M. J. (2003). A single malaria merozoite serine protease mediates 
shedding of multiple surface proteins by juxtamembrane cleavage. J Biol Chem 
278, 23890 -23898. 
Hui -Yuen, J., McAllister, S., Koganti, S., Hill, E. and Bhaduri -McIntosh, S. 
(2011). Establishment of Epstein -Barr virus growth- transformed lymphoblastoid 
cell lines. J Vis Exp 57, e3321. 
Jafarshad, A., Dziegiel, M. H., Lundquist, R., Nielsen, L. K., Singh, S. and 
Druilhe, P. L. (2007). A novel antibody- dependent cellular cytotoxicity 
mechanism involved in defense against malaria requires costimulation of 
monocytes FcgammaRll and FcgammaRlll. J. Immunol. 178, 3099 -3106. 
Janda, K. D., Shevlin, C. G. and Lerner, R. A. (1993). Antibody catalysis of a 
disfavored chemical transformation. Science 259, 490-493. 
Jeffery, C. J. (2009). Moonlighting proteins - an update. Mol Biosyst 5, 345 -350. 
Jeffery, G. M. (1966). Epidemiological significance of repeated infections with 
208 
homologous and heterologous strains and species of Plasmodium Bull World 
Health Organ 35, 873 -882. 
Jensen, J. B., Boland, M. T., Allan, J. S., Carlin, J. M., Vande Waa, J. A., Divo, 
A. A. and Akood, M. A. (1983). Association between human serum- induced 
crisis forms in cultured Plasmodium falciparum and clinical immunity to malaria 
in Sudan. Infect Immun 41, 1302 -1311. 
Jensen, J. B., Boland, M. T. and Akood, M. (1982). Induction of crisis forms in 
cultured Plasmodium falciparum with human immune serum from Sudan. 
Science 216, 1230 -1233. 
Jensen, J. B., Hoffman, S. L., Boland, M. T., Akood, M. A., Laughlin, L. W., 
Kurniawan, L. and Marwoto, H. A. (1984). Comparison of immunity to 
malaria in Sudan and Indonesia: crisis -form versus merozoite -invasion 
inhibition. Proc Natl Acad Sci USA 81, 922 -925. 
Jiang, G., Daubenberger, C., Huber, W., Matile, H., Tanner, M. and Pluschke, 
G. (2000). Sequence diversity of the merozoite surface protein 1 of Plasmodium 
falciparum in clinical isolates from the Kilombero District, Tanzania. Acta Trop 
74, 51-61. 
Jogdand, P. S., Singh, S. K., Christiansen, M., Dziegiel, M. H., Singh, S. and 
Theisen, M. (2012). Flow cytometric readout based on Mitotracker Red 
CMXRos staining of live asexual blood stage malarial parasites reliably assesses 
antibody dependent cellular inhibition. Malar .111, 235. 
John, C. C., O'Donnell, R. A., Sumba, P. 0., Moormann, A. M., de Koning- 
Ward, T. F., King, C. L., Kazura, J. W. and Crabb, B. S. (2004). Evidence 
that invasion -inhibitory antibodies specific for the 19 -kDa fragment of merozoite 
surface protein -1 (MSP -1 19) can play a protective role against blood -stage 
Plasmodium falciparum infection in individuals in a malaria endemic area of 
Africa. Jlmmunol 173, 666 -672. 
Jones, L. H., Harwig, C. W., Wentworth, P., Simeonov, A., Wentworth, A. D., 
Py, S., Ashley, J. A., Lerner, R. A. and Janda, K. D. (2001). Conversion of 
enediynes into quinones by antibody catalysis and in aqueous buffers: 
implications for an alternative enediyne therapeutic mechanism. JAm Chem Soc 
123, 3607 -3608. 
Joos, C., Marrama, L., Polson, H. E. J., Corre, S., Diatta, A.-M., Diouf, B., 
Trape, J.-F., Tall, A., Longacre, S. and Perraut, R. (2010). Clinical protection 
from falciparum malaria correlates with neutrophil respiratory bursts induced by 
merozoites opsonized with human serum antibodies. PLoS ONE 5, e9871. 
Jouin, H., Garraud, 0., Longacre, S., Baleux, F., Mercereau -Puijalon, O. and 
Milon, G. (2005). Human antibodies to the polymorphic block 2 domain of the 
Plasmodium falciparum merozoite surface protein 1 (MSP -1) exhibit a highly 
skewed, peptide -specific light chain distribution. Immunol Cell Biol 83, 392- 
209 
395. 
Jouin, H., Rogier, C., Trape, J. F. and Mercereau- Puijalon, O. (2001). Fixed, 
epitope- specific, cytophilic antibody response to the polymorphic block 2 
domain of the Plasmodium falciparum merozoite surface antigen MSP -1 in 
humans living in a malaria- endemic area. Eur Jlmmunol 31, 539 -550. 
Kadekoppala, M., O'Donnell, R. A., Grainger, M., Crabb, B. S. and Holder, A. 
A. (2008). Deletion of the Plasmodium falciparum merozoite surface protein 7 
gene impairs parasite invasion of erythrocytes. Eukaryotic Cell 7, 2123 -2132. 
Kara, U. A., Stenzel, D. J., Ingram, L. T., Bushell, G. R., Lopez, J. A. and 
Kidson, C. (1988). Inhibitory monoclonal antibody against a (myristylated) 
small -molecular- weight antigen from Plasmodium falciparum associated with 
the parasitophorous vacuole membrane. Infect Immun 56, 903 -909. 
Karpas, A., Dremucheva, A. and Czepulkowski, B. H. (2001). A human myeloma 
cell line suitable for the generation of human monoclonal antibodies. Proc Natl 
Acad Sci USA 98, 1799 -1804. 
Kauth, C. W., Woehlbier, U., Kern, M., Mekonnen, Z., Lutz, R., Mücke, N., 
Langowski, J. and Bujard, H. (2006). Interactions between merozoite surface 
proteins 1, 6, and 7 of the malaria parasite Plasmodium falciparum. JBiol Chem 
281, 31517-31527. 
Keeley, A. and Soldati, D. (2004). The glideosome: a molecular machine powering 
motility and host -cell invasion by Apicomplexa. Trends Cell Biol. 14, 528 -532. 
Kinyanjui, S. M., Conway, D. J., Lanar, D. E. and Marsh, K. (2007). IgG 
antibody responses to Plasmodium falciparum merozoite antigens in Kenyan 
children have a short half -life. Malar J6, 82. 
Klonis, N., Tan, O., Jackson, K., Goldberg, D., Klemba, M. and Tilley, L. (2007). 
Evaluation of pH during cytostomal endocytosis and vacuolar catabolism of 
haemoglobin in Plasmodium falciparum. Biochem J 407, 343 -354. 
Kocken, C. H., van der Wel, A. M., Dubbeld, M. A., Narum, D. L., van de Rijke, 
F. M., van Gemert, G. J., van der Linde, X., Bannister, L. H., Janse, C., 
Waters, A. P., et al. (1998). Precise timing of expression of a Plasmodium 
falciparum- derived transgene in Plasmodium berghei is a critical determinant of 
subsequent subcellular localization. JBiol Chem 273, 15119- 15124. 
Koncarevic, S., Rohrbach, P., Deponte, M., Krohne, G., Prieto, J. H., Yates, J., 
Rahlfs, S. and Becker, K. (2009). The malarial parasite,Plasmodium falciparum 
imports the human protein peroxiredoxin 2 for peroxide detoxification. Proc 
Natl Acad Sci USA 106, 13323 -13328. 
Koussis, K., Withers- Martinez, C., Yeoh, S., Child, M., Hackett, F., Knuepfer, 
210 
E., Juliano, L., Woehlbier, U., Bujard, H. and Blackman, M. J. (2009). A 
multifunctional serine protease primes the malaria parasite for red blood cell 
invasion. EMBO J 28, 725 -735. 
Kozbor, D. and Roder, J. C. (1981). Requirements for the establishment of high - 
titered human monoclonal antibodies against tetanus toxoid using the Epstein - 
Barr virus technique. Jlmmunol 127, 1275 -1280. 
Kozbor, D., Roder, J. C., Chang, T. H., Steplewski, Z. and Koprowski, H. 
(1982). Human anti -tetanus toxoid monoclonal antibody secreted by EBV- 
transformed human B cells fused with murine myeloma. Hybridoma 1, 323 -328. 
Köhler, S., Delwiche, C. F., Denny, P. W., Tilney, L. G., Webster, P., Wilson, R. 
J., Palmer, J. D. and Roos, D. S. (1997). A plastid of probable green algal 
origin in Apicomplexan parasites. Science 275, 1485 -1489. 
Kriek, N., Tilley, L., Horrocks, P., Pinches, R., Elford, B. C., Ferguson, D. J. P., 
Lingelbach, K. and Newbold, C. I. (2003). Characterization of the pathway for 
transport of the cytoadherence- mediating protein, PfEMP1, to the host cell 
surface in malaria parasite- infected erythrocytes. Mol Microbiol 50, 1215 -1227. 
Krugliak, M., Zhang, J. and Ginsburg, H. (2002). Intraerythrocytic Plasmodium 
falciparum utilizes only a fraction of the amino acids derived from the digestion 
of host cell cytosol for the biosynthesis of its proteins. Mol Biochem Parasitol 
119, 249 -256. 
Kumaratilake, L. M., Ferrante, A. and Rzepczyk, C. (1991). The role of T 
lymphocytes in immunity to Plasmodium falciparum. Enhancement of 
neutrophil- mediated parasite killing by lymphotoxin and IFN- gamma: 
comparisons with tumor necrosis factor effects. Jlmmuno. 146, 762 -767. 
Kumaratilake, L. M., Ferrante, A. and Rzepczyk, C. M. (1990). Tumor necrosis 
factor enhances neutrophil -mediated killing of Plasmodium falciparum. Infect 
Immun 58, 788 -793. 
Kumaratilake, L. M., Ferrante, A., Robinson, B. S., Jaeger, T. and Poulos, A. 
(1997). Enhancement of neutrophil- mediated killing of Plasmodium falciparum 
asexual blood forms by fatty acids: importance of fatty acid structure. Infect 
Immun 65, 4152 -4157. 
Kyes, S. A., Rowe, J. A., Kriek, N. and Newbold, C. I. (1999). Rifins: a second 
family of clonally variant proteins expressed on the surface of red cells infected 
with Plasmodium falciparum. Proc Natl Acad Sci USA 96, 9333 -9338. 
Kyes, S., Horrocks, P. and Newbold, C. (2001). Antigenic variation at the infected 
red cell surface in malaria. Annu Rev Microbiol 55, 673 -707. 
Lamarque, M., Besteiro, S., Papoin, J., Roques, M., Vulliez -Le Normand, B., 
Morlon- Guyot, J., Dubremetz, J.-F., Fauquenoy, S., Tornavo, S., Faber, B. 
W., et al. (2011). The RON2-AMA1 interaction is a critical step in moving 
211 
junction- dependent invasion by apicomplexan parasites. PLoS Pathog 7, 
el 001276. 
Lambros, C. and Vanderberg, J. P. (1979). Synchronization of Plasmodium 
falciparum erythrocytic stages in culture. J. Parasitol 65, 418 -420. 
Lane, R. D., Renno, W., Nepomuceno, V., Schafer, C. and Mellgren, R. L. 
(1988). The influence of stimulated peritoneal feeder cells and mitogens upon 
antibody secreting hybridomas. Hybridoma 7, 289 -299. 
Lang, F. and Qadri, S. M. (2012). Mechanisms and significance of eryptosis, the 
suicidal death of erythrocytes. Blood Puri f33, 125 -130. 
Langhorne, J., Cross, C., Seixas, E., Li, C. and Weid, von der, T. (1998). A role 
for B cells in the development of T cell helper function in a malaria infection in 
mice. Proc Natl Acad Sci USA 95, 1730 -1734. 
Le Roch, K. G., Johnson, J. R., Florens, L., Zhou, Y., Santrosyan, A., Grainger, 
M., Yan, S. F., Williamson, K. C., Holder, A. A., Carucci, D. J., et al. (2004). 
Global analysis of transcript and protein levels across the Plasmodium 
falciparum life cycle. Genome Res 14, 2308 -2318. 
Le Roch, K. G., Zhou, Y., Blair, P. L., Grainger, M., Moch, J. K., Haynes, J. D., 
La Vega, De, P., Holder, A. A., Batalov, S., Carucci, D. J., et al. (2003). 
Discovery of gene function by expression profiling of the malaria parasite life 
cycle. Science 301, 1503 -1508. 
Leonhardt, H., Gordon, L. and Livingston, R. (1971). Acid -base equilibriums of 
fluorescein and 2 ", 7- "dichlorofluorescein in their ground and fluorescent states. 
The Journal of Physical Chemistry 75, 245 -249. 
Lew, V. L., Macdonald, L., Ginsburg, H., Krugliak, M. and Tiffert, T. (2004). 
Excess haemoglobin digestion by malaria parasites: a strategy to prevent 
premature host cell lysis. Blood Cells Mol Dis 32, 353 -359. 
Lew, V. L., Tiffert, T. and Ginsburg, H. (2003). Excess hemoglobin digestion and 
the osmotic stability of Plasmodium falciparum- infected red blood cells. Blood 
101, 4189 -4194. 
Li, T., Janda, K. D., Ashley, J. A. and Lerner, R. A. (1994). Antibody catalyzed 
cationic cyclization. Science 264, 1289 -1293. 
Lindesmith, L. C., Beltramello, M., Donaldson, E. F., Corti, D., Swanstrom, J., 
Debbink, K., Lanzavecchia, A. and Bark, R. S. (2012). Immunogenetic 
mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog 8, 
e1002705. 
Ling, I. T., Ogun, S. A. and Holder, A. A. (1995). The combined epidermal growth 
factor -like modules of Plasmodium yoelii Merozoite Surface Protein -1 are 
required for a protective immune response to the parasite. Parasite Immunol 17, 
212 
425 -433. 
Lobo, C.-A., Rodriguez, M., Reid, M. and Lustigman, S. (2003). Glycophorin C is 
the receptor for the Plasmodium falciparum erythrocyte binding ligand PfEBP -2 
(baebl). Blood 101, 4628 -4631. 
Locher, C. P., Tam, L. Q., Chang, S. P., McBride, J. S. and Siddiqui, W. A. 
(1996). Plasmodium falciparum: gp195 tripeptide repeat -specific monoclonal 
antibody inhibits parasite growth in vitro. Exp Parasitol 84, 74-83. 
Logie, D. E., McGREGOR, I. A., Rowe, D. S. and Billewicz, W. Z. (1973). 
Plasma immunoglobulin concentrations in mothers and newborn children with 
special reference to placental malaria: Studies in the Gambia, Nigeria, and 
Switzerland. Bull. World Health Organ 49, 547 -554. 
Lougovskoi, A. A., Okoyeh, N. J. and Chauhan, V. S. (1999). Mice immunised 
with synthetic peptide from N- terminal conserved region of merozoite surface 
antigen -2 of human malaria parasite Plasmodium falciparum can control 
infection induced by Plasmodium yoelii yoelii 265BY strain. Vaccine 18, 920- 
930. 
López, M. L., Vommaro, R., Zalis, M., de Souza, W., Blair, S. and Segura, C. 
(2010). Induction of cell death on Plasmodium falciparum asexual blood stages 
by Solanum nudum steroids. Parasitol lnt 59, 217 -225. 
Lyon, J. A., Carter, J. M., Thomas, A. W. and Chulay, J. D. (1997). Merozoite 
surface protein -1 epitopes recognized by antibodies that inhibit Plasmodium 
falciparum merozoite dispersal. Mol Biochem Parasitol 90, 223 -234. 
Lyon, J. A., Geller, R. H., Haynes, J. D., Chulay, J. D. and Weber, J. L. (1986a). 
Epitope map and processing scheme for the 195,000 -dalton surface glycoprotein 
of Plasmodium falciparum merozoites deduced from cloned overlapping 
segments of the gene. Proc Natl Acad Sci USA 83, 2989 -2993. 
Lyon, J. A., Haynes, J. D., Diggs, C. L., Chulay, J. D. and Pratt- Rossiter, J. M. 
(1986b). Plasmodium falciparum antigens synthesized by schizonts and 
stabilized at the merozoite surface by antibodies when schizonts mature in the 
presence of growth inhibitory immune serum. Jlmmunol 136, 2252 -2258. 
Lyon, J. A., Haynes, J. D., Diggs, C. L., Chulay, J. D., Haidaris, C. G. and Pratt- 
Rossiter, J. (1987). Monoclonal antibody characterization of the 195 -kilodalton 
major surface glycoprotein of Plasmodium falciparum malaria schizonts and 
merozoites: identification of additional processed products and a serotype- 
restricted repetitive epitope. Jlmmunol 138, 895 -901. 
Macagno, A., Bernasconi, N. L., Vanzetta, F., Dander, E., Sarasini, A., Revello, 
M. G., Gerna, G., Sallusto, F. and Lanzavecchia, A. (2010). Isolation of 
human monoclonal antibodies that potently neutralize human cytomegalovirus 
213 
infection by targeting different epitopes on the gH/gL/UL128-1 3 l A complex. J. 
Virol. 84, 1005 -1013. 
Malkin, E. M., Diemert, D. J., McArthur, J. H., Perreault, J. R., Miles, A. P., 
Giersing, B. K., Mullen, G. E., Orcutt, A., Muratova, O., Awkal, M., et al. 
(2005). Phase 1 clinical trial of apical membrane antigen 1: an asexual blood - 
stage vaccine for Plasmodium falciparum malaria. Infect Immun 73, 3677 -3685. 
Mandai, D., Mazumder, A., Das, P., Kundu, M. and Basu, J. (2005). Fas -, 
caspase 8 -, and caspase 3- dependent signaling regulates the activity of the 
aminophospholipid translocase and phosphatidylserine externalization in human 
erythrocytes. J Biol Chem 280, 39460 -39467. 
Margos, G., Bannister, L. H., Dluzewski, A. R., Hopkins, J., Williams, I. T. and 
Mitchell, G. H. (2004). Correlation of structural development and differential 
expression of invasion- related molecules in schizonts of Plasmodium 
falciparum. Parasitology 129, 273 -287. 
Marti, M., Good, R. T., Rug, M., Knuepfer, E. and Cowman, A. F. (2004). 
Targeting malaria virulence and remodeling proteins to the host erythrocyte. 
Science 306, 1930 -1933. 
Mawili- Mboumba, D. P., Borrmann, S., Cavanagh, D. R., McBride, J. S., 
Matsiegui, P.-B., Missinou, M. A., Kremsner, P. G. and Ntoumi, F. (2003). 
Antibody responses to Plasmodium falciparum merozoite surface protein -1 and 
efficacy of amodiaquine in Gabonese children with P. falciparum malaria. J 
Infect Dis 187, 1137 -1141. 
McBride, J. S. and Heidrich, H. G. (1987). Fragments of the polymorphic Mr 
185,000 glycoprotein from the surface of isolated Plasmodium falciparum 
merozoites form an antigenic complex. Mol Biochem Parasitol 23, 71 -84. 
McCall, M. B. B. and Sauerwein, R. W. (2010). Interferon -y -- central mediator of 
protective immune responses against the pre -erythrocytic and blood stage of 
malaria. J. Leukoc. Biol. 88, 1131 -1143. 
McCarthy, J. S., Marjason, J., Elliott, S., Fahey, P., Bang, G., Malkin, E., 
Tierney, E., Aked -Hurditch, H., Adda, C., Cross, N., et al. (2011). A phase 1 
trial of MSP2 -C1, a blood -stage malaria vaccine containing 2 isoforms of MSP2 
formulated with Montanide® ISA 720. PLoS ONE 6, e24413. 
McColl, D. J., Silva, A., Foley, M., Kun, J. F., Favaloro, J. M., Thompson, J. K., 
Marshall, V. M., Coppel, R. L., Kemp, D. J. and Anders, R. F. (1994). 
Molecular variation in a novel polymorphic antigen associated with Plasmodium 
falciparum merozoites. Mol Biochem Parasitol 68, 53 -67. 
McGregor, I. A. and Carrington, S. P. (1963). Treatment of East African P. 
falciparum Malaria With West African Human y- Globulin. Trans R Soc Trop 
Med Hyg 57, 170 -175. 
214 
McKerrow, J. H., Sun, E., Rosenthal, P. J. and Bouvier, J. (1993). The proteases 
and pathogenicity of parasitic protozoa. Annu Rev Microbiol 47, 821 -853. 
McLean, G. R., Nakouzi, A., Casadevall, A. and Green, N. S. (2000). Human and 
murine immunoglobulin expression vector cassettes. Mol Immunol 37, 837 -845. 
McMorran, B. J., Marshall, V. M., de Graaf, C., Drysdale, K. E., Shabbar, M., 
Smyth, G. K., Corbin, J. E., Alexander, W. S. and Foote, S. J. (2009). 
Platelets kill intraerythrocytic malarial parasites and mediate survival to 
infection. Science 323, 797 -800. 
Mendis, K. N., David, P. H. and Carter, R. (1991). Antigenic polymorphism in 
malaria: is it an important mechanism for immune evasion? Immunol Today 12, 
A34-7. 
Meraldi, V., Nebie, I., Tiono, A. B., Diallo, D., Sanogo, E., Theisen, M., Druilhe, 
P., Corradin, G., Moret, R. and Sirima, B. S. (2004). Natural antibody 
response to Plasmodium falciparum Exp -1, MSP -3 and GLURP long synthetic 
peptides and association with protection. Parasite Immunol 26, 265 -272. 
Meslin, B., Barnadas, C., Boni, V., Latour, C., de Monbrison, F., Kaiser, K. and 
Picot, S. (2007). Features of apoptosis in Plasmodium falciparum erythrocytic 
stage through a putative role of PfMCA1 metacaspase -like protein. Jlnfect Dis 
195, 1852 -1859. 
Metzger, W. G., Okenu, D. M. N., Cavanagh, D. R., Robinson, J. V., Bojang, K. 
A., Weiss, H. A., McBride, J. S., Greenwood, B. M. and Conway, D. J. 
(2003). Serum IgG3 to the Plasmodium falciparum merozoite surface protein 2 
is strongly associated with a reduced prospective risk of malaria. Parasite 
Immunol 25, 307 -312. 
Mharakurwa, S., Mutambu, S. L., Mudyiradima, R., Chimbadzwa, T., 
Chandiwana, S. K. and Day, K. P. (2004). Association of house spraying with 
suppressed levels of drug resistance in Zimbabwe. Malar J3, 35. 
Miller, G., Shope, T., Lisco, H., Stitt, D. and Lipman, M. (1972). Epstein -Barr 
virus: transformation, cytopathic changes, and viral antigens in squirrel monkey 
and marmoset leukocytes. Proc Natl Acad Sci USA 69, 383 -387. 
Miller, L. H., Roberts, T., Shahabuddin, M. and McCutchan, T. F. (1993). 
Analysis of sequence diversity in the Plasmodium falciparum merozoite surface 
protein -1 (MSP -1). Mol Biochem Parasitol 59, 1 -14. 
Monge -Maillo, B. and López -Vélez, R. (2012). Migration and malaria in europe. 
Mediterr J Hematol Infect Dis 4, e2012014. 
Morgan, W. D., Birdsall, B., Frenkiel, T. A., Gradwell, M. G., Burghaus, P. A., 
Syed, S. E., Uthaipibull, C., Holder, A. A. and Feeney, J. (1999). Solution 
215 
structure of an EGF module pair from the Plasmodium falciparum merozoite 
surface protein 1. J Mol Biol 289, 113 -122. 
Moss, D. K., Remarque, E. J., Faber, B. W., Cavanagh, D. R., Arnot, D. E., 
Thomas, A. W. and Holder, A. A. (2012). Plasmodium falciparum 19- 
kilodalton merozoite surface protein 1 (MSP 1)- specific antibodies that interfere 
with parasite growth in vitro can inhibit MSP1 processing, merozoite invasion, 
and intracellular parasite development. Infect Immun 80, 1280 -1287. 
Mulhern, T. D., Howlett, G. J., Reid, G. E., Simpson, R. J., McColl, D. J., 
Anders, R. F. and Norton, R. S. (1995). Solution structure of a polypeptide 
containing four heptad repeat units from a merozoite surface antigen of 
Plasmodium falciparum. Biochemistry 34, 3479 -3491. 
Murray, C. J. L., Rosenfeld, L. C., Lim, S. S., Andrews, K. G., Foreman, K. J., 
Haring, D., Fullman, N., Naghavi, M., Lozano, R. and Lopez, A. D. (2012). 
Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 
379, 413 -431. 
Müller, W. and Gautier, F. (1975). Interactions of heteroaromatic compounds with 
nucleic acids. A - T- specific non -intercalating DNA ligands. Eur J Biochem 54, 
385 -394. 
Nardi, M., Tomlinson, S., Greco, M. A. and Karpatkin, S. (2001). Complement - 
independent, peroxide -induced antibody lysis of platelets in HIV -1- related 
immune thrombocytopenia. Cell 106, 551 -561. 
Narum, D. L. and Thomas, A. W. (1994). Differential localization of full -length 
and processed forms of PF83 /AMA -1 an apical membrane antigen of 
Plasmodium falciparum merozoites. Mol Biochem Parasitol 67, 59-68. 
Narum, D. L., Ogun, S. A., Thomas, A. W. and Holder, A. A. (2000).. 
Immunization with parasite -derived apical membrane antigen 1 or passive 
immunization with a specific monoclonal antibody protects BALB /c mice 
against lethal Plasmodium yoelii yoelii YM blood -stage infection. Infect Immun 
68, 2899 -2906. 
Nwuba, R. I., Sodeinde, O., Anumudu, C. I., Omosun, Y. O., Odaibo, A. B., 
Holder, A. A. and Nwagwu, M. (2002). The human immune response to 
Plasmodium falciparum includes both antibodies that inhibit merozoite surface 
protein 1 secondary processing and blocking antibodies. Infect Immun 70, 5328- 
5331. 
Nyakeriga, A. M., Perlmann, H., Hagstedt, M., Berzins, K., Troye -Blomberg, 
M., Zhivotovsky, B., Perlmann, P. and Grandien, A. (2006). Drug- induced 
death of the asexual blood stages of Plasmodium falciparum occurs without 
typical signs of apoptosis. Microbes Infect 8, 1560 -1568. 
216 
Oakley, M. S. M., Kumar, S., Anantharaman, V., Zheng, H., Mahajan, B., 
Haynes, J. D., Moch, J. K., Fairhurst, R., McCutchan, T. F. and Aravind, L. 
(2007). Molecular factors and biochemical pathways induced by febrile 
temperature in intraerythrocytic Plasmodium falciparum parasites. Infect Immun 
75, 2012 -2025. 
Obando -Martinez, A. Z., Curtidor, H., Vanegas, M., Arévalo -Pinzón, G., 
Patarroyo, M. A. and Patarroyo, M. E. (2010). Conserved regions from 
Plasmodium falciparum MSP 11 specifically interact with host cells and have a 
potential role during merozoite invasion of red blood cells. J Cell Biochem 110, 
882 -892. 
Ockenhouse, C. F., Angov, E., Kester, K. E., Diggs, C., Soisson, L., Cummings, 
J. F., Stewart, A. V., Palmer, D. R., Mahajan, B., Krzych, U., et al. (2006). 
Phase I safety and immunogenicity trial of FMP1 /AS02A, a Plasmodium 
falciparum MSP -1 asexual blood stage vaccine. Vaccine 24, 3009 -3017. 
Oeuvray, C., Bouharoun -Tayoun, H., Gras -Masse, H., Bottius, E., Kaidoh, T., 
Aikawa, M., Filgueira, M. C., Tartar, A. and Druilhe, P. (1994). Merozoite 
surface protein -3: a malaria protein inducing antibodies that promote 
Plasmodium falciparum killing by cooperation with blood monocytes. Blood 84, 
1594 -1602. 
Okech, B. A., Corran, P. H., Todd, J., Joynson- Hicks, A., Uthaipibull, C., 
Egwang, T. G., Holder, A. A. and Riley, E. M. (2004). Fine specificity of 
serum antibodies to Plasmodium falciparum merozoite surface protein, PfMSP- 
1(19), predicts protection from malaria infection and high -density parasitemia. 
Infect Immun 72, 1557 -1567. 
Olivieri, A., Collins, C. R., Hackett, F., Withers -Martinez, C., Marshall, J., 
Flynn, H. R., Skehel, J. M. and Blackman, M. J. (2011). Juxtamembrane 
shedding of Plasmodium falciparum AMA 1 is sequence independent and 
essential, and helps evade invasion- inhibitory antibodies. PLoS Pathog 7, 
e1002448. 
Osier, F. H. A., Fegan, G., Polley, S. D., Murungi, L., Verra, F., Tetteh, K. K. A., 
Lowe, B., Mwangi, T., Bull, P. C., Thomas, A. W., et al. (2008). Breadth and 
magnitude of antibody responses to multiple Plasmodium falciparum merozoite 
antigens are associated with protection from clinical malaria. Infect Immun 76, 
2240 -2248. 
Pachebat, J. A., Ling, 1. T., Grainger, M., Trucco, C., Howell, S., Fernandez - 
Reyes, D., Gunaratne, R. and Holder, A. A. (2001). The 22 kDa component of 
217 
the protein complex on the surface of Plasmodium falciparum merozoites is 
derived from a larger precursor, merozoite surface protein 7. Mol Biochem 
Parasito1117, 83 -89. 
Pal, A. K., Bello, D., Budhlall, B., Rogers, E. and Milton, D. K. (2012). Screening 
for Oxidative Stress Elicited by Engineered Nanomaterials: Evaluation of 
Acellular DCFH Assay. Dose Response 10, 308 -330. 
Pearce, J. A., Mills, K., Triglia, T., Cowman, A. F. and Anders, R. F. (2005). 
Characterisation of two novel proteins from the asexual stage of Plasmodium 
falciparum, H101 and H103. Mol Biochem Parasitol 139, 141 -151. 
Perkins, M. E. and Rocco, L. J. (1988). Sialic acid -dependent binding of 
Plasmodium falciparum merozoite surface antigen, Pf200, to human 
erythrocytes. Jlmmunol 141, 3190 -3196. 
Pierce, S. K. and Miller, L. H. (2009). World Malaria Day 2009: what malaria 
knows about the immune system that immunologists still do not. The Journal of 
Immunology 182, 5171 -5177. 
Pizarro, J. C., Chitarra, V., Verger, D., Holm, I., Pêtres, S., Dartevelle, S., Nato, 
F., Longacre, S. and Bentley, G. A. (2003). Crystal structure of a Fab complex 
formed with PfMSP1 -19, the C- terminal fragment of merozoite surface protein 1 
from Plasmodium falciparum: a malaria vaccine candidate. J Mol Biol 328, 
1091 -1103. 
Polhemus, M. E., Magill, A. J., Cummings, J. F., Kester, K. E., Ockenhouse, C. 
F., Lanar, D. E., Dutta, S., Barbosa, A., Soisson, L., Diggs, C. L., et al. 
(2007). Phase I dose escalation safety and immunogenicity trial of Plasmodium 
falciparum apical membrane protein (AMA -1) FMP2.1, adjuvanted with 
ASO2A, in malaria -naïve adults at the Walter Reed Army Institute of Research. 
Vaccine 25, 4203 -4212. 
Pollack, S. J., Jacobs, J. W. and Schultz, P. G. (1986). Selective chemical catalysis 
by an antibody. Science 234, 1570 -1573. 
Polley, S. D., Conway, D. J., Cavanagh, D. R., McBride, J. S., Lowe, B. S., 
Williams, T. N., Mwangi, T. W. and Marsh, K. (2006). High levels of serum 
antibodies to merozoite surface protein 2 of Plasmodium falciparum are 
associated with reduced risk of clinical malaria in coastal Kenya. Vaccine 24, 
4233 -4246. 
Polley, S. D., Tetteh, K. K. A., Cavanagh, D. R., Pearce, R. J., Lloyd, J. M., 
Bojang, K. A., Okenu, D. M. N., Greenwood, B. M., McBride, J. S. and 
Conway, D. J. (2003). Repeat sequences in block 2 of Plasmodium falciparum 
merozoite surface protein 1 are targets of antibodies associated with protection 
from malaria. Infect Immun 71, 1833 -1842. 
218 
Pouvelle, B., Buffet, P. A., Lépolard, C., Scherf, A. and Gysin, J. (2000). 
Cytoadhesion of Plasmodium falciparum ring- stage- infected erythrocytes. Nat 
Med 6, 1264 -1268. 
Pouvelle, B., Spiegel, R., Hsiao, L., Howard, R. J., Morris, R. L., Thomas, A. P. 
and Taraschi, T. F. (1991). Direct access to serum macromolecules by 
intraerythrocytic malaria parasites. Nature 353, 73 -75. 
Przyborski, J. M., Wickert, H., Krohne, G. and Lanzer, M. (2003). Maurer's 
clefts -a novel secretory organelle? Mol Biochem Parasito1132, 17 -26. 
R (2005). Development Core Team, R: A language and environment for statistical 
computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3- 
900051 -07 -0. 
Rahlfs, S., Nickel, C., Deponte, M., Schirmer, R. H. and Becker, K. (2003). 
Plasmodium falciparum thioredoxins and glutaredoxins as central players in 
redox metabolism. Redox Rep 8, 246 -250. 
Ravetch, J. V. and Lanier, L. L. (2000). Immune inhibitory receptors. Science 290, 
84-89. 
Reddy, S. B., Anders, R. F., Beeson, J. G., Färnert, A., Kironde, F., Berenzon, S. 
K., Wahlgren, M., Linse, S. and Persson, K. E. M. (2012). High affinity 
antibodies to Plasmodium falciparum merozoite antigens are associated with 
protection from malaria. PLoS ONE 7, e32242. 
Reed, Z. H., Kieny, M. P., Engers, H., Friede, M., Chang, S., Longacre, S., 
Malhotra, P., Pan, W. and Long, C. (2009). Comparison of immunogenicity of 
five MSP1 -based malaria vaccine candidate antigens in rabbits. Vaccine 27, 
1651 -1660. 
Reeder, J. C. and Brown, G. V. (1996). Antigenic variation and immune evasion in 
Plasmodium falciparum malaria. Immunol Cell Biol 74, 546 -554. 
Richard, D., MacRaild, C. A., Riglar, D. T., Chan, J.-A., Foley, M., Baum, J., 
Ralph, S. A., Norton, R. S. and Cowman, A. F. (2010). Interaction between 
Plasmodium falciparum apical membrane antigen 1 and the rhoptry neck protein 
complex defines a key step in the erythrocyte invasion process of malaria 
parasites. JBiol Chem 285, 14815- 14822. 
Riley, E. M., Allen, S. J., Wheeler, J. G., Blackman, M. J., Bennett, S., Takacs, 
B., Schönfeld, H. J., Holder, A. A. and Greenwood, B. M. (1992). Naturally 
acquired cellular and humoral immune responses to the major merozoite surface 
antigen (PfMSP1) of Plasmodium falciparum are associated with reduced 
malaria morbidity. Parasite Immunol 14, 321 -337. 
Riley, E. M., Morris -Jones, S., Blackman, M. J., Greenwood, B. M. and Holder, 
219 
A. A. (1993). A longitudinal study of naturally acquired cellular and humoral 
immune responses to a merozoite surface protein (MSP1) of Plasmodium 
falciparum in an area of seasonal malaria transmission. Parasite Immunol 15, 
513 -524. 
Robinson, J., Halliwell, J. A., McWilliam, H., Lopez, R., Parham, P. and Marsh, 
S. G. E. (2012). The IMGT /HLA database. Nucleic Acids Research 41, D1222- 
D 1227. 
Roussilhon, C., Oeuvray, C., Müller -Graf, C., Tall, A., Rogier, C., Trape, J.-F., 
Theisen, M., Balde, A., Pérignon, J. L. and Druilhe, P. (2007). Long -term 
clinical protection from falciparum malaria is strongly associated with IgG3 
antibodies to merozoite surface protein 3. PLoS Med 4, e320. 
Ruwende, C., Khoo, S. C., Snow, R. W., Yates, S. N., Kwiatkowski, D., Gupta, 
S., Warn, P., Allsopp, C. E., Gilbert, S. C. and Peschu, N. (1995). Natural 
selection of hemi- and heterozygotes for G6PD deficiency in Africa by 
resistance to severe malaria. Nature 376, 246 -249. 
Sabchareon, A., Burnouf, T., Ouattara, D., Attanath, P., Bouharoun -Tayoun, 
H., Chantavanich, P., Foucault, C., Chongsuphajaisiddhi, T. and Druilhe, P. 
(1991). Parasitologic and clinical human response to immunoglobulin 
administration in falciparum malaria. Am J Trop Med Hyg 45, 297 -308. 
Sakamoto, H., Takeo, S., Maier, A. G., Sattabongkot, J., Cowman, A. F. and 
Tsuboi, T. (2012). Antibodies against a Plasmodium falciparum antigen 
PfMSPDBL1 inhibit merozoite invasion into human erythrocytes. Vaccine 30, 
1972 -1980. 
Salmon, B. L., Oksman, A. and Goldberg, D. E. (2001). Malaria parasite exit from 
the host erythrocyte: a two -step process requiring extraerythrocytic proteolysis. 
Proc Nall Acad Sci USA 98, 271 -276. 
Sargeant, T. J., Marti, M., Caler, E., Carlton, J. M., Simpson, K., Speed, T. P. 
and Cowman, A. F. (2006). Lineage -specific expansion of proteins exported to 
erythrocytes in malaria parasites. Genome Biol 7, R12. 
Sato, E., Suzuki, T., Hoshi, N., Sugino, T. and Hasegawa, H. (2008). Sodium 
azide induces necrotic cell death in rat squamous cell carcinoma SCC 131. Med 
Mol Morphol 41, 211 -220. 
Saul, A., Lord, R., Jones, G. L. and Spencer, L. (1992). Protective immunization 
with invariant peptides of the Plasmodium falciparum antigen MSA2. J. 
Immunol. 148, 208 -211. 
Scherf, A., Hernandez -Rivas, R., Buffet, P., Bottius, E., Benatar, C., Pouvelle, 
B., Gysin, J. and Lanzer, M. (1998). Antigenic variation in malaria: in situ 
switching, relaxed and mutually exclusive transcription of var genes during 
220 
intra -erythrocytic development in Plasmodium falciparum. EMBO J 17, 5418- 
5426. 
Schofield, L. and Mueller, I. (2006). Clinical immunity to malaria. Curr Mol Med 
6, 205 -221. 
Shay, J. W. and Wright, W. E. (2005). Senescence and immortalization: role of 
telomeres and telomerase. Carcinogenesis 26, 867 -874. 
Sherman, L W. and Zidovetzki, R. (1992). A parasitophorous duct in Plasmodium - 
infected red blood cells. Parasitol Today 8, 2 -3. 
Siddiqui, W. A., Tam, L. Q., Kramer, K. J., Hui, G. S., Case, S. E., Yamaga, K. 
M., Chang, S. P., Chan, E. B. and Kan, S. C. (1987). Merozoite surface coat 
precursor protein completely protects Aotus monkeys against Plasmodium 
falciparum malaria. Proc Nall Acad Sci USA 84, 3014 -3018. 
Sim, B. K., Chitnis, C. E., Wasniowska, K., Hadley, T. J. and Miller, L. H. 
(1994). Receptor and ligand domains for invasion of erythrocytes by 
Plasmodium falciparum. Science 264, 1941 -1944. 
Singh, S., Soe, S., Weisman, S., Barnwell, J. W., Pérignon, J. L. and Druilhe, P. 
(2009). A conserved multi -gene family induces cross -reactive antibodies 
effective in defense against Plasmodium falciparum. PLoS ONE 4, e5410. 
Slomianny, C. (1990). Three- dimensional reconstruction of the feeding process of 
the malaria parasite. Blood Cells 16, 369 -378. 
Slomianny, C. and Prensier, G. (1986). Application of the serial sectioning and 
tridimensional reconstruction techniques to the morphological study of the 
Plasmodium falciparum mitochondrion. J. Parasitol 72, 595 -598. 
Smythe, J. A., Peterson, M. G., Coppel, R. L., Saul, A. J., Kemp, D. J. and 
Anders, R. F. (1990). Structural diversity in the 45- kilodalton merozoite surface 
antigen of Plasmodium falciparum. Mol Biochem Parasitol 39, 227 -234. 
Snow, R. W., Nahlen, B., Palmer, A., Donnelly, C. A., Gupta, S. and Marsh, K. 
(1998). Risk of severe malaria among African infants: direct evidence of clinical 
protection during early infancy. Jlnfect Dis 177, 819 -822. 
Spence, P. J. and Langhorne, J. (2012). T cell control of malaria pathogenesis. 
Curr Opin Immunol 24, 1 -5. 
Spencer Valero, L. M., Ogun, S. A., Fleck, S. L., Ling, I. T., Scott- Finnigan, T. 
J., Blackman, M. J. and Holder, A. A. (1998). Passive immunization with 
antibodies against three distinct epitopes on Plasmodium yoelii merozoite 
surface protein 1 suppresses parasitemia. Infect Immun 66, 3925 -3930. 
Spielmann, T., Fergusen, D. J. P. and Beck, H. -P. (2003). etramps, a new 
Plasmodium falciparum gene family coding for developmentally regulated and 
221 
highly charged membrane proteins located at the parasite -host cell interface. Mol 
Biol Cell 14, 1529 -1544. 
Spielmann, T., Hawthorne, P. L., Dixon, M. W. A., Hannemann, M., Klotz, K., 
Kemp, D. J., Klonis, N., Tilley, L., Trenholme, K. R. and Gardiner, D. L. 
(2006). A cluster of ring stage -specific genes linked to a locus implicated in 
cytoadherence in Plasmodium falciparum codes for PEXEL- negative and 
PEXEL -positive proteins exported into the host cell. Mol Biol Cell 17, 3613- 
3624. 
Spycher, C., Klonis, N., Spielmann, T., Kump, E., Steiger, S., Tilley, L. and 
Beck, H.-P. (2003). MAHRP -1, a novel Plasmodium falciparum histidine -rich 
protein, binds ferriprotoporphyrin IX and localizes to the Maurer's clefts. J Biol 
Chem 278, 35373- 35383. 
Staines, H. M., Alkhalil, A., Allen, R. J., De Jonge, H. R., Derbyshire, E., Egée, 
S., Ginsburg, H., Hill, D. A., Huber, S. M., Kirk, K., et al. (2007). 
Electrophysiological studies of malaria parasite- infected erythrocytes: current 
status. Int J Parasitol 37, 475 -482. 
Steinitz, M., Klein, G., Koskimies, S. and Makel, O. (1977). EB virus -induced B 
lymphocyte cell lines producing specific antibody. Nature 269, 420 -422. 
Steinitz, M., Koskimies, S., Klein, G. and Mäkelä, O. (1979). Establishment of 
specific antibody producing human lines by antigen preselection and Epstein - 
Barr virus (EBV)- transformation. J Clin Lab Immunol 2, 1 -7. 
Stewart, S. A. and Weinberg, R. A. (2006). Telomeres: cancer to human aging. 
Annu Rev Cell Dey Biol 22, 531 -557. 
Stubbs, J., Olugbile, S., Saidou, B., Simpore, J., Corradin, G. and Lanzavecchia, 
A. (2011). Strain -transcending Fc- dependent killing of Plasmodium falciparum 
by merozoite surface protein 2 allele -specific human antibodies. Infect Immun 
79, 1143 -1152. 
Sugimoto, M., Tahara, H., Ide, T. and Furuichi, Y. (2004). Steps involved in 
immortalization and tumorigenesis in human B- lymphoblastoid cell lines 
transformed by Epstein -Barr virus. Cancer Res 64, 3361 -3364. 
Sztajer, H., Gamain, B., Aumann, K. D., Slomianny, C., Becker, K., Brigelius- 
Flohé, R. and Flohé, L. (2001). The putative glutathione peroxidase gene of 
Plasmodium falciparum codes for a thioredoxin peroxidase. J Biol Chem 276, 
7397 -7403. 
Tanabe, K., Mackay, M., Goman, M. and Scaife, J. G. (1987). Allelic dimorphism 
in a surface antigen gene of the malaria parasite Plasmodium falciparum. J Mol 
Biol 195, 273 -287. 
Taraschi, T. F., Pouvelle, B. and Howard, R. J. (1992). A parasitophorous duct in 
Plasmodium -infected red blood cells - reply. Parasitol Today 8, 17. 
222 
Taylor, R. R., Egan, A., McGuinness, D., Jepson, A., Adair, R., Drakely, C. and 
Riley, E. (1996). Selective recognition of malaria antigens by human serum 
antibodies is not genetically determined but demonstrates some features of clonal 
imprinting. Int Immunol 8, 905 -915. 
Tebo, A. E., Kremsner, P. G. and Luty, A. J. (2001). Plasmodium falciparum: a 
major role for IgG3 in antibody- dependent monocyte- mediated cellular 
inhibition of parasite growth in vitro. Exp Parasitol 98, 20-28. 
Tetteh, K. K. A., Stewart, L. B., Ochola, L. I., Amambua -Ngwa, A., Thomas, A. 
W., Marsh, K., Weedall, G. D. and Conway, D. J. (2009). Prospective 
identification of malaria parasite genes under balancing selection. PLoS ONE 4, 
e5568. 
Tham, W. -H., Wilson, D. W., Lopaticki, S., Schmidt, C. Q., Tetteh -Quarcoo, P. 
B., Barlow, P. N., Richard, D., Corbin, J. E., Beeson, J. G. and Cowman, A. 
F. (2010). Complement receptor 1 is the host erythrocyte receptor for 
Plasmodium falciparum PfRh4 invasion ligand. Proc Natl Acad Sci USA 107, 
17327 -17332. 
Theisen, M., Soe, S., Jessing, S. G., Okkels, L. M., Danielsen, S., Oeuvray, C., 
Druilhe, P. and Jepsen, S. (2000). Identification of a major B -cell epitope of the 
Plasmodium falciparum glutamate -rich protein (GLURP), targeted by human 
antibodies mediating parasite killing. Vaccine 19, 204 -212. 
Tompa, P., Szász, C. and Buday, L. (2005). Structural disorder throws new light on 
moonlighting. Trends Biochem Sci 30, 484-489. 
Totino, P. R. R., Daniel -Ribeiro, C. T., Corte -Real, S. and de Fátima Ferreira - 
da -Cruz, M. (2008). Plasmodium falciparum: erythrocytic stages die by 
autophagic -like cell death under drug pressure. Exp Parasitol 118, 478 -486. 
Trager, W. (1993). FCR -3, chloroquine resistance and cross -contamination of 
culture lines of Plasmodium falciparum. Parasitol Today 9, 127 -author reply 
127. 
Traggiai, E., Becker, S., Subbarao, K., Kolesnikova, L., Uematsu, Y., Gismondo, 
M. R., Murphy, B. R., Rappuoli, R. and Lanzavecchia, A. (2004). An 
efficient method to make human monoclonal antibodies from memory B cells: 
potent neutralization of SARS coronavirus. Nat Med 10, 871 -875. 
Tramontano, A., Janda, K. D. and Lerner, R. A. (1986). Catalytic antibodies. 
Science 234, 1566 -1570. 
Trieu, A., Kayala, M. A., Burk, C., Molina, D. M., Freilich, D. A., Richie, T. L., 
Baldi, P., Feigner, P. L. and Doolan, D. L. (2011). Sterile protective immunity 
to malaria is associated with a panel of novel P. falciparum antigens. Mol Cell 
Proteomics 10, M111.007948. 
Trucco, C., Fernandez -Reyes, D., Howell, S., Stafford, W. H., Scott- Finnigan, T. 
223 
J., Grainger, M., Ogun, S. A., Taylor, W. R. and Holder, A. A. (2001). The 
merozoite surface protein 6 gene codes for a 36 kDa protein associated with the 
Plasmodium falciparum merozoite surface protein -1 complex. Mol Biochem 
Parasitol 112, 91 -101. 
Tutterrow, Y. L., Salanti, A., Avril, M., Smith, J. D., Pagano, I. S., Ako, S., 
Fogako, J., Leke, R. G. F. and Taylor, D. W. (2012). High avidity antibodies 
to full- length VAR2CSA correlate with absence of placental malaria. PLoS ONE 
7, e40049. 
van Ooij, C., Tamez, P., Bhattacharjee, S., Hiller, N. L., Harrison, T., Liolios, 
K., Kooij, T., Ramesar, J., Balu, B., Adams, J., et al. (2008). The malaria 
secretome: from algorithms to essential function in blood stage infection. PLoS 
Pathog. 4, e 1000084. 
Vivas, L., Easton, A., Kendrick, H., Cameron, A., Lavandera, J.-L., Barros, D., 
las Heras, de, F. G., Brady, R. L. and Croft, S. L. (2005). Plasmodium 
falciparum: stage specific effects of a selective inhibitor of lactate 
dehydrogenase. Exp Parasitol 111, 105 -114. 
Vouldoukis, I., Mazier, D., Moynet, D., Thiolat, D., Malvy, D. and Mossalayi, M. 
D. (2011). IgE mediates killing of intracellular Toxoplasma gondii by human 
macrophages through CD23- dependent, interleukin -10 sensitive pathway. PLoS 
ONE 6, e18289. 
Waisberg, M., Cerqueira, G. C., Yager, S. B., Francischetti, I. M. B., Lu, J., 
Gera, N., Srinivasan, P., Miura, K., Rada, B., Lukszo, J., et al. (2012). 
Plasmodium falciparum merozoite surface protein 1 blocks the proinflammatory 
protein S10013. Proc Natl Acad Sci USA 109, 5429 -5434. 
Waller, R. F., Reed, M. B., Cowman, A. F. and McFadden, G. I. (2000). Protein 
trafficking to the plastid of Plasmodium falciparum is via the secretory pathway. 
EMBO J19, 1794 -1802. 
Warrell, D. A. and Gilles, H. M. (2003). Essential Malariology. Hodder Arnold. 
Weatherall, D. J. and Clegg, J. B. (2001). Inherited haemoglobin disorders: an 
increasing global health problem. Bull World Health Organ 79, 704 -712. 
Weid, von der, T., Honarvar, N. and Langhorne, J. (1996). Gene -targeted mice 
lacking B cells are unable to eliminate a blood stage malaria infection. J 
Immunol 156, 2510 -2516. 
Wentworth, A. D., Jones, L. H., Wentworth, P., Janda, K. D. and Lerner, R. A. 
(2000). Antibodies have the intrinsic capacity to destroy antigens. Proc Nall 
Acad Sci USA 97, 10930 -10935. 
224 
Wentworth, P., Jones, L. H., Wentworth, A. D., Zhu, X., Larsen, N. A., Wilson, 
I. A., Xu, X., Goddard, W. A., Janda, K. D., Eschenmoser, A., et al. (2001). 
Antibody catalysis of the oxidation of water. Science 293, 1806 -1811. 
Wentworth, P., McDunn, J. E., Wentworth, A. D., Takeuchi, C., Nieva, J., 
Jones, T., Bautista, C., Ruedi, J. M., Gutierrez, A., Janda, K. D., et al. 
(2002). Evidence for antibody -catalyzed ozone formation in bacterial killing and 
inflammation. Science 298, 2195 -2199. 
Wickham, M. E., Culvenor, J. G. and Cowman, A. F. (2003). Selective inhibition 
of a two -step egress of malaria parasites from the host erythrocyte. J Biol Chem 
278, 37658- 37663. 
Wickham, M. E., Rug, M., Ralph, S. A., Klonis, N., McFadden, G. I., Tilley, L. 
and Cowman, A. F. (2001). Trafficking and assembly of the cytoadherence 
complex in Plasmodium falciparum- infected human erythrocytes. EMBO J 20, 
5636 -5649. 
Wilson, C. F., Anand, R., Clark, J. T. and McBride, J. S. (1987). Topography of 
epitopes on a polymorphic schizont antigen of Plasmodium falciparum 
determined by the binding of monoclonal antibodies in a two -site 
radioimmunoassay. Parasite Immunol 9, 737 -746. 
Wipasa, J., Xu, H., Makobongo, M., Gatton, M., Stowers, A. and Good, M. F. 
(2002). Nature and specificity of the required protective immune response that 
develops postchallenge in mice vaccinated with the 19- kilodalton fragment of 
Plasmodium yoelii merozoite surface protein 1. Infect Immun 70, 6013 -6020. 
Withers, M. R., McKinney, D., Ogutu, B. R., Waitumbi, J. N., Milman, J. B., 
Apollo, O. J., Allen, O. G., Tucker, K., Soisson, L. A., Diggs, C., et al. (2006). 
Safety and reactogenicity of an MSP -1 malaria vaccine candidate: a randomized 
phase Ib dose -escalation trial in Kenyan children. PLoS Clin Trials 1, e32. 
Woehibier, U., Epp, C., Hackett, F., Blackman, M. J. and Bujard, H. (2010). 
Antibodies against multiple merozoite surface antigens of the human malaria 
parasite Plasmodium falciparum inhibit parasite maturation and red blood cell 
invasion. Malar J 9, 77. 
Woehibier, U., Epp, C., Kauth, C. and Lutz, R. (2006). Analysis of antibodies 
directed against merozoite surface protein 1 of the human malaria parasite 
Plasmodium falciparum. Infect Immun 74, 1313 -1322. 
World Malaria Report 2011 (2011). World Malaria Report 2011. World Health 
Organization. 
Yu, X., McGraw, P. A., House, F. S. and Crowe, J. E. (2008a). An optimized 
225 
electrofusion -based protocol for generating virus -specific human monoclonal 
antibodies. Journal of Immunological Methods 336, 142 -151. 
Yu, X., Tsibane, T., McGraw, P. A., House, F. S., Keefer, C. J., Hicar, M. D., 
Tumpey, T.M., Pappas, C., Perrone, L.A., Martinez, O., et al. (2008b). 
Neutralizing antibodies derived from the B cells of 1918 influenza pandemic 
survivors. Nature 455, 532 -536. 
226 
